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ABSTRACT 
 
The stress responses of cardiomyocytes are likely to constitute a significant aspect of the 
development of cardiac pathologies.  Oxidative stress is a common theme in the 
pathophysiology of ischaemic and non-ischaemic cardiomyopathy.  On the other hand, 
hypertrophic agonists (e.g. endothelin-1, ET-1) are important mediators of the 
hypertrophic response to hemodynamic overloading, and cardiac pathologies such as 
heart failure are usually preceded by cardiac hypertrophy.  Microarray studies indicate 
that one of the genes most potently induced by H2O2 (as an oxidative stress) or ET-1 in 
cardiac myocytes is the transcription factor ATF3.  This thesis examines the regulation 
and role of ATF3 in neonatal rat ventricular cardiomyocytes.  
 
The increase in expression of ATF3 mRNA was confirmed in neonatal rat 
cardiomyocytes exposed to H2O2 or ET-1 using RT-PCR and Q-PCR.  Using 
immunoblotting, it was confirmed that H2O2 or ET-1 increased ATF3 protein expression. 
ATF3 is an immediate early gene since the upregulation of ATF3 mRNA by ET-1 was 
not inhibited by cycloheximide (20 μM).  Upregulation of ATF3 was inhibited by U0126 
(10 µM), suggesting that signalling through ERK1/2 (extracellular signal-regulated 
kinases 1/2) was required.  Other studies suggest that ATF3 downregulates interleukin-6 
(IL-6) in human cells. The rat IL-6 promoter possesses an ATF consensus sequence, and 
chromatin immunoprecipitation (ChIP) analysis indicated that ET-1 or H2O2 increased the 
association of ATF3 with the IL-6 promoter. IL-6 mRNA and protein expression was 
transiently upregulated in cardiomyocytes exposed to H2O2 or ET-1, and this was shown 
to be an immediate early gene response.  Following IL-6 mRNA upregulation, its 
expression was more rapidly downregulated than that of ATF3.  The peak of ATF3 
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protein expression coincided with the return of IL-6 mRNA to basal levels after 
stimulation with either ET-1 or H2O2.  This suggests that ATF3 operates in a negative 
feedback loop to downregulate IL-6 mRNA expression in cardiomyocytes.  This was 
confirmed by adenoviral-mediated overexpression of full-length ATF3 antisense RNA, 
which attenuated ATF3 mRNA and protein expression following stimulation with ET-1. 
Inhibition of ATF3 expression was associated with superinduction of IL-6 mRNA as 
shown by Q-PCR.  Other potential downstream targets of ATF3 were identified from 
microarray studies using bioinformatics.  Those with ATF/CRE consensus sequences in 
their promoters included epiregulin and leukaemia inhibitory factor (LIF) (also shown to 
be immediate early genes).  Epiregulin and LIF mRNA expression was superinduced by 
ATF3 antisense RNA.  Taken together, these experiments indicate that ATF3 operates in 
a negative feedback loop by downregulating a cluster of immediate early genes induced 
by ET-1.  Thus, ATF3 may play an important role in the establishment and fine-tuning of 
an organised and compensatory hypertrophic response in the cardiomyocyte secondary to 
hypertrophic stimulation. 
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1.0 General introduction 
 
In the United Kingdom, cardiovascular diseases account for the death of one in three 
people each year (36%) (Allender et al., 2007). Heart failure is the end result of most 
diseases affecting the cardiovascular system and it has been estimated that at least 10 
million patients in Europe have symptomatic heart failure with a similar number of 
patients having asymptomatic left ventricular dysfunction (Swedberg et al., 2005). The 
prognosis of this disease is very poor if the causes cannot be rectified, with mortality rates 
of 50% within four years of diagnosis, and this is even worse in patients with severe heart 
failure in which the mortality is more than 50% within a year (Swedberg et al., 2005). 
 
The clinical syndrome of heart failure is the end result of most disease processes affecting 
the cardiovascular system, and the pathophysiology of heart failure has proven to be 
multifactorial and complex. Despite some progress over the past two decades in the 
diagnosis and the advent of novel pharmacological therapy targeting neurohumoral 
activation in heart failure, the number of cases is steadily increasing as a result of 
increased survival of coronary artery disease, and the general trend to higher life 
expectancy in developed and developing countries with a consequent increase in the 
aging population worldwide in recent years (Poole-Wilson, 2007). Additionally, mortality 
rates for this disease are still very high despite careful implementation of guidelines for 
the management of the disease, mainly because the use of current therapy slows but does 
not stop the progressive nature of this disease. Therefore there is an urgent need to gain a 
better understanding of the pathophysiological mechanisms of heart failure, and the 
development of novel pharmacological agents that hopefully will help to stop the 
progression of this disease. 
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 1.1 Cardiac hypertrophy and heart failure 
 
1.1.1 Compensatory cardiac hypertrophy is stimulus dependent 
In the most general sense, cardiac hypertrophy is an adaptive response to increased 
haemodynamic demands. Cardiomyocytes are terminally differentiated cells which 
withdraw from the cell cycle soon after birth (Li et al., 1996; Soonpa et al., 1996), 
therefore cardiac hypertrophy is the result of increased cellular growth (e.g. increased 
cellular content of, for example, myofibrils) in the absence of cell division. Immediate 
early genes (IEGs) are a class of genes whose upregulation is acute and usually transient, 
preceded by activation of intracellular signalling cascades and occurs in the absence of de 
novo protein synthesis (Clerk et al., 2007). In cardiomyocytes, the hypertrophic 
phenotype is associated with changes in the expression of IEGs (e.g. c-jun, c-fos, c-myc), 
and re-expression of a pattern of genes usually expressed during development, the so 
called “foetal pattern” of gene expression (e.g. atrial natriuretic peptide, ANP; B-type 
natriuretic peptide, BNP; and β-myosin heavy chain), which are often used as markers of 
hypertrophy (Hoshijima and Chien, 2002; Dorn and Force, 2005).  
 
Two different types of haemodynamic overload lead to two very well defined patterns of 
ventricular hypertrophy. Thus, pressure-overload, as occurs in hypertensive states, leads 
to concentric cardiac hypertrophy in which the ventricular wall thickness is increased 
with minimal or no increase in the ventricular diameter of the chamber (Grossman, 1975). 
Due to the circumferential disposition of muscle fibres in the heart, this pattern of 
hypertrophy correlates with an increase in the cross-sectional area of the cardiomyocytes, 
as a result of sarcomeric assembly in parallel (Grossman, 1975). In contrast, volume 
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overload, as occurs in mitral or aortic regurgitation, leads to eccentric hypertrophy which 
is characterized by an increase in chamber diameter and a proportional increase in wall 
thickness. At the cellular level, this pattern of hypertrophy correlates with a proportional 
increase in myocyte cross-sectional area and length, and sarcomeric assembly occurs in 
series as well as in parallel. These two patterns of hypertrophy are necessary to achieve a 
compensated state with normal or near normal systolic wall stress in accordance with the 
law of Laplace (Grossman, 1975). 
 
The distinction between eccentric and concentric hypertrophy is important for several 
reasons. The specific adaptation of the structure of the ventricle to a particular 
haemodynamic load virtually forbids aberrant conditions such as the development of 
eccentric hypertrophy and a predominant increase in myocyte cell length in the setting of 
pressure-overload. Such a change in the morphology of the ventricle and the 
cardiomyocytes will be clearly maladaptive. Importantly, cumulative data indicates that 
intrinsic abnormalities in the cardiomyocytes, which include myocyte elongation and 
myocyte slippage, and collectively known as cardiomyocyte remodelling (reviewed in 
Gerdes, 2002), contribute to the process of ventricular remodelling and the progression to 
heart failure (see also section 1.1.3) (for a recent review, see, for example Opie et al., 
2006).  
 
1.1.2 From cardiac hypertrophy to heart failure 
Although initially a compensatory response to increased workload, sustained cardiac 
hypertrophy over a prolonged period of time is usually accompanied by adverse outcomes 
secondary to arrhythmias, coronary artery disease and the development of heart failure 
(Levy et al., 1990; Bikkina et al., 1993; Gosse, 2005). The current paradigm of the 
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progression from cardiac hypertrophy to heart failure was proposed by Felix Meerson 
almost 40 years ago by using a model of acute sub-occlusion of the aorta in dogs 
(Meerson, 1962; Meerson, 1969; Meerson 1976). Thus, after an initial insult to the heart 
whether by an increase in its haemodynamic demands (e.g. hypertension) or loss of the 
contractile tissue of the heart (e.g. myocardial infarction), an initial phase of “transient 
breakdown” (Stage 1) is observed. If the organism survives to this initial phase, 
compensatory hypertrophy develops to maintain cardiac output (Stage 2 or 
“compensatory hyperfunction”). However, when this initial insult persists (e.g. 
uncontrolled hypertension) or is irreversible as in myocardial infarction, a final phase 
called “chronic myocardial exhaustion” (Stage 3) will take place over months to years 
(Meerson 1962; Meerson 1969). This third stage is characterized by progressive left 
ventricular failure, further hypertrophy and replacement of dead cardiomyocytes by 
fibrotic tissue (Katz, 1989). The clinical outcome of this process is cardiac 
decompensation and overt heart failure. From Meerson’s studies it is clear that under 
conditions of increased haemodynamic demands after a compensated hypertrophic state 
with a stable period of months or years, invariably the heart will progress to a phase of 
“chronic exhaustion” which is manifest by heart failure. 
 
One of the important implications of Meerson’s work is the amazing ability of the heart to 
compensate in response to increased work demands (in contrast to other organs), not only 
being able to recover from near in extremis conditions (transient breakdown) after acute 
imposition of pressure-overloading, but also in way that allows it to completely recover 
functional capacity and remain in a compensated state for a prolonged period of time 
before chronic exhaustion supervenes and heart failure develops. Thus, Meerson also 
postulated that during the imposition of the pressure-overload, “antibreakdown” 
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mechanisms should be activated in order to maintain the viability of the animal. This 
leads to the conclusion that the heart possesses an innate capacity to recover from very 
precarious haemodynamic conditions, and probably does so not only by activating 
compensatory mechanisms, but also antibreakdown systems. Although the compensatory 
mechanisms leading to cardiac hypertrophy have been extensively studied over the past 
two decades, the antibreakdown systems have not received considerable attention. Of 
note, some of the pathways involved in the hypertrophic phenotype also promote survival 
of the myocyte [e.g. the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (see 
section 1.3.1.6), and the protein kinase B (PKB, also known as Akt) pathway (see section 
1.3.2.2)]. However, cardiac hypertrophy from concomitant pressure-overload in the 
setting of overexpression of Gαq subunits from guanine nucleotide proteins (G-proteins), 
paradoxically leads to heart failure associated with increased apoptosis and eccentric 
rather than concentric remodelling (Sakata et al., 1998). Thus, it is possible that the 
hypertrophic phenotype is accompanied by both cytoprotective and pro-apoptotic 
signalling, and probably the final outcome ultimately depends on the nature of the stimuli 
and the context of the cells (cardiac milieu) at the time of the stimuli.  
 
1.1.3 Ventricular remodelling: the road to heart failure progression 
Changes in the ventricular architecture and the cardiomyocyte size and shape have 
collectively received the name of ventricular remodelling. The seminal studies of Janice 
Pfeffer and colleagues, lead to the concept of ventricular remodelling in the late 1970s. 
Initially, during her PhD studies at Frohlich laboratory, she noticed that with 
spontaneously hypertensive rats, as the animals aged the shape of the ventricle 
progressively changed towards a dilated, thinned and spherical morphology rather than 
the normal elliptical one (Pfeffer et al., 1979a; Pfeffer et al., 1979b). To this change in the 
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characteristics of the ventricle after a period of compensatory hypertrophy, the name of 
ventricular remodelling was given. Later, these findings were extended to a model of 
myocardial infarction in rats, where a similar remodelling process was documented. An 
initial phase of compensatory hypertrophy was followed by progressive dilatation and 
thinning of the ventricular cavities (Fletcher et al., 1981). One of the important clinical 
applications of these studies is the current anti-remodelling strategy following myocardial 
infarction in patients. Initially, while testing the effects of several vasodilators, 
remodelling of the ventricle was found to be attenuated by what was then a new class of 
drug, the angiotensin converting-enzyme (ACE) inhibitors, which had a major effect in 
ameliorating this process (Pfeffer et al., 1982; Pfeffer et al., 1985). This finally led to the 
concept of cardioprotection and anti-remodelling therapy, and the current use in clinical 
practice of antiremodelling drugs such as the ACE inhibitors, which has led to significant 
reductions in morbidity and mortality after myocardial infarction (Pfeffer et al., 1992; 
Sutton et al., 1997). This therapy has been extended to improve the prognosis of patients 
with heart failure (Pfeffer et al., 1988; Kiowski et al., 1996). 
 
The molecular mechanisms underlying the progression to heart failure have been under 
intensive investigation over the past two decades. The weight of evidence supports the 
notion that this process is the end result of increased neurohumoral stimulation which 
activates multiple signalling cascades that change the phenotype of the myocardium by 
altering the patterns of gene expression controlling growth, survival and apoptosis of 
cardiomyocytes. The resulting terminal phenotype is characterized by poor contractility, 
altered myocardial energetics, myocardial fibrosis, and ventricular dilatation with a 
corresponding increase in myocyte length (Colucci et al., 1997; Hunter and Chien, 1999; 
Katz, 2003). In the next section the general classification of the different neurohumoral 
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factors that have been implicated in inducing cardiomyocyte hypertrophy will be 
summarized. Then in section 1.3 a detailed description of the different signalling 
pathways involved in cardiomyocyte hypertrophy and which are activated by these 
neurohumoral factors will presented. 
 
  
1.2 Hypertrophic agonists 
 
Haemodynamic stress in the form of pressure-overload and volume overload is associated 
with the autocrine/paracrine release of a plethora of hypertrophic factors. The majority 
can be classified in three groups: vasoactive agonists, peptide growth factors and the 
cytokine members of the interleukin-6 (IL-6) family (Molkentin and Dorn, 2001). In 
addition to their ability to cause hypertrophic growth of the heart and cardiomyocytes, 
vasoactive agonists can also act in the smooth muscle of the blood vessels and induce 
vasoconstriction and as a consequence also raise blood pressure (Sugden, 2002). These 
include peptide hormones like angiotensin II (ANGII), and endothelin-1 (ET-1), and 
cathecholamines such as noradrenaline. Collectively the effects of these vasoactive 
agonists are mediated through G-protein-coupled receptors (GPCRs). Thus, ANGII 
activities are mediated via the AT1 (AT1a/b in rodents) or AT2 receptors. Hypertrophic 
actions are thought to be mediated principally through the AT1a receptors, although 
studies in genetically-modified mice suggest a role for the AT2 receptor subtype 
(Ishiwara et al., 2001). In mammals the actions of ET-1 are mediated via ET-A and ET-B 
receptors, both of which have been cloned (Davenport, 2000). However, the ET-A 
receptor predominates in the rodent heart (Hilal-Dandan et al., 1997). The actions of 
noradrenaline in the cardiovascular system are generally mediated through α1, β1 and β2 
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adrenoceptors, but those involved in cardiac hypertrophy are mainly derived from 
activation of α1-adrenoceptors. In experimental settings, the most commonly used agonist 
is phenylephrine (PE) which is a more selective synthetic agonist for α-adrenoceptors 
compared with noradrenaline. 
 
Of note, although ANGII stimulation of cardiomyocytes usually results in a hypertrophic 
phenotype that is mediated through the AT1a receptor (Inagami et al., 1999), some 
studies suggest that the hypertrophic effects on cardiomyocytes are relatively weak 
compared with agonists like ET-1 or PE (reviewed in Sugden, 2002). Thus, the direct role 
of ANGII in mediating cardiac hypertrophy has been object of debate for several years 
(Reudelhuber et al., 2007). It is has been postulated that most of the actions of ANGII in 
cardiac hypertrophy are probably secondary to the release of other autocrine/paracrine 
hypertrophic factors such as ET-1 (Ito et al., 1993, Xia et al., 2004; Laplante and 
Champlain 2006), peptide growth factors such epidermal growth factor (EGF) (Shah et 
al., 2003; Smith et al., 2004), and/or by AT1-mediated transactivation of the EGF 
receptor (EGFR) (Zhai et al., 2006). With the considerations for ANGII mentioned above, 
the discussion of the actions derived from the activation of GPCR in cardiac hypertrophy 
will be centered on the observations made with the α-adrenoceptor agonist PE, and 
particularly with ET-1 (see section 1.3.1). 
 
Peptide growth factors can promote cardiomyocyte hypertrophy. However, there are 
significant differences in their relative potency in inducing the response. Thus, EGF, 
platelet derived growth factor (PDGF) or fibroblast growth factor (FGF) cause significant 
hypertrophic response in cardiomyocytes (as assessed by measurements of cell area), 
whereas insulin, insulin-like growth factor-1 (IGF-1) or nerve growth factor (NGF) do not 
 35
induce significant hypertrophy of cardiomyocytes (Clerk et al., 2006). Peptide growth 
factors activate receptor protein tyrosine kinases (RPTK) to mediate their actions. The 
archetypical model of RPTK signalling is the EGF receptor (EGFR) signalling system 
which will be discussed in detail in section 1.3.2. 
 
The IL-6 family of cytokines [also known as the gp130 (glycoprotein 130) cytokines], 
include IL-6, cardiotrophin-1 (CT-1), leukaemia inhibitory factor (LIF), IL-11, oncostatin 
M, and ciliary neurotrophic factor. The best studied of this family are CT-1, LIF and IL-6 
(Pennica et al., 1996; Wollert et al., 1996). These agonists activate signalling cascades by 
coupling to heteromeric plasma membrane receptor complexes which contain one or more 
copies of the common signal transducing receptor chain glycoprotein 130 (gp130), (Bravo 
and Heath, 2000). The hypertrophic effects of this family of cytokines in cardiomyocytes 
are characterized by a prominent increase in myocyte length, rather than increased cross-
sectional area (as occurs with ET-1), thus causing myocyte elongation (Wollert et al., 
1996). A detailed description of the mechanisms of signal transduction pathways 
activated by this family of cytokines will be discussed in section 1.3.3. 
 
 
1.3 Intracellular signalling pathways activated by hypertrophic agonists 
 
All hypertrophic agonists cause the activation of several intracellular signalling pathways, 
some of which may be common to many, but their relative potency in term of degree of 
activation and initial mechanistic steps at the membrane receptor level differ 
considerably. Here, I will discuss the events leading to the activation of the different 
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signalling cascades by the different hypertrophic agonists. The supporting evidence of 
their role in the hypertrophic process will be also discussed. 
 
1.3.1 Signal transduction pathways activated by ET-1 or PE 
 
1.3.1.1 ET-1 or PE activate second messengers at the plasma membrane-cytoplasm 
interface 
In cardiomyocytes, the receptors through which pro-hypertrophic signalling of ET-1 and 
PE is activated are the ET-A and α1-adrenergic receptors respectively. These receptors 
belong to a large superfamily receptors which characteristically consist of seven 
transmembrane α-helical domains (H1-H7), thus the name heptahelical receptors. The N-
terminal domain and three loops that connect the H2-H3, H4-H5 and H6-H7 domains are 
located facing the extracellular space, whereas the C-terminal domain and three loops that 
connect the H1-H2, H3-H4 and H5-H6 domains are located facing the intracellular space. 
The ET-A and α1-adrenergic receptors are coupled mainly to heterotrimeric G-proteins of 
the q/11 family (and are therefore collectively known as GqPCRs) which activate the 
enzyme phospholipase Cβ (PLC-β). 
 
Heterotrimeric G-proteins are composed of three subunits, namely alpha (α), beta (β) and 
gamma (γ). In the basal state, the heterotrimeric G-proteins form a complex, with the Gα 
subunit bound to GDP (Linder and Gilman, 1992). Upon ligand binding to their specific 
GqPCR receptors, a conformational change at the intracellular domain occurs triggering 
the association of the G-protein complex with third C-terminal loop and the C-terminal 
tail of the receptor (Conklin et al., 1993). This is followed by rapid exchange of GTP for 
GDP in the Gαq subunit and the dissociation of the heterotrimer into Gαq·GTP and Gβγ 
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(Figure 1.1). Both Gαq·GTP and Gβγ are capable of inducing direct and independent 
activation of PLC-β (Rhee, 2001), which catalyzes the hydrolysis of the membrane 
phospholipid phosphatidylinositol 4,5 bis phosphate [PtdIns(4,5)P2] with the formation of 
the soluble inositol 1,4,5 tris phosphate [Ins(1,4,5)P3] and hydrophobic and membrane-
localized diacylglycerol (DAG). The actions of Gαq·GTP are terminated by the intrinsic 
GTPase activity of Gαq, although this can be accelerated by GTPase-activating proteins 
(GAPs) known as regulator of G-protein signalling (RGS) proteins (Ross et al., 2000), 
which can reduce considerably the time of activation of the effectors of Gαq. Finally, 
there is re-association of Gαq·GDP with Gβγ dimers. 
 
1.3.1.2 Downstream signals activated by DAG in response to ET-1 or PE 
Protein kinase C (PKC) enzymes are the best characterized immediate effectors of DAG 
(Figure 1.2). The PKC family comprises multiple related genes which are serine/threonine 
kinases, and play an important role in the regulation of cellular growth and viability. 
PKCs are subdivided into three subfamilies: the classical or conventional cPKCs (α, βI, 
βII, γ) which are Ca2+-dependent and are activated by both DAG and phosphatidylserine; 
the novel nPKCs (δ, ε, η, θ) which are Ca2+-independent but require DAG and 
phosphatidylserine for activation; and the atypical aPKCs (ζ, ι/λ) which are Ca2+- and 
DAG-independent but phosphatidylserine can regulate their functions (Mellor and Parker, 
1998; Steinberg, 2004). Of the PKCs that require DAG for their activation, 
cardiomyocytes express cPKCα (Clerk et al., 1994; Disatnik et al., 1994; Rhode et al., 
2000), nPKCδ and nPKCε (Clerk et al., 1994; Disatnik et al., 1994; Clerk et al., 1995). In 
addition to DAG-dependent PKCs the atypical aPKCζ and aPKCι/λ have also been 
detected in cardiomyocytes (Clerk et al., 1994; Disatnik et al., 1994; Steinberg, 2004). 
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Figure 1.1 Activation of heterotrimeric Gq protein complex by noradrenaline in 
cardiomyocytes. In the resting cardiomyocyte (A and B), heterotrimeric Gq-proteins 
remain inactive and bound to GDP. Upon noradrenaline (NA) binding to the α-1 
adrenergic receptor (C) a conformational change in the receptor (at the C-terminal) leads 
to binding of GTP to the Gαq-subunit (depicted in blue). This is followed by dissociation 
of the Gq protein complex into Gαq·GTP and Gβγ subunits (green and orange) (D). Then 
Gαq·GTP (or Gβγ) binds to and activates the enzyme phospholipase-Cβ (PLC-β) (E). The 
activity of Gαq is terminated by its intrinsic GTPase activity and this is followed by 
reassociation of the heterotrimeric Gq protein complex (F). Abbreviations: EC = 
extracellular space; IC = Intracellular space. Protein data bank (PDB) files obtained from 
Research Collaboratory for Structural Bioinformatics PDB web site. Figures were created 
with imported ribbon structures using the software 3D Studio Max ® from Discreet 
software Inc. 
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PKCs are soluble kinases that remain in the cytosol in the inactive state and upon 
stimulation of cardiomyocytes with ET-1, nPKCδ and nPKCε translocate to the 
membrane fraction to bind to DAG and phosphatidylserine, a response that is indicative 
of their activation (Clerk et al., 1994). Although a rapid translocation of nPKCε to the 
membrane also occurs in response to PE, this is significantly less than with ET-1, and 
translocation of nPKCδ to the membrane fraction is almost undetectable with this agonist 
(Clerk et al., 1994). Characteristically, nPKCδ and nPKCε begin to return to the cytosolic 
fraction (retrotranslocation) within 3-5 min (probably because DAG is rapidly 
phosphorylated by DAG kinases, thus terminating its actions), although a significant 
proportion of nPKCε remains bound to the membrane fraction up to 15 min (Clerk et al., 
1994). The EC50 of ET-1 in promoting translocation of nPKCε to the membrane is about 1 
nM whereas that for nPKCδ is significantly greater (10 nM) (Clerk et al., 1994). 
Interestingly, ET-1 causes rapid translocation of the nPKCδ pool to the membrane 
fraction (within 30 s) an event that is associated with phosphorylation of Tyr-residues on 
this kinase (Markou et al., 2006). nPKCδ retains its activity even after retrotranslocation 
and is therefore presumably involved in phosphorylation of substrates elsewhere (Markou 
et al., 2006).  
 
With respect to cPKCα, this isoform appears to be up to 8 times more abundant on a 
molar basis than nPKCε in cardiomyocytes (Rohde et al., 2000) and, assuming similar 
activities for both isoforms, only a small fraction of the cPKCα may need to be 
translocated to get a similar change in activity as for complete translocation of nPKCε. 
However, again noradrenaline, acting through α1-adrenoceptors only activated nPKCδ 
and nPKCε, but not cPKCα (Clerk et al., 1994; Rohde et al., 2000). The role of cPKCα in 
cardiac hypertrophy cannot be dismissed because of this, as downregulation of cPKCα 
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with antisense oligonuclotides leads to suppression of some of the molecular criteria of 
hypertrophy induced by PE or ET-1. It also correlates with a reduction in the activation of 
ERK1/2 by PE, an important cascade involved in cardiac hypertrophy (see section 
1.3.1.5), implicating cPKCα as an upstream effector of ERK1/2 activation in 
cardiomyocytes (Kerkelä et al., 2002). An important role for cPKCα in cardiomyocyte 
hypertrophy has also been suggested by the demonstration that adenoviral-mediated 
overexpression of cPKCα results in a hypertrophic phenotype (through downstream 
activation of the ERK1/2 cascade), whereas overexpression of dominant negative cPKCα 
blunts the hypertrophic response to PE (Braz et al., 2002; Braz et al., 2004). 
 
1.3.1.3 Downstream signals activated by Ins(1,4,5)P3 in response to ET-1 or PE 
Upon diffusion from the plasma membrane to the cytosolic space, Ins(1,4,5)P3 binds to 
Ins(1,4,5)P3 receptors (IP3R) located in several membranes of organelles including the 
endoplasmic reticulum, the mitochondria and the nucleus. IP3R operate as Ca+2 channels 
and, upon activation by Ins(1,4,5)P3, mobilize Ca2+ ions from the organelle. Although this 
mobilization of Ca2+ ions into the cytosol has been considered of different nature and 
consequences to the process of “excitation-contraction coupling” that regulates the 
activation of the myofilaments during systole and diastole in the heart, its physiological 
significance in cardiomyocytes has remained obscure for several years. 
 
Recently, a process has been described whereby Ins(1,4,5)P3 signalling by ET-1 or PE 
results in activation of gene expression secondary to localized mobilization of Ca2+ into 
the nucleus. Ca2+ binds to calmodulin (CaM) and increases the activity of Ca2+/CaM 
kinase II (CaMKII). The homologous name “excitation-transcription coupling” has been 
given to this process (Wu et al., 2006) (Figure 1.2). The consequences of activation of 
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CaMKII in the perinuclear envelope involves phosphorylation, nuclear export to the 
cytoplasm of histone deacetylase 5 (HDAC5) which remains bound by inhibitory proteins 
14-3-3 (McKinsey et al., 2000). HDAC5 is a negative regulator of the myocyte enhancer 
factor 2 (MEF2) transcription factor (Wu et al., 2006, reviewed in Backs and Olson, 
2006), and therefore activation of CaMKII ultimately leads to derepression of MEF2 (Lu 
et al., 2000), an important transcripton factor in cardiac development and growth 
(reviewed in Akazawa and Komuro, 2003). HDAC5 belongs to the class II HDAC family 
which are commonly involved in the negative regulation of gene expression by increasing 
the coiled structure of DNA into the nucleosomes (chromatin condensation), a widely 
used mechanism for the control of gene expression by the cells (see section 1.6). The 
important implications of this novel mechanism of Ins(1,4,5)P3 regulation of cellular 
processes is that cardiomyocytes, and possibly other cells, have the ability to distinguish 
local mobilization of Ca2+ within the nucleus which is involved in the control of gene 
expression, and global mobilization of Ca2+ ions which is involved in contraction and 
relaxation of the cardiomyocytes. 
 
1.3.1.4 Activation of small G-protein Ras by GqPCR agonists 
One of the next events regulated by GqPCR agonists is the activation of the small (21 
kDa) guanine nucleotide binding proteins of the Ras family (Figure 1.2). The Ras family 
belongs to the small G-protein superfamily which is classified into five subfamilies with 
over 100 members, and it is even possible that more members and subfamilies remain to 
be identified (Schultz et al., 2000). Three Ras proteins have been the most studied over 
the years including Harvey (Ha-Ras), Kirsten (Ki-Ras) and N-Ras, and these are the 
archetypical Ras members (Takai et al., 2001). 
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Figure 1.2 Activation of signalling pathways by GqPCR agonists ET-1 or PE in 
cardiomyocytes. Binding of ET-1 or PE to their GqPCRs, activates Gq-proteins leading 
to activation of phosholipase Cβ (PLC-β). This triggers the hydrolysis of PtdIns(4,5)P2 
into soluble inositol 1,4-5-trisphosphate [Ins(1,4,5)P3] and DAG. Ins(1,4,5)P3 activates 
Ins(1,4,5)P3 receptors (IP3R) in the nuclear envelope causing a localized increase in Ca2+ 
ions, which activates calmodulin (CaM) and CaM kinase II (CaMKII), this later inducing 
phosphorylation of histone deacetylase 5 (HDAC5) and its nuclear export to the cytosol 
and binding to inhibitory proteins 14-3-3, thus derepressing  transcription MEF2 activated 
transcription. DAG remains in the membrane locale where it activates several members of 
the n/cPKCs (cPKCα, nPKCδ and nPKCε). This result in activation of Ras and a cascade 
of events including activation of c-Raf, MKK1/2 and finally activation of ERK1/2, which 
can be blocked by specific inhibitors such as U0126 or PD98059 (see section 1.3.1.5).  
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In a manner similar to heterotrimeric G-proteins, small G-proteins are inactive when 
bound to GDP and are activated upon exchange of GDP for GTP, triggering a change in 
the conformational structure of the Ras effector-binding region, which allows it to interact 
with its effectors including Raf, the upstream kinase of the ERK1/2 cascade (see next 
section). Thus, the Ras proteins work as molecular switches for the activation of 
signalling cascades. The process of GDP for GTP exchange and activation of Ras can be 
accelerated by guanine nucleotide exchange factors (GEFs) such as Son of sevenless 
(Sos). The inactivation of Ras is partly dependent on the intrinsic GTPase activity of Ras 
leading to Ras·GDP and termination of its actions. However, the intrinsic GTPase activity 
of Ras is very low and it is thought that GTPase activating proteins (GAP) like Ras·GAP, 
which in most cases are specific for the Ras family, play a major role in the rapid 
termination of their actions in vivo (Boguski and McCormick, 1993). Other proteins 
modulating the actions of Ras are the guanine nucleotide dissociation inhibitors (GDI) 
which, by reducing the exchange of GDP for GTP on Ras, prevents their activation 
(Boguski and McCormick, 1993). 
 
Upon stimulation with ET-1 or PE in cardiomyocytes, total Ras is maximally activated 
(Ras·GTP loading) within 1-2 min (Chiloeches et al., 1999), and although it has been 
possible to confirm this for Ha-Ras and N-Ras, whether or not Ki-Ras is also activated in 
the same way has not been established. However, activation of all Ras members peptide 
growth factors such as EGF, has been demonstrated recently (Clerk et al., 2006). Because 
lower concentrations of ET-1 are needed for the rapid activation of nPKCε (EC50 1.4-1.7 
nM)  (Clerk et al., 1994), it is most likely that this PKC has a role in the activation of Ras 
in vivo where lower physiological concentrations of ET-1 than those used in experimental 
settings are usually found. The mechanisms of Ras activation by PKC are not clear, but 
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given the maximal activation achieved within 1-2 min by GqPCRs (Chiloeches et al., 
1999), it is likely that this process involves the activation of a GEF. 
 
1.3.1.5 Activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade by 
GqPCR agonists 
The amino acid residues in proteins that are susceptible of being regulated through 
phosphorylation by kinases, or dephosphorylation by phosphoprotien phosphatases are 
Ser, Thr and Tyr. The kinases and phosphoprotein phosphatases are classified in three 
groups, Ser-/Thr- specific, Tyr- specific, or capable of modifying Ser-/Thr- and Tyr-, in 
which case they are termed dual-specificity. One of the most important signalling events 
involved in cardiomyocyte hypertrophy secondary to the stimulation with ET-1 or PE is 
the activation of ERK1/2 (Figure 1.2), members of the mitogen-activated protein kinase 
(MAPK) superfamily. The MAPK cascades are highly conserved signal transduction 
pathways essential for the adaptation, survival and preservation of homeostasis of the 
organism (Chan et al., 2001). They comprise three-tiered protein kinase cascades 
culminating in the dual Thr-/Tyr- phosphorylation in the activation loop of the terminal 
MAPK. Thus, upstream MAPK kinase kinases (MKKKs) phosphorylate and activate 
intermediate MAPK kinases (MKKs), which in turn finally phosphorylate and activate the 
effector MAPKs. To date, four MAPK subfamilies have been extensively characterized. 
There are two subclasses of ERKs: ERK1 and 2 (ERK1/2), and ERK5 or big MAPK 
(BMK1). ERKs have the activation motif (Thr-Glu-Tyr) (Payne et al., 1991; Mody et al., 
2003). The c-Jun N-terminal kinases (JNKs) have the activation motif (Thr-Pro-Tyr) 
(Lawler et al., 1998), and p38-MAPKs have the motif (Thr-Gly-Tyr) (Han et al., 1994). 
The different components of these MAPKs cascades are summarized in Figure 1.3.  
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For the ERK1/2 cascade the upstream MKKKs are members of the Raf family (A-Raf, B-
Raf or c-Raf), which activate the intermediate MKK1 or MKK2 by phosphorylating two 
Ser-residues on these. MKK1 and MKK2 are dual-specificity kinases and phosphorylate a 
Tyr- and a Thr- residue on the Thr-Glu-Tyr motif of ERK1/2.  The activation of Raf (best 
characterized for c-Raf) is achieved by its translocation to the plasma membrane, which is 
triggered by activation of Ras. This promotes the interaction of c-Raf N-terminal 
regulatory domain with Ras with consequent c-Raf activation, although the mechanism 
involves additional steps. Briefly, in the inactive state the N-terminal regulatory domain 
of c-Raf appears to bind to and inactivate the C-terminal kinase domain. c-Raf is also 
phosphorylated at Ser-259 and Ser-621 and remains bound to 14-3-3 inhibitory proteins 
in the cytoplasm. Upon Ras·GTP loading, the 14-3-3 protein located at the N-terminal 
domain of c-Raf is displaced by binding of c-Raf by Ras (Rommel et al., 1997), and Ser-
259 is dephosphorylated by protein phosphatase 2A (PP2A) (Ory et la., 2003). Further 
phosphorylations also occur after binding of Ras to c-Raf, the most critical being 
phosphorylation of Tyr-341 mediated probably by Src tyrosine kinase, and Ser-338 
phosphorylation, which is possibly mediated by p21-activated kinase (PAK) or another 
unidentified kinase (Wellbrock et al., 2004; Dumaz et al., 2005). These phosphorylations 
occur at the region between the N-terminal and the C-terminal domains (hinge region), 
thus releasing the inhibition form the N-terminal regulatory domain over the C-terminal 
kinase domain.  
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Figure 1.3 Components of the MAPK signalling cascades. MAPKs (mitogen-activated 
protein kinases) are the final components of three-tiered cascades and phosphorylate and 
regulate a range of substrates. The best studied MAPKs are ERK1/2, ERK5, p38-MAPKs and 
JNKs. MAPKs are phosphorylated in their Thr-Xaa-Tyr motif and activated by dual-
specificity Thr-/Tyr- MAPKKs (MAPK kinases). MAPKK are in turn phosphorylated and 
activated by MAPKKKs (MAPK kinase kinases). 
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 As in the case of Ras (Chiloeches et al., 1999), ET-1 stimulation of cardiomyocytes 
causes a rapid and powerful activation of Raf (c-Raf and A-Raf) which is maximal within 
3-5 min (Bogoyevitch et al., 1995a), and also maximal activation of MKK1/2 occurs 
within 3-5 min (Bogoyevitch et al., 1994). This acute activation of the upstream MKKKs 
and MKKs of ERK1/2 correlates with the rapid activation of ERK1/2 (maximal within 5 
min) following stimulation of cardiomyocytes with ET-1 or PE (Bogoyevitch et al., 1993; 
Bogoyevitch et al., 1996). The stimulation of cardiomyocytes with phorbol 12-myristate 
13-acetate (PMA), a phorbol ester which acts as a pharmacological mimic of DAG, thus 
producing sustained activation of DAG-sensitive PKCs, causes acute activation of 
ERK1/2 which is initially detected in the cytoplasm and after 4 min in the nucleus 
(Chiloeches et al., 1999), suggesting that activated ERK1/2 may influence the 
phosphorylation state of nuclear proteins such as transcription factors and, by implication, 
influence transcriptional regulation in cardiomyocytes.  
 
ERK1/2 are Pro- directed Ser-/Thr- kinases which phosphorylate Ser-/Thr- residues 
usually located towards the N-terminal of Pro- residues (Songyang et al., 1996). 
However, the Ser-/Thr-Pro- sequence is very common with up to 80% of all proteins 
exhibiting this sequence, leading to the conclusion that other mechanisms are involved in 
determining the substrate specificity of ERK1/2. Several of the important factors 
determining the specificity of the substrates of ERK1/2 may include the presence of 
docking sites (i.e. short amino acid sequences) on the potential substrate (reviewed in 
Bardwell, 2006), scaffold proteins such as kinase suppressor of Ras which, in addition to 
increasing the specificity, also appears to increase the efficiency of activation of the 
cascade (reviewed in Sacks, 2006), and compartmentalization (e.g. nuclear localization) 
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of the ERK1/2 signal (reviewed in Kolch, 2005). The substrates of ERK1/2 are not 
completely characterized but some of them include transcription factors (reviewed in 
Yoon and Seger, 2006), which is consistent with the nuclear localization of ERK1/2 
within 4 min after stimulation with PMA (Chiloeches et al., 1999). As an example, one of 
these transcription factors is Elk-1, a member of the ternary complex factor subfamily of 
ETS-domain transcription factors. The phosphorylation of the C-terminal activation 
domain of Elk-1 induces a conformational change accompanied by the stimulation of 
DNA binding and transcriptional activity (Marais et al., 1993; Yang et al., 1999). The 
transcription factor c-Fos, an IEG, is a member of the activated protein 1 (AP-1) family of 
transcription factors (see section 1.5). It has been shown that upregulation of c-Fos upon 
stimulation of cardiomyocyte hypertrophy with PE requires the phosphorylation of Elk-1 
and binding Elk-1 to the promoter of c-fos, all of which is dependent on the activation of 
the ERK1/2 cascade (Babu et al., 2000).  
 
ERK1/2 are also involved in the regulation of the translational machinery, suggesting that 
the ERK1/2 cascade is also partly responsible for increased protein synthesis, a 
characteristic feature of the increased cellular mass observed during the growth response 
of cardiomyocytes induced by GqPCR agonists. Many mRNAs contain a 7methyl-GTP 
5’-cap structure which is required for cap-dependent initiation of translation of mRNA 
into protein. Translation initiation, the rate limiting step of protein translation, requires the 
interaction of the 7methyl-GTP 5’-cap structure with the eukaryotic initiation factor 4E 
(eIF4E) and binding to the initiation complex scaffold eIF4G, thus allowing the formation 
of active initiation complexes (reviewed in Proud, 2004). The binding of eIF4E and 
eIF4G is regulated by eIF4E-binding proteins (4EBPs) which, in their dephosphorylated 
state, bind to and inhibit eIF4E (Gingras et al., 1999a). Several phosphoaceptor sites have 
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been described for 4EBP1, and phosphorylation of these reduces the ability of 4EBP1 to 
interact with eIF4E (Gingras et al., 1999b). Phosphorylation of 4EBP1 by ET-1 or PE was 
recently demonstrated in cardiomyocytes and appears to be mediated through the ERK1/2 
pathway acting in concert with other regulatory proteins like the 70-kDa ribosomal S6 
kinase (S6K1) and mammalian target of rapamicin (mTOR), thus activating protein 
synthesis (Wang and Proud, 2002).  
 
1.3.1.6 Role of the ERK1/2 cascade in cardiac hypertrophy 
As stated earlier, ERK1/2 are strongly activated by hypertrophic stimuli and appear to be 
important for the hypertrophic process (Yue et al., 2000; Sugden, 2001; Sugden, 2003). 
The involvement of the ERK1/2 cascade in cardiomyocyte signalling to hypertrophy has 
been evaluated using small molecule inhibitors of the cascade such as U0126 and 
PD98059. These inhibitors, used at a concentration of 10 μM for U0126 and below 50 
μM for PD98059, are highly selective for inhibition of MKK1/2 in the ERK1/2 cascade in 
several systems including cardiomyocytes (Alessi et al., 1995; Favata et al., 1998; Clerk 
et al., 2002). Thus, U0126 selectively inhibits ET-1 or PE-induced activation of ERK1/2, 
and this is associated with inhibition of the associated increases in protein synthesis and 
cell size (Yue et al., 2000). Indeed, several characteristics usually associated with 
cardiomyocyte hypertrophy (i.e. expression of ANP) are attenuated with the use of U0126 
following stimulation with ET-1 or PE (Yue et al., 2000). Preincubation of 
cardiomyocytes for 15 min with the ERK1/2 inhibitor PD98059, followed by exposure to 
ET-1 or PE over 24 h, results in decreased myofibrilar organization further supporting a 
role for the ERK1/2 cascade in cardiomyocyte hypertrophy; however, a decrease in cell 
size was not observed (Clerk et al., 1998a).  
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Other studies also show that following PE-stimulation of cardiomyocytes, overexpression 
of constitutively-activated MKK1 augments ANP promoter activity (one of the marker 
genes of cardiac hypertrophy), whereas a dominant negative form attenuates this response 
in cardiomyocytes (Gillespie-Brown et al., 1995). Similarly, downregulation of ERK1/2 
expression using antisense oligonucleotides attenuates the morphological characteristics 
of cardiomyocyte hypertrophy (sarcomerogenesis and cell size) and the expression of the 
ANP (promoter activity and ANP mRNA) following exposure of cardiomycotes to PE 
over 48 h (Glennon et al., 1996). 
 
The important role of the ERK1/2 cascade in hypertrophy is also highlighted by studies in 
genetically-modified mice with cardiospecific overexpression of a constitutively-activated 
form of MKK1 under the control of α-myosin heavy chain (α-MHC) promoter (Bueno et 
al., 2000). In this model, the resultant phenotype is mild concentric cardiac hypertrophy 
characterized by a thicker septum, thicker left ventricular posterior wall and reduced 
ventricular chambers size. There was also increased contractility in MKK1 transgenic 
mice compared with wild-type animals at 2 and 6 months of age consistent with a 
hyperdynamic ventricular function, which suggests a phenotype of compensated cardiac 
hypertrophy (Bueno et al., 2000). MKK1 transgenic animals also demonstrated increased 
resistance to ischaemia/reperfusion induced apoptosis (Bueno et al., 2000). Taken 
together, the studies mentioned above suggest a strong relationship between the activation 
of the ERK1/2 pathway in mediating the cardiac hypertrophic response both in vitro and 
in vivo, and this appears to be associated to an intrinsic cytoprotective effect of this 
pathway in the heart. 
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1.3.2. Other signalling cascades activated by GqPCR agonists 
In addition to the ERK1/2 signalling cascade, other signalling cascades are also activated 
by GqPCR agonists including the p38-MAPK and JNK cascades, Calcineurin-NFAT 
(nuclear factor of activated-T cell transcription) pathway, and the PKB also known as Akt 
pathway. The PKB/Akt pathway is not as strongly activated by GqPCR agonists as it is 
by growth factors like EGF, insulin and IGF-1, therefore this pathway will be discussed in 
section 1.4. 
 
1.3.2.1 Stress-activated protein kinase cascades 
Other members of the MAPKs also activated by ET-1 or PE are the JNK and p38-
MAPKs, commonly termed stress-activated protein kinases (SAPKs) because they are 
potently activated by cytotoxic stresses (e.g. hyperosmotic shock, oxidative stress, 
ischaemia/reperfusion) (Figure 1.3). JNKs have the activation motif (Thr-Pro-Tyr) 
(Lawler et al., 1998), and p38-MAPKs have the activation motif (Thr-Gly-Tyr) (Han et 
al., 1994). The dual specificity MKKs responsible for JNK activation are MKK4 (also 
known as SEK-1) and MKK7, and those for p38-MAPK are MKK3 and MKK6. 
Upstream, several MKKKs analogous to Raf have been described (e.g. apoptosis 
signalling regulating kinase 1, ASK1) (Kyriakis and Avruch, 2001) (Figure 1.3). Three 
Jnk (Jnk1-3) genes generate at least 10 JNK protein isoforms by alternative-splicing 
(Gupta et al., 1996). JNK1 and JNK2 are expressed in many tissues including the heart 
(Liang et al., 2003; Kaiser et al., 2005), whereas JNK3 proteins are mainly expressed in 
the brain (Mohit et al., 1995; Martin et al., 1996). However, as in other tissues, JNK1 is 
the main JNK activated in cardiomyocytes and is identified as two bands of 46 and 54 
kDa by immunoblotting (Bogoyevitch et al., 1995c, Clerk et al., 1998b). Of the four 
genes encoding p38-MAPKs (α, β, γ and δ), the most highly expressed protein isoforms in 
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the human heart are the alternatively spliced isoforms p38-MAPK-α1 and α2, with little 
or no detection of the alternatively-spliced p38-MAPKβ1 or β2 (Lemke et al., 2001). 
Although p38-MAPKγ (also known as ERK6 or SAPK3) and p38-MAPKδ are also 
expressed in the heart, their functional role is not clear (Lemke et al., 2001; Court et al., 
2002).  
 
Hypertrophic agonists such as ET-1 or PE activate JNKs and p38-MAPKs in 
cardiomyocytes, but this activity is comparatively less than that obtained by cellular 
stresses particularly when compared with hyperosmotic shock (0.5 M sorbitol) 
(Bogoyevitch et al., 1995c; Clerk et al., 1998a). Consistent with an activating pathway 
through Gαq, activation of JNK and p38-MAPK cascades has also been observed in 
transgenic mice with cardiac overexpression of Gαq (D’Angelo et al., 1997). The role of 
SAPKs in cardiomyocyte hypertrophy or even in cell death is controversial (Sugden and 
Clerk 1998; Liang and Molkentin 2003; Petrich and Wang, 2004) and possibly depends 
on the signalling context and status of the cell.  
 
1.3.2.2 Role of stress-activated protein kinase cascades in cardiac hypertrophy 
Initial studies indicating that JNKs and p38-MAPK are activated by GqPCR agonists 
(Bogoyevitch et al., 1995c; Clerk et al., 1998a) suggested a role for SAPKs in the 
regulation of cardiomyocyte hypertrophy. Further studies using PE in the isolated 
perfused rat heart revealed activation of SAPKs as well as ERK1/2 cascades (Lazou et al., 
1998) and led to the more general hypothesis that all MAPKs could be involved in the 
regulation of cardiac hypertrophy. This hypothesis was further supported by studies 
involving overexpression or inactivation of the different components of these signalling 
cascades in cultured cardiomyocytes. Thus, overexpression of constitutively-activated 
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MKK3 or MKK6 (caMKK3 or caMKK6) results in cardiomyocyte hypertrophy 
(increased cell size and sarcomeric organization) and correlates with the expression of 
ANP, implicating p38-MAPK in the development of the hypertrophic phenotype (Zechner 
et al., 1997; Nemoto et al., 1998; Wang et al., 1998a). Similarly, the use of the p38-
MAPKα/β inhibitor SB203580 blocks all growth features (increased cell size, and ANP 
and α-skeletal actin promoter activities) in cardiomyocytes exposed to caMKK6 or PE 
(Zechner et al., 1997). Although, collectively these studies suggest an important role for 
the p38-MAPK cascade in mediating cardiac hypertrophy, other studies indicated that 
blockade of this pathway with the inhibitor SB203580 is not sufficient to attenuate all 
aspects of ET-1 or PE-induced hypertrophy (Choukroun et al., 1998; Clerk et al., 1998a). 
 
A similar paradigm was also established for the JNK cascade in cardiac hypertrophy. 
Thus, the hypertrophic agonists, ET-1 or PE, induce activation of JNK in cardiomyocytes 
(Bogoyevitch et al., 1995c; Ramirez et al., 1997). ANGII infusion in rats cause elevated 
blood pressure and cardiac hypertrophy. This is associated with increased activity of the 
JNK cascade, but not the ERK1/2 cascade, implicating JNKs in cardiac hypertrophy 
secondary to hypertension induced by ANGII (Yano et al., 1998). Overexpression of 
wild-type MKK7 or constitutively active MKK7 (caMKK7) also leads to cardiomyocyte 
hypertrophy as evidenced by increased cell size, sarcomeric organization and expression 
of ANP (Wang et al., 1998b). Consistent with a role for the JNK cascade in 
cardiomyocyte hypertrophy, overexpression of a dominant negative mutant of MKK4 
(dnMKK4) decreases all aspects of hypertrophy in cardiomyocytes exposed to ET-1 or 
PE (Choukroun et al., 1998; de Windt et al., 2000), as well as cardiac hypertrophy  
induced in vivo by pressure-overload in rats (Choukroun et al., 1999).  
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Taken together, all the above data suggest that there is a strong link between activation of 
SAPKs and cardiac hypertrophy. However, the use of in vivo gain of function studies of 
JNK or p38-MAPK cascades in transgenic mice overexpressing activated forms of several 
components of these cascades does not produce compensated cardiac hypertrophy (in 
contrast to overexpression of components of the ERK1/2 cascade in the heart, see section 
1.3.1.6), but are usually associated with decompensated heart failure and myocardial 
fibrosis (see Table 1.1). Thus, transgenic mice with cardiospecific overexpression of 
either MKK3 or MKK6 present bilateral atrial enlargement and ventricular interstitial 
fibrosis without any significant increase in heart-weight to body-weight ratios (Liao et al., 
2001). Interestingly, the MKK3 transgenic mice exhibit myocyte atrophy rather than 
hypertrophy (Liao et al., 2001). Transgenic mice overexpressing MKK7 in the heart, also 
exhibit bilateral atrial enlargement with little or no ventricular enlargement. These 
transgenic animals also present with diastolic dysfunction, secondary to increased 
myocardial stiffness probably as a consequence of extracellular matrix remodelling (e.g. 
increased fibronectin deposition) (Petrich et al., 2002; 2003; 2004). These studies suggest 
that unregulated overexpression of upstream MKKs for both p38-MAPK and JNK 
cascades leads to restrictive cardiomyopathy in the absence of ventricular hypertrophy, 
which is opposite to the findings of most studies performed in cultured cardiomyocytes.  
 
Consistent with the above in vivo data, other studies using either gene-targeted mice or 
transgenic overexpression in the heart of dominant-negative proteins for one or more 
components of the SAPKs cascades have suggested that JNKs and p38-MAPKs may 
indeed have an antihypertrophic effect in the heart (Table 1.1). For instance, mice 
expressing dominant-negative mutants of p38-MAPKα (dn-p38-MAPKα), dnMKK3 or 
dnMKK6, under the control of the α-MHC promoter show selective reduction in p38-
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MAPK activity associated with progressive concentric hypertrophy at 2-4 months of age. 
After 8 months this progresses to lethal cardiomyopathy in most animals (Braz et al., 
2003). One mechanistic explanation of the hypertrophic response in these transgenic 
animals may be attributed to the increased activity of NFAT dependent transcription 
(Braz et al., 2003) (see section 1.3.2.3).  
 
Similarly, inhibition of the JNK cascade through inactivation of several components of 
this cascade has also revealed an antihypertrophic and cytoprotective role for this 
signalling cascade (Table 1.1). Thus, transgenic animals overexpressing dominant-
negative forms of JNK1 or JNK2 (dnJNK1 or dnJNK2) or knockout mice with targeted 
deletion of JNK1-/-, JNK2-/- or three allele JNK1+/-JNK2-/-, all exhibit selective 
reduction in JNK activity associated with increased cardiac hypertrophy following TAC 
(Liang et al., 2003). The morphological pattern found in these animals was consistent 
with marked eccentric hypertrophic growth (Liang et al., 2003). These data suggest that 
the JNK cascade probably antagonises adaptive cardiac hypertrophy in vivo. The 
increased hypertrophic response observed in these genetically-modified mice with 
reduced JNK activity is linked to increased activity of NFAT transcription factors, 
demonstrated in vitro as well as in vivo (see section 1.3.2.3). Consistent with this, 
concomitant targeting of the calcineurin Aβ gene, a regulator of the NFAT transcription 
factor (see section 1.3.2.3), abrogates the hypertrophic response observed in dnJNK1 and 
dnJNK2 transgenic animals (Liang et al., 2003).  
 
Collectively the data presented above are consistent with a complex role for the SAPKs in 
regulating cardiac hypertrophy with opposing results depending on the model studied. As 
stated earlier, this may represent the intrinsic complexity of the role of these MAPKs in 
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the regulation of the hypertrophic or even the apoptotic response in cardiomyocytes (see 
Table 1.1). The final event (hypertrophy vs buffering of hypertrophy or apoptosis vs 
cytoprotection) may ultimately depend on the signalling context and status of the 
cardiomyocyte at the time of application of a particular stimulus. 
 
1.3.2.3 Calcineurin/NFAT pathway in cardiac hypertrophy 
The Ca2+/calmodulin-activated protein Ser-/Thr-phosphatase calcineurin (also known as 
protein phosphatise 2B), represents an important signalling pathway in the development 
of cardiac hypertrophy and heart failure (Heineke and Molkentin, 2006). This signalling 
pathway and the consequences of its activation were initially described in the context of T 
cell activation, the classical system of study. Thus, T cell receptor engagement increases 
intracellular Ca2+ which binds to calmodulin, a Ca2+ sensor protein, and then the Ca2+-
calmodulin complex binds to and activates calcineurin (Crabtree and Olson, 2002; Gallo 
et al., 2006). Calcineurin is conserved from yeast to humans and is composed of three 
subunits: a catalytic A subunit (CnA) of aprox 57-61 kDa, bound to two small EF-hand 
calcium binding proteins, the regulatory subunit calcineurin B (CnB) and calmodulin 
(Klee et al., 1998). In mammals, three different genes encode three separate CnA 
isoforms (CnAα, CnAβ and CnAγ), of which CnAα and CnAβ are ubiquitously expressed 
whereas CnAγ is expressed only in testis and brain (Rusnak and Mertz, 2000; Molkentin, 
2000). Two genes encode two different isoforms of the regulatory subunit in mammals 
(CnB1 and CnB2), of which CnB1 is ubiquitously expressed in many tissues including 
the heart (Rusnak and Mertz, 2000; Molkentin, 2000). 
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Table 1.1. SAPKs cascades in the heart – studies of gain and/or loss of function. This 
table is limited to studies involving MAPKKKs, MAPKKs or MAPKs for JNK or p38-
MAPK cascades. Commonly-used transcriptional indices of hypertrophy are increased 
expression of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), skeletal 
muscle (SkM) α-actin and β-myosin heavy chain (β-MHC); reduced expression of α-
myosin heavy chain (α-MHC), sarcoplasmic (endoplasmic) reticulum Ca2+-ATPase 2 
(SERCA2) and possibly phospholamban (PLB). 
 
Target Gene Phenotype Reference 
JNK Cascade 
Conditional1 or 
inducible2 
expression of 
activated MKK7. 
Development of cardiomyopathy/congestive heart failure and premature death (~7 
w). Bilateral atrial but little or no ventricular enlargement. Ventricular 
extracellular matrix ‘remodelling’ with increased fibronectin deposition and 
increased ‘stiffness’. Ventricular gap junction ‘remodelling’ and slowed 
conduction. No increase in apoptosis. 
Petrich et al., 
2002, 2003, 
2004 
JNK1-/-, JNK2-/-, 
JNK3-/-, 
JNK1+/-/JNK2-/-. 
Inhibitory 
JNK1/JNK2. 
Reduction in JNK activity increases hypertrophy in the basal state or following 
TAC. Antagonised by targeted inactivation of calcineurin A gene. Reduction in 
JNK activity also protects against I/R damage and apoptosis, and promotes anti-
apoptotic phosphorylation of Bad. JNKs interact with the calcineurin-NFAT 
pathway to promote nuclear export of NFATs thus preventing hypertrophy. 
Liang et al., 
2003a 
Kaiser et al., 
2005 
MKK7-JNK1 
chimaeric gene. 
Activated 
MKK7. 
MKK7-JNK1 antagonises hypertrophy after expression of activated calcineurin. 
With activated MKK7, lethality before breeding age in the majority of lines. In 
one line: severe dilated cardiomyopathy at 5 w. One low copy number line: 4-5 
fold increase JNK activity with some evidence of ERK1/2 activation. Normal 
histological examination, slightly hyperdynamic/hypertrophied hearts. 
Paradoxical protection against I/R damage and myocyte apoptosis, with 
anomalous decrease in anti-apoptotic phosphorylation of Bad. 
Liang et al., 
2003a 
Kaiser et al., 
2005 
JNK1-/-, JNK2-/-, 
JNK3-/-. 
Hypertrophy following TAC same as wild-type, but JNK1-/- shows an early 
decrease in mechanical performance and an increase in apoptosis. Normalised at 
later stages. JNK1 protective in the initial stages of pressure-overload, preventing 
early deterioration. 
Tachibana et al., 
2006 
p38-MAPK Cascade 
Conditional1 
expression of 
activated MKK3 
or MKK6. 
Although producing a slightly different phenotype, each transgene resulted in 
early mortality (5-7 w) secondary to heart failure with systolic depression. 
Bilateral atrial enlargement and ventricular interstitial fibrosis without significant 
increase in Hwt/Bwt. Myocyte atrophy with MKK3 transgene. Hypertrophic 
pattern of gene expression. Therefore increased activity of p38 MAPK in the heart 
leads to cardiac remodelling and restrictive cardiomyopathy. 
Liao et al., 
2001 
Inhibitory p38-
MAPK, MKK3 
or MKK6. 
Enhanced increase in Hwt/Bwt at baseline or in response to AAB compared with 
wild-type. Late lethal cardiomyopathy with inhibitory p38-MAPK 
or MKK3 genotypes. Increased interstitial fibrosis and decreased fractional 
shortening. Increased NFAT-dependent transcription. Increased expression of 
ANF and BNP. Inhibitory p38-MAPK-induced hypertrophy and contractile 
dysfuction antagonised by targetted inactivation of calcineurin A gene. Protection 
against I/R damage including apoptosis. 
Braz et al., 
2003,  
Kaiser et al., 
2004 
Conditional1 
targetted 
inactivation of 
p38-MAPK. 
Normal heart structure and function. Increase in Hwt/Bwt after TAC identical to 
control. After TAC or infusion of isoproterenol, targetted inactivation was 
associated with LV systolic dysfunction, dilatation, myocardial fibrosis and 
increased apoptosis. After TAC, targetted inactivation also associated with 
increased JNK and MKK3/MKK6 phosphorylation with no change in ERK1/2 
phosphorylation. 
Nishida et al., 
2004 
Overexpression 
of MKK6. 
MKK6-overexpression increased resistance to I/R damage, and decreased 
apoptosis. Bcl-2 expression was increased. 
Martindale et 
al., 2005 
Notes: 1Conditional gene-targeted inactivation or expression is achieved by loxP site/Cre-mediated recombination with the floxed target 
gene and Cre expression controlled by a cardiac myocyte-specific, postnatally-expressed promoter (often the α-MHC promoter). 2A 
chimaeric gene in which the Cre coding region was ligated to a copy of the oestrogen-binding domain of the oestrogen receptor (mER) at 
both the 5' and the 3' ends was placed under the control of the α-MHC promoter (α-MHC-mER-Cre-mER). Expressed Cre is inactive until 
tamoxifen administration removes the inhibitory effect of mER. Abbreviations: AAB, banding of the abdominal aorta (to induce 
haemodynamic pressure-overload); ASK1, apoptosis signal-regulating kinase; Hwt/Bwt, heart weight/body weight ratio; I/R, 
ischemia/reperfusion; TAC, transverse aortic constriction (to induce haemodynamic pressure-overload). Adapted from Clerk et al. (2007). 
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In T lymphocytes the major biological responses to calcineurin involve activation of 
NFAT transcription factors, which are encoded by five genes (NFATc1-NFATc4 and 
NFAT5) producing multiple alternatively-spliced transcripts (Crabtree and Olson, 2002). 
In their phosphorylated form, NFAT transcription factors are retained in the cytoplasm 
possibly bound to 14-3-3 inhibitory proteins (Liao et al., 2005). Upon dephosphorylation 
by calcineurin, NFATs translocate to the nucleus with subsequent activation of 
transcriptional activity. In cardiomyocytes, a similar sequence of events has been 
proposed. Interestingly, in this system, the calcineurin/NFAT pathway represents a 
mechanism whereby changes in cytosolic Ca2+ concentrations can affect growth of the 
cardiomyocyte. In cardiomyocytes, ET-1 causes dephosphorylation of NFATc1 which 
translocates to the nucleus. This translocation is prevented by cyclosporine A, an 
immunosuppressant commonly used to implicate calcineurin in biological responses 
(Kawamura et al., 2004). Indeed, some aspects of the effects of ET-1 and PE on 
calcineurin-A gene transcription have also been identified (Oka et al., 2005).  
 
Most evidence implicating calcineurin/NFATs in cardiac hypertrophy derives from 
genetically-modified mice with overexpression of regulatory components of the pathway 
in the heart. Thus, transgenic mice overexpressing activated forms of calcineurin or 
NFATc4 in the heart results in a massive form of cardiac hypertrophy which frequently 
evolves to heart failure and death (Molkentin et al., 1998). However, cumulative evidence 
suggests that NFATc3 (rather than NFATc4, as was initially proposed) is an important 
mediator of the hypertrophic response (Molkentin et al., 1998; Wilkins et al., 2002; 
Wilkins and Molkentin, 2004). Thus, CnAβ or NFATc3 null mice, but not NFATc4 null 
mice, exhibit impaired hypertrophic responses following pressure-overload induced by 
abdominal aortic constriction, or following ANGII or isoproterenol infusion (Bueno et al., 
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2002; Wilkins et al., 2002). The general view with respect to the role of the 
calcineurin/NFAT signalling cascade in cardiac hypertrophy is that activation of 
calcineurin in the heart is associated with the development of cardiac hypertrophy which 
ultimately progresses to decompensated heart failure (Wilkins and Molkentin, 2004). 
 
 
1.3.2 Signal transduction pathways activated by peptide growth factors in 
cardiomyocytes 
The hypertrophic response of cardiomyocytes has been studied mostly using GqPCR 
agonists. However, cardiomyocytes also respond to peptide growth factors which activate 
RPTKs, although there are differences in their relative potency for the activation of the 
pathways involved in cellular growth in many cell systems including cardiomyocytes. For 
the purpose of this overview, the model described will be the activation of the EGFR and 
downstream signalling cascades by the peptide growth factor EGF. The differences in the 
relative degree of activation of the ERK1/2 and PKB/Akt pathway in cardiomyocytes by 
several peptide growth factors and their contribution to cardiomyocyte hypertrophy will 
also be discussed. 
 
1.3.2.1 Activation of the ERK1/2 cascade by peptide growth factors 
The general mechanisms of activation of signalling pathways by the EGFR and other 
RPTKs upon binding by their cognate ligands were elucidated during the 1990s (for 
reviews see Schlessinger, 2000; Dreux et al., 2006; Iwamoto and Mekada, 2006). With 
the exception of the insulin receptors, all other RPTKs (i.e EGFR, FGFR) remain as 
inactive monomers in the cell membrane, and form dimers upon stimulation by the 
agonists. There are four EGF receptors, known as ErbB1 (EGFR), ErbB2, ErbB3 and 
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ErbB4. However, only ErbB1 (the archetypical EGFR) and ErbB4 possesses both ligand-
binding and tyrosine-kinase activity. In addition to EGF, other EGF-related peptides also 
bind to the EGFR, including transforming growth factor-α (TGF-α), heparin-binding 
EGF-like growth factor (HB-EGF), epiregulin (Ereg), amphiregulin and betacellulin. 
 
Upon binding of EGF to the EGFR, there is homo- or heterodimerization of the receptor 
(e.g. ErbB1 dimerization), thus inducing a conformational change in the receptor resulting 
in autophosphorylation of the intracellular tyrosine-residues secondary to activation of the 
tyrosine-kinase domains of the receptor. These tyrosine autophosphorylations occur in 
regions of the receptor devoid of catalytic activity. These sites function as binding sites 
for a variety of signalling proteins containing SH2 (Src homology 2) domains or PTB 
(phosphotyrosine binding) domains, including adaptor proteins such as Grb2 and Shc. In 
particular, Grb2 links a variety of cell surface receptors to the Ras/ERK1/2 signalling 
cascade. Thus, Grb2 interacts with the dimerized and activated ErbB1 receptor via its 
SH2 domain and through its SH3 domain recognizes proline-rich sequences in the Ras 
GEF, Sos. This places Sos at the plasma membrane where it activates Ras (Pawson, 1995; 
Schlessinger, 2000) (Figure 1.4). The ERK1/2 cascade is then activated as described in 
section 1.3.1.5. The ERK1/2 cascade is maximally activated within 5-10 minutes by EGF 
through Ras/Raf and a similar sequence of events also occurs with FGF (Clerk et al., 
2006). However, despite PDGF causes a similar activation of this cascade, PDGF uses an 
alternative pathway requiring tyrosine phosphorylation of PLC-γ1 and subsequent 
activation of DAG-dependent nPKCδ (as evidenced by Tyr- phosphorylation) (Clerk et 
al., 2006). Although insulin and IGF-1 also activate the ERK1/2 pathway, in 
cardiomyocytes this is significantly less than that for GqPCR agonists and that for EGF, 
FGF and PDGF (Clerk et al., 2006). 
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Figure 1.4 EGFR-mediated activation of the ERK1/2 pathway. Upon stimulation with 
EGF, the EGFR (ErbB1) heterodimerizes and is autophosphorylated on Tyr-residues in 
the intracellular domains. This allows the binding of adaptor proteins (Shc and Grb2) 
through their Src homology 2 (SH2) domains. The Grb2 SH3 domain binds to son of 
sevenles (Sos), thus positioning this guanine exchange factor (GEF) in the membrane 
where it activates Ras, and the cascade of events that culminates in the activation of 
ERK1/2. 
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 The transactivation of RPTKs by GqPCRs has also been demonstrated in several systems 
including cardiomyocytes. For ANGII the mechanism appears to involve the direct 
transactivation of EGFRs by several residues that have been mapped to the C-terminal 
domain of AT1 receptors with the Tyr-319 in the motif Tyr-Ile-Pro-Pro (YIPP) critical for 
this transactivation mechanism (Seta and Sadoshima, 2003). In support of a role for this 
mechanism of EGFR transactivation in pathological hypertrophy, transgenic mice with 
cardiac overexpression of a mutant form of the receptor Tyr-319-Phe (Y319F) in the 
YIPP motif (Tg-Y319F), which is devoid of EGFR transactivating activity, or 
overexpression of wild-type AT1 receptors (Tg-WT) were compared. The Tg-WT 
presented with significant cardiac hypertrophy compared with Tg-Y319F, which was 
enhanced by ANGII infusion (Zhai et al., 2006). Upon infusion of ANGII, Tg-Y319F 
developed significantly less apoptosis and fibrosis than Tg-WT animals. 
 
1.3.2.2 Activation of the PKB/Akt signalling pathway by peptide growth factors 
The initial steps in the activation of the PKB/Akt pathway by growth factors proceed in a 
similar manner as described above, upon stimulation with EGF, there is formation of 
receptor dimers and autophosphorylation of the ErbB1 receptor. This promotes the 
recruitment of the p110α catalytic subunit of phosphatidylinositol 3’-kinase (PI3K) to the 
cell membrane, which is triggered by the interaction of SH2 domains of PI3K p85 subunit 
(the regulatory subunit of PI3K) with tyrosine phosphorylated residues of the active 
ErbB1 receptor. This is followed by the release of an autoinhibitory constraint on p110α 
activating its catalytic activity (Figure 1.5) (Schlessinger, 2000). PI3K is a lipid kinase 
that initiates cell signalling by phosphorylating the hydroxyl group at position 3 in 
membrane phosphoinositides. Thus, phosphorylation of phosphatidylinositol 4,5 bis 
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phosphate (PtdInsP2) produces phosphatidylinositol 3,4,5 tris phosphate (PtdInsP3). 
Accumulating PtdInsP3 in the membrane leads to recruitment of PDK1 (3-
phosphoinositide-dependent protein kinase-1) and PKB/Akt triggering the activation of 
PDK1 which phosphorylates and activates PKB/Akt (Figure 1.5) (Vanhaesebroeck and 
Alessi, 2000). 
 
Downstream effectors of PKB/Akt include glycogen synthase kinase 3 (GSK3α, GSK3β). 
Phosphorylation of an N-terminal residue of GSK3α (Ser-21) or GSK3β (Ser-9) by 
insulin inhibits their activity (Cross et al., 1995). Interestingly, other kinases also 
phosphorylate these sites including PKA (cAMP-dependent protein kinase) and the 90-
kDa ribosomal protein S6 kinases (p90RSKs) (Cohen and Frame, 2001; Frame and 
Cohen, 2001). Thus, GSK3 appears to be at a convergence point for several signalling 
pathways. Several potential targets of GSK3 have been described including a number of 
transcription factors. Thus, phosphorylation of c-Jun by GSK3 mainly at Ser-243 
(although Thr-239 and Ser-249 are also phosphorylated by this enzyme), inhibits its 
DNA-binding and transactivating activity (Boyle et al., 1991; Nikolakaki et al., 1993). 
Similarly, phosphorylation of NFAT transcription factors within their NFAT homology 
domain inhibits their DNA-binding activity and results in their nuclear export (Beals et 
al., 1997; Neal and Clipstone, 2001). In the active (unphosphorylated) state GSK3α/β 
inhibits hypertrophy (reviewed in Kerkela et al., 2006). 
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Figure 1.5 Activation of the PKB/Akt pathway by growth factors. Upon activation of 
the EGFR (ErbB1) by EGF, there is induction of receptor dimerization and 
autophosphorylation. This triggers the recruitment of PI3K (p110α catalytic subunit) to 
the membrane by the regulatory subunit (p85). Activation of PI3K occurs as a result of 
removal of an autoinhibitory constraint. PI3K then catalyses the formation of 
phosphatidylinositol 3,4,5 tris phosphate (PtdInsP3) by phosphorylation of 
phosphatidylinositol 4,5 bis phosphate (PtdInsP2). Accumulating PtdInsP3 in the 
membrane leads to recruitment of the 3-phosphoinositide-dependent protein kinase-1 
(PDK1) and PKB/Akt to the membrane, where activated PDK1 phosphorylates and 
activates PKB/Akt. Activation of PKB/Akt leads to phosphorylation and inactivation of 
glycogen synthase kinase 3 (GSK3α/β), which may phosphorylate and inactivate of 
transcription factors (e.g. NFAT). PKB also promotes inhibition of tuberous sclerosis 
complex proteins (TSC1/2), GTPase-activating proteins for the small G protein Rheb. 
This promotes increased activity of Rheb·GTP and subsequent activation of mammalian 
target of rapamycin complex 1 (mTORC1). This complex, containing mTOR, mLST8 and 
Raptor, is sensitive to the antifungal macrolide rapamycin. Activation of mTORC1, 
promotes ribosome biogenesis by phosphorylation and inactivation of 4EBP and 
phosphorylation of S6K1, thus increasing the rate of protein synthesis. 
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Consistent with the above, inhibition of GSK3 by ET-1 promotes nuclear accumulation of 
NFAT transcription factors, which then stimulates cardiac hypertrophy (Haq et al., 2000). 
It has been suggested that this hypertrophic response is mediated, at least in part, by a 
PI3K-independent kinase. In support of this, activation of the PI3K/Akt pathway by 
GqPCR agonists like ET-1 is relatively minor compared with the classical regulators of 
the pathway insulin and IGF-1 (Clerk et al., 2006). In addition, as mentioned above, other 
kinases activated by ET-1 via ERK1/2, such as p90RSKs (Frödin and Gammeloft, 1999), 
promote phosphorylation of GSK3α/β, suggesting the existence of a PKB/Akt-
independent route to GSK3 phosphorylation in cardiomyocytes. Interestingly, inhibition 
of GSK3 with the small molecule inhibitor 1-azakenpaullone does indeed causes 
hypertrophic growth in cardiomyocytes. However, this growth response is characterized 
by increased cell length (elongation) which is accompanied by increased binding of JunB 
(a member of the AP-1 family of transcription factors, see section 1.5) to the AP-1 
consensus binding sequence as demonstrated by electrophoretic mobility shift assay 
(EMSA) (Markou et al., 2008). Comparatively, ET-1 promotes more marked AP-1 
transcription factor binding to the AP-1 consensus than 1-azakenpaullone, and PE induces 
hypertrophic growth of cardiomyocytes by increasing cell size in both length and width 
(as is observed in concentric hypertrophy following pressure-overload, see section 1.1). In 
addition, ET-1 causes significantly less phosphorylation of GSK3 compared with insulin. 
Therefore, although GSK3 may contribute to some aspects of cardiomyocyte 
hypertrophy, it does not seem to contribute significantly to this response following ET-1-
stimulation of cardiomyocytes (Markou et al., 2008). 
 
In other cell systems, activation of PKB/Akt is associated with increased protein synthesis 
and cytoprotection (Vanhaesebroeck and Alessi, 2000). The cytoprotective effects of this 
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pathway result from phosphorylation of proteins involved in the apoptotic process such as 
the pro-apoptotic Bcl-2 family member Bad (at Ser-136), which results in its inactivation, 
thus preventing apoptosis (Datta et al., 1997; Peso et al., 1997). Also associated with 
cytoprotection are the changes in gene expression mediated by Forkhead box, group O 
(FoxO, or FOXO) transcription factors, which are involved in the transcriptional 
regulation of Fas ligand and other apoptotic proteins. The FoxO transcription factors are 
located to the nucleus upon proapoptotic stimulation, and their phosphorylation by 
activated PKB/Akt (e.g. by growth factors) causes their translocation to the cytoplasm, 
thus preventing apoptosis (Sen et al., 2003). 
 
The effects on protein synthesis are mediated by changes in the activities of existing 
translation factors and the regulation of ribosome biogenesis. In other cell systems, 
PKB/Akt associates with mammalian target of rapamycin (mTOR) in different complexes 
(reviewed in Bhaskar and Hay, 2007). mTOR complex 1 (mTORC1), which is sensitive 
to the antifungal macrolide, rapamycin, is a complex containing mTOR, mLST8 and 
Raptor (Figure 1.5). In mTORC1, mTOR is activated downstream of PKB/Akt and 
appears to be involved in protein synthesis by phosphorylation and inactivation of eIF4E 
binding protein 4EBP, and phosphorylation of S6K1, thus promoting ribosome biogenesis 
and increased protein synthesis (see Figure 1.5). Whether or not this process also occur in 
the heart remains to be determined.  
 
In cardiomyocytes, EGF, PDGF and IGF-1 induce potent activation of PKB/Akt, which is 
maximal at 5-10 minutes (Clerk et al., 2006). Direct comparison of agonists demonstrates 
that insulin promotes the most potent activation of PKB/Akt compared with that of 
PDGF, EGF, FGF and even IGF-1. In contrast, ET-1 promotes minimal activation of 
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PKB/Akt, with PMA resulting in no measurable effect (Pham et al., 2000; Clerk et al., 
2006). Consistent with the studies in cardiomyocytes, in whole hearts, potent activation of 
PKB/Akt by insulin has also been reported (Huisamen et al., 2001) and a similar response 
is also observed in mice with cardiac overexpression of IGF-1 (Li et al., 1997; Yamashita 
et al., 2001). Inhibition of the pathway in cardiomyocytes can be achieved with selective 
inhibitors of PI3K such as wortmannin and LY294002. These promote reduced 
hypertrophy of cardiomyocytes with a reduction in the basal rate of protein synthesis and 
that induced by insulin (Schülter et al., 1998; Pham et al., 2000). Also, genetic 
manipulation of the PKB/Akt pathway in vitro and in vivo suggests that activation of 
PKB/Akt promotes cardiomyocyte survival (reviewed in Matsui and Rosenzweig, 2005 
and Heineke and Molkentin, 2006). Although it has been suggested that the PKB/Akt 
pathway is involved in cardiac hypertrophy, the hypertrophic effect of insulin (the most 
potent activator of the pathway in cardiomyocytes, see above) is minimal compared with 
that of ET-1. ET-1, in contrast has a minimal effect on the activation of the PKB/Akt 
pathway, despite potent induction of cardiomyocyte hypertrophy (Clerk et al., 2006). 
  
Overall, it is possible that the PKB/Akt pathway is an important regulator of 
cardiomyocyte postnatal maturational growth, as a general growth mechanism, coupling 
insulin levels to nutritional status. It may also be important in the regulation of cardiac 
hypertrophy in response to exercise training in athletes, so-called “physiological 
hypertrophy”. Thus, in genetically-modified mice, cardiac overexpression of 
constitutively-activated p110α PI3K, causes cardiac hypertrophy, associated with 
resistance to apoptosis (Shioi, et al., 2000). The opposite is seen with overexpression in 
the heart of a dominant-negative form of p110α PI3K, in which the hypertrophic response 
to exercise is blunted whereas a normal hypertrophic response is still observed in 
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response to pressure-overload (McMullen et al., 2003). This is in accord with previous 
observations that IGF-1 is the direct mediator of growth hormone actions. Thus, upon 
growth hormone release, there is increased secretion of IGF-1 (formerly known as 
somatomedin-1), which then acts on growing cells by increasing anabolic functions such 
as protein synthesis, and promoting cell division (Christoforidis et al., 2005). Mice 
harbouring an Akt1 knockout exhibit a general reduction in the size, with reduced size of 
all organs including the heart, despite an otherwise normal phenotype (Cho et al. 2001). 
Taken together, the overall conclusion is that PKB/Akt pathway may play an important 
role in myocyte general growth and survival (Heineke and Molekentin, 2006). However, 
despite a probable important role for this pathway in cardiac postnatal eutrophy and 
physiological cardiac hypertrophy, the current evidence in favour of a role for the 
PKB/Akt pathway in cardiac hypertrophy in response to haemodynamic overloading is 
not yet conclusive. 
 
1.3.3 Signalling pathways activated by gp130 cytokines 
Members of the IL-6 family of cytokines which, for the purpose of clarity in this 
discussion will be collectively referred to as gp130 cytokines, include CT-1, IL-6, LIF, 
oncostatin M, interleukin-11, and ciliary neurotrophic factor. Since its discovery, CT-1 
has been shown to induce myocyte elongation by directing sarcomeric assembly in series, 
and these observations have been extended to other members of the gp130 cytokines 
(Wollert et al., 1996). Therefore, since the discovery of CT-1, this and other members of 
this family of cytokines have been postulated as probable mediators of eccentric 
hypertrophy and more importantly the dilatation of the heart observed in the progression 
to heart failure, assuming that the circumferential arrangement of cardiomyocytes in the 
heart translates myocyte elongation into ventricular cavity dilatation (see section 1.1) 
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(Wollert et al., 1996, Hunter and Chien, 1999). The most studied members of this family 
are CT-1, LIF and IL-6, and the relative order of potency for induction of the 
hypertrophic response is CT-1 ≥ LIF  > IL-6 (Pennica et al., 1996; Wollert et al., 1996). 
The receptors for this family are multimeric and share the transducing receptor chain 
gp130 (also known as CD130) (Bravo and Heath, 2000). Intracellular signalling is 
activated by inducing homodimerization of gp130 (Murakami et al., 1993) or 
heterodimerization of gp130 with a related transmembrane protein, the LIF receptor β 
subunit (LIFRβ) (Gearing et al., 1991, reviewed in Müller-Newen, 2003). Thus, LIF or 
CT-1 signal through gp130/LIFRβ heterodimers (Gearing et al., 1991, Wollert et al., 
1996). Interestingly, IL-6 requires an additional receptor, the IL-6 receptor α subunit (IL-
6Rα), and the formation of the IL-6/IL-6Rα complex then triggers dimerization of gp130 
thus forming a heterotrimeric receptor complex for activation of signal transduction (Taga 
et al., 1989, reviewed in Henrich et al., 2003).  
 
The gp130/LIFβ or IL-6Rα/gp130 activate a diverse array of signalling cascades, 
including the Janus kinase (JAK)/STAT (Signal transducer and activator of transcription) 
pathway, the PKB/Akt pathway, and the ERK1/2 and ERK5 MAPK signalling cascades 
(Figure 1.6). Whereas all other cascades activated by these agonists are probably involved 
in resistance to cell stress and survival (reviewed in Hilfiker-Kleiner et al., 2006), ERK5 
seems to be responsible for the hypertrophic response involving elongation of 
cardiomyocytes observed with these agonists (Nicol et al., 2001; Takahashi et al., 2005). 
The adapter protein Gab1, a member of the Grb2-associated binder (Gab) family, contains 
a N-terminal pleckstrin homology (PH) domain, and several conserved tyrosine residues 
that are targets of tyrosine kinases and binding sites for SH2 and SH3 domains (reviewed 
in Nishida et al., 2003 and Sármay et el., 2006). Recently it was demonstrated that Gab1 
 70
phosphorylation and SHP2 (SH2 domain-containing protein tyrosine phosphatase) 
binding are required for LIF-induced activation of the ERK5 cascade in cardiomyocytes, 
which ultimately leads to increased sarcomeric organization in series (myocyte 
elongation) associated with selective marker gene regulation (Nakaoka et al., 2003) 
(Figure 1.6). 
 
The N-terminal domain of ERK5 which contains the kinase domain and the activation 
loop is homologous to that of ERK1/2 (Nishimoto and Nishida, 2006). As with other 
MAPKs, the activation of ERK5 requires upstream MKKs and MKKKs. Thus, MKKK2 
or MKKK3 activates the dual-specificity kinase MKK5, which in turn phosphorylates and 
activates ERK5 (Figure 1.3) (Chao et al., 1999; Sun et al., 2001). In support of a major 
role for the ERK5 cascade in promoting an elongated phenotype in cardiomyocytes, 
overexpression of constitutively-active MKK5 elicits serial assembly of sarcomeres, 
whereas a dominant-negative form of MKK5 blocks LIF-induced elongation of 
cardiomyocytes (Nicol et al., 2001). Consistent with the in vitro effects of the ERK5 
cascade, cardiac overexpression of constitutively-activated MKK5 in transgenic mice 
results in eccentric hypertrophy, heart failure and sudden death (Nicol et al., 2001). 
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Figure 1.6 Signalling cascades activated by cardiotrophin-1. Upon stimulation of 
cardiomyocytes with CT-1, there is induction of heterodimerization of gp130 (shown in 
yellow) and the LIFRβ (shown in green). This leads to binding of SHP2 and Gab1. The 
mechanistic details are not yet clear, but there is subsequent activation of upstream 
MKKKs (possibly MKKK2/3), and subsequent activation of the dual-specificity MKK5 
which then activates ERK5. Activation of the MKK5/ERK5 pathway is associated with 
myocyte elongation. Other pathways also appear to be activated by the gp130/LIFRβ 
heterodimer upon CT-1 stimulation, including the ERK1/2 pathway, JAK/STAT 
signalling and the PKB/Akt pathway. All of these other pathways activated by CT-1 (and 
other members of the gp130 cytokines) are associated with increased myocyte survival. 
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 Although initial studies suggested that the JAK/STAT3 pathway could also be involved in 
the hypertrophic response to these agonists, this is not supported by a recent study which 
systematically assessed different components of the cascades activated by the gp130 
receptor signalling system (Takahashi et al., 2005). Whereas overexpression of suppressor 
of cytokine signalling (SOCS) 1 or 3, endogenous inhibitors of the JAK/STAT cascade, 
inhibit elongation of cardiomyocytes secondary to CT-1 stimulation, overexpression of a 
dominant-negative STAT3 mutant (STAT3F) does not prevent the elongation in this 
setting, despite a reduction in STAT3 phosphorylation. This suggests that another 
pathway apart from STAT3 is involved in elongation of myocytes following CT-1 
exposure. In this same study, dominant-negative MKK1 only inhibited the hypertrophic 
response of cardiomyocytes in response to ET-1, whereas overexpression of dominant-
negative MKK5 completely abrogated cardiomyocyte elongation in response to CT-1, 
thus clearly demonstrating that the ERK5 cascade is responsible for the hypertrophic 
phenotype observed with CT-1 (Takahashi et al., 2005).  
 
Importantly, myocardial expression of CT-1 and LIF is augmented in animal models of 
heart failure (Aoyama et al., 2000; Jougasaki et al., 2003) and in explanted hearts from 
patients with chronic heart failure (Zolk et al., 2002). However, in the study of Zolk et al. 
(2002), the protein levels of gp130 were decreased, with a concomitant increase in gp130 
transcript levels, indicative of augmented gp130 protein turnover, potentially a 
consequence of adaptive desensitization and degradation with concomitant reduced 
protein synthesis (Zolk et al., 2002). Consistent with tissue levels, circulating levels of 
CT-1 are increased in patients with dilated cardiomyopathy (Tsutamoto et al., 2001), and 
IL-6 and CT-1 circulating levels have been proposed to be important prognostic markers 
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of death and/or heart failure in patients following myocardial infarction (Takahashi et al., 
2003; Fisman et al., 2006). Thus, accumulating evidence implicates gp130 cytokines and 
the activation of the ERK5 cascade by these agonists in eccentric hypertrophy of the heart 
which may be responsible for progression to heart failure. 
 
 
1.4 Oxidative stress and ventricular remodelling 
 Cardiomyocytes have very limited capacity for regeneration which renders the heart 
particularly vulnerable to damage induced by, for example, oxidative stress. Cells may die 
by necrosis and/or apoptosis, secondary to increased production of reactive oxygen 
species (ROS). ROS production in the heart occurs during ischaemia alone (Ambrosio et 
al., 1993; Becker et al., 1999), and this is exacerbated by reperfusion (Ambrosio et al., 
1993; Du et al., 1998). Even in non-ischemic cardiomyopathy, the increased muscle mass 
of cardiac hypertrophy (or intrinsic abnormalities during diastole in the pacing-induced 
heart failure model) renders the heart vulnerable to ischaemia because of reduced 
coronary reserve, and this is particularly important in the subendocardium due to 
increased wall stress (Vatner et al., 1990; Vatner et al., 1993; Helmer et al., 1996). ROS 
production is also implicated in several non-acute processes, whereby increased 
production of ROS by the mitochondria or outside the mitochondria by enzymes like 
NAD(P)H oxidase and xanthine oxidase, appear to be involved in the development of 
cardiac hypertrophy and LV remodelling.   
 
 
 
 74
1.4.1 Sources and types of ROS 
Several potential sources of ROS in the heart have been identified, including the 
mitochondria, xanthine oxidases (XO), uncoupled NO synthases, NAD(P)H oxidases 
(NOX), and infiltrating inflammatory cells. Of note, NOX enzymes appear to be 
particularly important for redox signalling in the heart and are implicated in processes 
such as hypertrophy in response to pressure-overload and LV remodelling post MI. 
 
1.4.1.1 Mitochondria 
Under normal conditions, up to 1-2% of the mitochondrial O2 uptake leads to ROS 
production (Turrens, 1997; Gnaiger and Kuznetsov, 2002) and, as mentioned before, this 
rate increases during ischaemia and ischaemia/reperfusion (Ambrosio et al., 1993; Du et 
al., 1998; Becker et al., 1999). These conditions are of high impact to the heart given that 
up to 40% of the cytoplasmic volume of the cardiomyocyte is occupied by mitochondria 
(Barth et al., 1992; Ayettey et al., 1993). Molecular O2 contains two unpaired electrons on 
its outermost shell, and is highly reactive. As a consequence, O2 tends to initiate chain 
reactions that result in several types of ROS production which may induce irreversible 
chemical changes in lipids or proteins and therefore cellular damage. 
 
 During metabolism, superoxide anion radicals (O2˙¯) are a by product of normal 
respiration through the one-electron reduction of O2 (Davies 1995; Raha and Robinson, 
2000; Genova et al., 2003). Complete reduction of oxygen to water (H2O), the final event 
in the electron transport chain requires donation of three more electrons after the 
formation of superoxide. Superoxide is rapidly metabolized in the mitochondria by the 
enzyme manganese superoxide dismutase (Mn2+-SOD) and in the cytosol by Cu2+/Zn2+--
SOD to form hydrogen peroxide (H2O2), a less potent but more stable oxidizing agent 
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(Kinnula and Capro, 2004). H2O2 is usually removed by the actions of catalase, 
glutathione peroxidase, and peroxiredoxin (Nohl and Jordan, 1980; Halliwell, 1989; 
Schroder and Ponting, 1998). However, in pathological circumstances in the presence of 
cuprous or ferrous ions, H2O2 forms the highly reactive hydroxyl radical (·OH), a process 
that could be facilitated by the release of ferrous iron from the iron-sulphur cluster 
[Fe4S4]2+ containing enzyme aconitase when damaged by O2˙¯ (Vasquez-Vivar et al., 
2000). 
 
Evidence indicating that mitochondria are an important source of ROS production is 
derived from experiments in which efflux of H2O2 is observed in intact mitochondria as 
well as from perfused organs, suggesting that mitochondria produce O2˙¯ in vivo which 
then is reduced to H2O2 (Chance et al., 1979). O2˙¯ production by mitochondria has been 
attributed to mitochondrial complexes I and III (Raha and Robinson, 2000; St-Pierre et 
al., 2002; Ide et al., 1999). Increased production of ROS occurs in cardiomyocytes 
derived from animal models of pacing-induced heart failure and in heart failure secondary 
to MI in mice (Ide et al., 1999; Ide et al., 2000; Ide et al., 2001). The mitochondria are 
also a source of ROS (through mitochondrial complex III) in cardiomyocytes exposed to 
TNFα, and this leads to mitochondrial dysfunction and mitochondrial DNA damage. This 
suggests that one of the probable pathologic effects of TNFα during ventricular 
remodelling is derived, at least in part, from induction of ROS production and secondary 
mitochondrial dysfunction (Suematsu et al., 2003). Of note, H2O2 is implicated as the 
signalling molecule responsible for apoptotic killing of cells in culture exposed to TNFα 
(Pletjuskina et al., 2005). 
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Although, under normal physiological conditions, the production of ROS by the 
mitochondria is relatively low (Boveris et al., 1972), a phenomenon of ROS-induced ROS 
release (RIRR) has been described, whereby mitochondria respond to increased 
concentrations of ROS (either exogenous or endogenous) by increasing their own ROS 
production (Nieminen et al., 1997; Zorov et al., 2000; Leach et al., 2002). In the 
mitochondria, at least two different mechanisms are involved in RIRR, one of them 
involves the activation of the mitochondrial permeability transition pore (MPTP), and the 
second mechanism involves opening of the inner mitochondrial anion channel (IMAC) 
(reviewed in Zorov et al., 2006). The MPTP is a non-specific pore that spans both 
membranes of the mitochondria and contains the voltage dependent anion channel 
(VDAC, also known as porin) in the outer membrane, the adenine nucleotide translocase 
(ANT) in the inner membrane, and cyclophilin D in the matrix, with probably also the 
peripheral benzodiazepine receptor (PBR), which appears to be in close contact with the 
VDAC in the outer membrane (Halestrap et al., 2002; Crompton et al., 2002; Galiegue et 
al., 2003). RIRR through the MPTP leads to an increased burst of ROS production from 
the electron transport chain, a mechanism which may be involved in the regulation of 
apoptotic and preconditioning pathways in cardiomyocytes (Shanmuganathan et al., 2005; 
Davidson et al., 2006). In the second mechanism of RIRR, the opening of the IMAC 
channel secondary to elevated ROS concentrations also results in an increased transient 
burst of ROS derived from the electron transport chain. This latter mechanism may be 
involved in triggering postischaemic arrhythmias (Akar et al., 2005).  
 
Most ROS species like O2˙¯ and ·OH possesses limited diffusion capabilities probably 
because they are short-lived, so their actions are limited to a short period of time and are 
confined in space. In contrast, H2O2 is a more stable and diffusible form of ROS. Of note, 
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H2O2 could be the key signalling mediator of apoptosis signal propagation in 
cardiomyocytes through amplification of the response in waves of activation from 
mitochondrion to mitochondrion via MPTP-mediated RIRR (Lakatta and Sollot, 2002). 
As mentioned earlier, probably because of its more rapid diffusion, H2O2 has been 
implicated as the signalling molecule responsible for long distance apoptotic killing of 
cells in culture exposed to TNFα (Pletjuskina et al., 2005).  
 
Exposure to increasing concentrations of H2O2 has different effects in cardiomyocytes. 
Thus, high concentrations of H2O2 (> 0.5 mM) cause necrotic cell death (Kwon et al., 
2003), whereas intermediate concentrations (0.1 – 0.5 mM) promote an apoptotic 
phenotype (Cook et al., 1999; Kang et al., 2000). In contrast, low concentrations of H2O2 
(≤0.04 mM) are non-toxic and, interestingly, may be hypertrophic and/or cytoprotective 
in cardiomyocytes (Kwon et al., 2003). Therefore, H2O2 constitutes a physiologically 
relevant example of oxidative stress that is readily manipulatable in experimental settings.  
 
1.4.1.2 Xanthine oxidases 
The enzyme xanthine oxidoreductase (XOR) is encoded by a single gene, but the protein 
exists as a homodimer in two interconvertible forms, xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO) (Stirpe and la Conte, 1969). These two forms differ in that XO 
reduces only oxygen, whereas XDH can also reduce, with higher affinity, NAD+ (Waud 
and Rajagopalan, 1976). Both forms of XOR are reduced during the process of uric acid 
synthesis from xanthine. The reoxidation process of fully reduced XOR is then carried out 
in 4 sequential steps. During the first two steps, two electrons are transferred to O2 
molecules, thus generating H2O2 (Olson et al., 1974). In the final two steps, the remaining 
two electrons are transferred separately to O2 molecules to generate O2˙¯. Therefore 
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during each cycle this enzyme generates two molecules of H2O2 and two molecules of 
O2˙¯ (Hille and Massey, 1981). Recent evidence suggest that XOR is expressed at low 
levels in cardiomyocytes (Cappola et al., 2001), and is probably localized to the 
sarcoplasmic reticulum (Khan et al., 2004). Elevation of XOR expression and activity has 
been documented in end-stage human heart failure and in a canine model of pacing-
induced heart failure (Cappola et al., 2001; Ukai et al., 2001). Of note, treatment with the 
XO inhibitor, allopurinol, improves contractility and decreases myocardial oxygen 
consumption in pacing-induced heart failure in dogs (Ekelund et al., 1999; Ukai et al., 
2001). 
  
There is also evidence that allopurinol significantly reduces LV remodelling secondary to 
experimental MI in mice (Engberding et al., 2004), further supporting a role of increased 
XO activity in cardiac pathologies. Of note, in a model of pressure-overload induced 
hypertrophy in rats, the increased XO activity is only detected as congestive heart failure 
develops, and not during compensated hypertrophy (de Jong et al., 2000). This suggests 
that, in ventricular remodelling secondary to pressure-overload, the activity of XO is 
more important at the advanced stages and may play a role in the transition to heart 
failure (de Jong et al., 2000). Recently, in a model of spontaneously hypertensive rats 
with established heart failure, treatment with the XO inhibitor oxypurinol for 4 weeks 
decreased XO activity and superoxide production, all of which correlated with beneficial 
effects from the treatment as evidenced by reverse remodelling of the left ventricles 
(Minhas et al., 2006).  
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1.4.1.3 NAD(P)H oxidases 
The membrane-associated NOX enzymes are a major source of ROS in the cardiovascular 
system. Each enzyme contains a catalytic subunit termed Nox, of which five isoforms 
have been described (Nox1-5) encoded by separate genes (Lambeth, 2004). Each Nox 
subunit forms a heterodimer with the p22phox subunit, constituting the heterodimeric 
catalytic core (or cytochrome b558) where electron transfer from NAD(P)H to molecular 
O2 results in the formation of O2˙¯. Of note, whereas Nox1 and Nox2 clearly require the 
association of additional cytosolic regulatory subunits (p47phox, p67phox, p40phox and Rac1) 
to activate O2˙¯ production, Nox4 does not require these (Ambasta et al., 2004; Martyn et 
al., 2006). The tissue distribution of different Nox isoforms varies considerably. Thus, 
Nox1 is more abundantly expressed in vascular smooth muscle cells (Griendling et al., 
2000), whereas Nox2 and Nox4 are abundantly expressed in cardiomyocytes (Li et al., 
2002; Xiao et al., 2002), and endothelial cells (Li et al., 2004). In fibroblasts, the 
expression of Nox2, Nox4 (Colston et al., 2005) and Nox5 (Cucoranu et al., 2005) has 
been described. 
 
Although during development of cardiomyocytes, Nox4 is the predominant isoform with 
a role in cardiac differentiation (Li et al., 2006), in the adult heart the predominant 
isoform is Nox2. Nox2 is implicated in the regulation of redox-sensitive signalling 
pathways including the modulation of kinase and phosphatase activities (Sabri et al., 
2003), gene expression (Wenzel et al., 2001), and ANGII induced superoxide-dependent 
inactivation of nitric oxide (Kinugawa et al., 2005). Accumulating evidence indicates that 
NOX enzymes play an important role in cardiac hypertrophy, ventricular remodelling and 
heart failure. In pressure-overload-induced left ventricular hypertrophy, the expression 
and activity of Nox2 are increased in cardiomyocytes and endothelial cells (Li et al., 
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2002). In humans, the expression of Nox2 in cardiomyocytes is increased after 
myocardial infarction (Krijnen et al., 2003), and in end-stage heart failure (Heymes et al., 
2003). Recently, Nox2 knockout mice (Nox2 -/-) have provided important information 
regarding the role of Nox2 in cardiac hypertrophy and remodelling. Nox2 -/- animals 
exhibit a blunted hypertrophic response to subpressor doses of ANGII infused over 7 to 
14 days, which parallels reduced activation of NOX activity, ANP expression, and 
reduced myocardial fibrosis compared with wild-type controls (Bendall et al., 2002).  
 
Despite an important role for Nox2 in agonist-induced hypertrophy, the situation may be 
different during to pressure-overload, where Nox2 may play a role in mediating 
pathological remodelling. Thus, mice deficient in Nox2 subjected to TAC develop cardiac 
hypertrophy and increased expression of ANP in correlation with increased NOX activity, 
attributed to Nox4 (Byrne et al., 2003). However, systolic function was relatively 
preserved with reduction of myocardial interstitial fibrosis (Byrne et al., 2003). More 
recently, the same group reported a detailed analysis of LV contractile function in mice 
deficient in Nox2 compared with wild-type animals after TAC. They were able to 
demonstrate that Nox2 -/- animals are protected against the LV systolic and diastolic 
dysfunction in the whole heart as well as in isolated cardiomyocytes (Grieve et al., 2006). 
 
The activity of NOX is significantly increased by several stimuli relevant to the 
pathophysiology of cardiac hypertrophy, ventricular remodelling and heart failure, 
including mechanical stretch (Matushita et al., 2001), ANGII (Mollnau et al., 2002), ET-1 
(Lund et al., 2005), α-adrenergic agonists (Amin et al., 2001) and TNFα (Suematsu et al., 
2003). Membrane translocation of the subunit p47phox is important for the activation of the 
NOX enzyme in response to ANGII (Li et al., 2003). Consistent with this, p47phox (-/-) 
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mice in which MI was induced exhibit reduced ventricular dilatation with significant 
reduction in mortality. This is associated with reduced apoptosis, reduced activity of 
MMP-2 gelatinolitic activity and preserved endothelial NO production compared with 
wild-type animals (Doerries et al., 2007). Of note, not only NOX activity but also XO 
were reduced in p47phox (-/-) mice after MI compared with wild-type (Doerries et al., 
2007), confirming previous in vitro studies suggesting that XO activity is probably 
triggered secondary to NOX activation (McNally et al., 2005). 
 
1.4.2 Antioxidant mechanisms 
Given the potential deleterious and unspecific actions that increased ROS production may 
have within cells, an important aspect of ROS production is the tight control that (under 
normal physiological conditions) is exerted over the systems responsible for its 
production and buffering systems to remove ROS. There are several cellular mechanisms 
that regulate ROS levels. Here, two key systems will be discussed: SOD and thioredoxin 
(Trx). 
 
In the heart, SOD is expressed in two isoforms: Mn2+-SOD in the mitochondrial matrix, 
and Cu2+/Zn2+-SOD, the cytosolic form (Ohta et al., 1994). The rapid production of H2O2 
and O2 from O2˙¯ by SOD is usually coupled with the actions of catalases (in tissue 
peroxisomes) glutathione peroxidases (in the cytoplasm) and peroxiredoxins (Nohl and 
Jordan, 1980; Halliwell, 1989; Schroder and Ponting, 1998; Dhalla et al, 2000). 
Consistent with this, mice with cardiospecific overexpression of glutathione peroxidase 
exhibit reduced ventricular remodelling after MI (Shiomi et al., 2004). Similarly, 
cardiospecific overexpression of Mn2+-SOD in mice protects from myocardial 
ischaemia/reperfusion injury (Chen et al., 1998), whereas post-ischaemic functional 
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contractile recovery is impaired in mice with heterozygous (-/+)Mn2+-SOD knockout 
(Asimakis et al., 2002).  
 
Thioredoxin1 (Trx1) is a 12 kDa multifunctional protein which limits oxidative stress by 
direct ROS scavenging and the regeneration of several antioxidant molecules including 
ascorbic acid, ubiquinone (Q10), and lipoic acid. It therefore constitutes an important 
defence mechanism against ROS (Yamawaki et al., 2003). Collectively, Trx1, Trx 
reductase and  NAD(P)H are called the Trx system which operates as a potent protein-
disulfide oxidoreductase system (Masutani and Yodoi, 2002). Serum levels of Trx1 are 
elevated in patients with heart failure and coronary artery disease (Kishimoto et al., 
2001b). Inhibition of Trx1 in the heart causes increased oxidative stress and cardiac 
hypertrophy, with further increases upon imposition of pressure-overload. This correlates 
with increased activation of the ERK1/2 cascade (Yamamoto et al., 2003). In contrast, 
cardiospecific overexpression of Trx1 reduces oxidative stress and cardiac hypertrophy 
after pressure-overload (Yamamoto et al., 2003).  
 
Although it would seem desirable to have evolved more robust antioxidant systems, 
particularly in view that an excess in oxidative stress is at the very heart of degenerative 
pathologies like heart failure and neoplastic diseases, it is possible that excessive 
antioxidant activities may completely abolish physiological processes that require 
controlled amounts and localized production of ROS. It is for this reason that oxidative 
stress related diseases such as heart failure (the so called “cancer of cardiology”) and 
cancer are the principal causes of death in the modern aging population with the increased 
life expectancy gained at least in part as a result of the “post antibiotic era”. 
 
 83
1.5  Regulation of gene expression in cardiomyocytes 
 
The changes in the phenotype of the heart with hypertrophic growth of cardiomyocytes 
and ventricular remodelling is the end result of alterations of the patterns of gene 
expression which occur in response to changes in haemodynamic loads (e.g. mechanical 
stretch) and/or neurohumoral stimulation. The expression of protein-coding genes can be 
regulated at several stages including transcription (initiation, elongation and termination), 
mRNA processing and stability, and translation and protein degradation. However, the 
current belief is that most regulation occurs at the level of initiation of transcription 
(Maston et al., 2006). In this section, a general overview of the mechanisms controlling 
gene expression through transcriptional regulation, specifically the initiation of 
transcription, will be discussed. 
 
1.5.1. Overview of transcriptional regulation 
Chromatin is the complex of DNA and protein that forms the chromosomes. Cytological 
studies distinguish two forms of chromatin. Heterochromatin is a more densely packed 
form which characteristically stains more darkly (heteropicnotic) and contains multiple 
repetitive sequences. It is not devoid of genes as it was classically thought (Cosma, 2002). 
Euchromatin is less densely packed (Elgin, 1996; Richards and Elgin, 2002) and contains 
protein-coding genes. DNA in a diploid human cell is more than two meters long; but is 
highly compacted in the nucleus which is only a few microns in size. This means a high 
level of organization must be maintained. The primary level of organization is into 
structural units called nucleosomes (Figure 1.7). The nucleosome comprises double-
stranded DNA (dsDNA) of 146 bp, wrapped in 1.65 left-handed spherical turns around an 
octameric core composed of highly basic proteins, the histones [a histone (H3-H4)2 
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heterotetramer and two histone H2A-H2B dimers] (Luger et al., 1997, reviewed in 
Kornberg and Lorch, 1999) (Figure 1.7).  
 
One of the main characteristics of the regulation of gene expression in eukaryotic cells is 
that in principle it is restrictive, mainly as a result of the dense packaging of DNA into the 
nucleosomes. Nucleosomes repress general gene expression except for some which are 
actively transcribed under the influence of very specific positive regulatory mechanisms. 
Nucleosomes interfere with gene expression by at least three different mechanisms. First, 
as a direct consequence of the packing of DNA into nucleosomes, the specific sequences 
on core promoters which are usually recognized by regulatory proteins (e.g. transcription 
factors) are blocked (Workman and Kinsgton, 1998). Secondly, chains of nucleosomes 
can be further coiled into higher-order structures through linker histones such as histone 
H1 and other chromatin-associated proteins including members of the high mobility 
group (HMG) proteins, which may even shut down the transcription of entire domains 
within a chromosome (Ding et al., 1997; Dutnall and Ramakrishnan, 1997; Bell and 
Fenselfeld, 1999). Thirdly, the interaction of nucleosomes with additional chromosomal 
proteins in heterochromatin appears to cause hereditary repression of gene expression 
(Grunstein, 1998). This occurs for example in the X chromosome that is inactivated in 
females, where genes on a randomly selected X chromosome, are condensed and silenced 
(Richards and Elgin, 2002).  
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Figure 1.7 Nucleosome structure. Top view of a nucleosome shown colored by histone 
subunit type (H2A blue, H2B red, H3 yellow, H4 green). DNA structure is shown 
colored by strand (turquoise and orange). PDB file from Research Collaboratory for 
Structural Bioinformatics (RCSB) PDB web site. Picture customized and generated with 
WebLab Viewer Pro 4.0 (Molecular Simulations Inc.). 
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 The restrictive nature of gene expression in eukaryotes makes it a matter of necessity that 
several proteins in addition to transcription factors interact with the chromatin in a 
positive and negative way to determine whether a gene is expressed or not. The regulatory 
proteins required for the control of gene expression can be classified into four groups:  
 
1. Histone acetylation 
2. Basal transcriptional machinery which includes general transcription factors 
3. Gene activator proteins commonly known as transcription factors 
4. Coactivators (cofactors) 
 
1.5.1.1 Histone acetylation 
As discussed above, packaging of DNA into nucleosomes is a basic mechanism for 
restricting the transcription of genes. Therefore, modification of the chromatin is an 
important initial step in order to allow or prevent access of trans-acting regulatory 
proteins to genomic DNA. Remodelling of chromatin is usually achieved by covalent 
modifications such as addition of acetyl groups, methyl groups, phosphorylation, and 
reversible ubiquitination (reviewed in Lee and Young, 2000, Näär et al., 2001 and 
Shilatifard, 2006). Of these mechanisms, the best studied is acetylation/deacetylation of 
histones. Modification of core histone proteins by acetylation appears to “relax” the 
nucleosome structure allowing transcription factors to bind. This process is induced by 
histone acetyltransferases (HATs), which promote gene expression, and is reversed by 
histone deacetylases (HDACs) which suppress it.  
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There are three classes of HDACs, which operate to promote DNA coiling and 
transcriptional repression. Class II HDACs, appear to be important in the regulation of 
gene expression during cardiac hypertrophy. These enzymes (compared with other 
classes) contain N-terminal extensions of approximately 500 amino acid residues which 
harbour binding sites for other transcriptional regulators. One characteristic of class II 
HDACs is that they usually form large multiprotein complexes with transcriptional co-
repressors (Verdin et al., 2003). The N-terminal extensions of class II HDACs also 
contain conserved phosphorylation sites and shuttle between the cytoplasm and the 
nucleus according to their phosphorylation status. For example, (as discussed earlier; see 
section 1.3.1.3 and Figure 1.2), local alterations in the concentration of Ca2+ in the 
nucleus, secondary to stimulation with ET-1 or PE, promotes activation of CaM and 
CaMKII, and leads to phosphorylation of the class II HDAC, HDAC5, which translocates 
from the nucleus to the cytoplasm where it remains sequestered bound to inhibitory 14-3-
3 proteins (Wu et al., 2006). HDAC5 is a negative regulator of MEF2 transcription factor, 
so phosphorylation of HDAC5 with transfer to the cytoplasm promotes transcriptional 
activity of MEF2. Class II HDACs appear to be particularly important in regulating 
cardiac specific gene expression and may play a role in cardiac hypertrophy and 
ventricular remodelling as suggested by studies in HDACs knockout mice (reviewed in 
Olson et al., 2006). However, paradoxically trichostatin A and scriptaid (small molecule 
inhibitors of HDAC I and II) significantly reduced the hypertrophic response in mice after 
TAC, compared with vehicle-treated animals (Kong et al., 2006). Importantly, treatment 
with these same HDAC inhibitors also prevented ventricular dysfunction and fibrosis 
without any observable increase in apoptosis, compared with vehicle-treated control 
animals and sham-operated animals. As expected in vitro experiments revealed that 
treatment of cardiomyocytes with HDAC inhibitors significantly increased acetylation of 
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target proteins such as histone 3 (H3) or α-tubulin. Taken together this study suggests that 
inhibitors of class I and II HDACs may have a promising therapeutic potential in the 
treatment of heart failure (Kong et al., 2006). 
 
Probably the best characterized HATs are p300 and CBP (cAMP response element 
binding protein) which were initially thought to be transcriptional co-activators 
(Kalkhoven, 2004). p300/CBP are recruited to specific promoters by enhancer-specific 
transcription factors, and both the transcription factors interactions and HAT activities 
may be influenced by their phosphorylation state. Whether or not their activity is 
regulated by phosphorylation in cardiomyocytes remains to be defined. However, 
hyperphosphorylation of p300 via p38-MAPK signalling may target the protein for 
degradation in cardiomyocytes (Poitza et al., 2005). Importantly, p300 and/or CBP are 
required for cardiomyocyte hypertrophy (Gusterson et al., 2003). 
 
1.5.1.2 Basal transcriptional apparatus 
The enzymes that catalyze the transcription of DNA into RNA are collectively called 
RNA polymerases, of which there are three RNA polymeraese I, II and III. They were 
originally characterized on the basis of their sensitivity to the poisonous cyclic 
octapeptide, α-amanitin. Thus, RNA polymerase I is very insensitive to α-amanitin, RNA 
polymerase II is very sensitive and RNA polymerase III exhibits intermediate sensitivity 
(Roeder, 1974). From a functional perspective, RNA polymerase II is responsible for 
transcription of all protein-coding genes into messenger RNA (mRNA), RNA polymerase 
I is responsible for synthesis of ribosomal RNAs (rRNAs), and RNA polymerase III 
synthesizes transfer RNA (tRNA) and some small RNAs such as U6 (which is involved in 
mRNA splicing) (Roeder, 1974). 
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 RNA polymerase II is a large multi-subunit enzyme which requires additional factors for 
accurate transcription initiation. These with RNA polymerase II are referred to as general 
transcription factors (GTFs) (reviewed in Roeder, 1996). These GTFs include (in addition 
to RNA polymerase II) TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH, each of which has 
specific roles such as positioning RNA polymerase II on the promoter (TFIIB) or 
unwinding of DNA (TFIIH). TFIID is itself a multi-subunit complex and, as the major 
sequence-specific DNA-binding component of GTFs, is generally involved in promoter 
recognition. This complex contains the TATA-binding protein (TBP) and several TBP-
associated factors (TAFIIs) which also appear to be highly promoter selective (reviewed 
in Green, 2000). The TATA-box is a common theme in the promoter of most, but not all 
genes and consists of a consensus sequence whose most common sequence is 
TATA(A/T)A(A/T)(A/G) (Bucher, 1990). It is usually localized 25-35 bp upstream of the 
transcriptional start site and, characteristically, genes containing a TATA-box frequently 
start with an adenine nucleotide. Binding of TFIID to the TATA-box is the critical initial 
step in the formation of the preinitiation complex PIC. After this event, other GTFs 
including RNA polymerase II assemble on the promoter in an ordered fashion through 
protein-protein interactions (see section 1.5.1.5). It is currently believed that enhancer 
specific transcription factors (see next section) interact through their activation domain 
with one or more components of the basal transcriptional machinery known as the 
“targets” to stimulate the formation of the PIC. The mechanisms and the “targets” in this 
activation process are becoming clearer, although they are not yet completely understood 
(reviewed in Green, 2005). 
 90
1.5.1.3 Gene activator proteins (classical transcription factors) 
Research into transcriptional control in eukaryotes has identified cis-acting regulatory 
elements in the DNA particularly in the 5’ promoter region. This includes the core 
promoter and proximal regulatory elements, and other distal DNA regulatory elements 
such as enhancers, silencers, insulators and Locus Control Regions (LCR) (for a review 
see Maston et al., 2006). The delineation of cis-acting regulatory elements can be 
determined by mutagenesis analysis. Research into transcriptional regulation also 
identified trans-acting DNA-binding regulatory proteins that bind mainly to silencers and 
enhancers in the promoters and inhibit or stimulate transcription. These are commonly 
referred to as transcription factors or trans-activators. To easily differentiate these 
transcription factors from the GTFs, I will also use the term enhancer-specific 
transcription factors, particularly when this distinction is necessary for clarity of the 
discussion.  
 
Detection of transcriptional activators can be performed by DNA-binding analysis, which 
has revealed the existence of many types of transcription factors (Luscombe et al., 2000). 
Transcription factors usually stimulate gene transcription (i.e. the synthesis of RNA from 
a protein-coding gene) and may be referred to as transcriptional activators, although some 
transcription factors can inhibit gene transcription and are therefore called transcriptional 
repressors. These selectively regulate expression of genes in a tissue and cell specific 
manner, although they can also stimulate transcription in response to specific stimuli (e.g. 
hypertrophic agonists), or in a temporal fashion (e.g. embryonic vs postnatal expression 
of genes). One characteristic of transcription factors is their modular structure with both 
DNA-binding domains and activation domains. The most typical structure found in the 
DNA-binding domains of most transcription factors is an α-helix (which inserts into the 
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major groove of DNA) in the proximity of several positively charged amino acids 
(Luscombe et al., 2000). This domain binds specifically to short segments of DNA 
usually 5 to 10 bp long, called consensus binding sites. Of note, transcription factors do 
not usually work alone, but in a co-operative manner, and complex interactions between 
several transcription factors bound to their specific consensus binding sequences in the 
promoter region may increase the efficiency of transcription of genes by forming an 
enhanceosome (Veitia, 2003; Arnosti and Kulkarni, 2005). The activation domain 
mediates the co-operative binding of transcription factors to DNA-regulatory elements, 
and postranslational modifications such as phosphorylation is a common mechanism of 
transactivation of transcription factors by extracellular signals (Hill and Treisman, 1995). 
 
The recurrent structural motifs in the DNA-binding domain of transcription factors form 
the basis for their classification. Although there are at least eight functional/structural 
groups of protein-DNA complexes, most transcription factors contain one of four motifs: 
zinc finger, leucine zipper, helix-turn-helix (HTH) or helix-loop-helix (HLH) (reviewed 
in Luscombe et al., 2000). Of particular interest for this thesis are the leucine zipper 
transcription factors which will be briefly described here. Leucine zipper family of 
transcription factors comprise a single α-helix of 60 or more amino acid residues and are 
structurally divided into two parts: a dimerization region and a DNA-binding region. The 
C-terminal region of each zipper protein spans approx 30 amino acids, and contains 
leucine or another hydrophobic amino acid every seven amino acids in the sequence. 
These leucine amino acids are essential for the interaction with the corresponding leucine 
amino acids from a dimerization partner, which results in the formation of a molecular 
coil that stabilizes (or “zips up”) two proteins containing the same leucine zipper motif. 
The DNA-binding region is structurally an extension of the α-helix towards the N-
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terminal region and is rich in basic amino acids that interact with phosphates within the 
major groove of DNA.  
 
The correct configuration of a pair of leucine zippers is the formation of dimers that 
virtually grip the DNA, and these can be identical proteins (homodimers) or two different 
proteins with the same leucine zipper motif (heterodimers) (Figure 1.8). This leucine 
zipper motif is found in the transcription factors c-Jun and c-Fos of the activator protein 
family (AP-1). c-Jun can form homodimers or heterodimerize with c-Fos, and bind to the 
AP-1 consensus (5'-TGAGTCA-3') (Glover and Harrison, 1995) (Figure 1.8). Also of 
common occurrence is the formation of heterodimers of members of the AP-1 family with 
those of the activating transcription factor (ATF)/CRE (cAMP responsive element) family 
with resulting activating and repressing effects on target genes when bound to AP-1 
consensus or ATF/CRE consensus (5’-TGACGTCA-3’) (Hai et al., 1999). On the basis of 
the presence of the amino acid leucine in all leucine zipper family transcription factors, 
and the invariable presence of basic amino acids at the N-terminal region, the leucine 
zipper proteins are also called basic (leucine) zippers (bZip).  
 
Transcriptional activators can interact with proteins of the basic transcriptional apparatus 
and increase the rate of formation of the PIC (see above), or promote a step in the 
transcription process (e.g. initiation, elongation). Recently, an additional feature of 
transcription factors has also been described whereby they promote the recruitment of 
chromatin-modifying proteins (e.g. HATs/HDACs) and influence their activities to 
facilitate transcription or repress it (reviewed in Green, 2005) (see section 1.5.1.1). 
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Figure 1.8 c-Jun and c-Fos heterodimer bound to DNA. The α-helix in both c-Jun 
(shown in Red) and c-Fos (shown in Blue) contains the activation domain (C-terminal) 
through which leucine zipper transcription factors heterodimerize. The DNA-binding 
domain (N-terminal domain) is an extension of this same α-helix which interact with 
DNA and enter the major grooves at both sides of the DNA double helix.  
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1.5.1.4 Coactivators (cofactors) 
Coactivators are proteins that interact with and affect the functions of enhancer specific 
transcription factors. Amongst the most studied, although not completely understood in 
higher eukaryotes is the Mediator complex. The Mediator complex is a large multi-
subunit coactivator (more than 20 subunits) which was initially characterized in 
Saccharomyces cerevisiae (Hampsey and Reinberg, 1999). More recently, a mammalian 
Mediator complex has been characterized and the multi-subunit structure and the 
functional characteristics are evolutionary conserved from yeast to human Mediators. The 
Mediator complex appears to serve as an interacting protein that facilitate the 
communication of RNA polymerase II/GTFs within the core promoter with enhancer-
specific transcription factors, thus modulating the transcriptional activity (reviewed in 
Conaway et al., 2005). Of note, several subunits of the Mediator complex also appear to 
be “targets” of enhancer specific transcription factors, although the mechanistic details 
are still under investigation (Malik and Roeder, 2005). What is clear, however, is that in 
vivo transcription by RNA polymerase II requires a Mediator complex (Malik and 
Roeder, 2005). 
 
1.5.1.5 General overview of the induction of transcription initiation by enhancer 
specific transcription factors 
In this section, an overview of the different steps involved transcription initiation induced 
by enhancer specific transcription factors will be summarized. Although not yet 
completely defined in cardiomyocytes, it can be assumed that transcription factors are 
probably phosphorylated at their activating domain (e.g. AP-1 or ATF/CRE family 
members) downstream of, for example, the ERK1/2 cascade following stimulation with 
ET-1 or PE. There is recruitment of HATs such as CBP/p300 to facilitate the remodelling 
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of chromatin by acetylation of core histone proteins on the nucleosomes. This allows 
exposure of proximal regulatory elements such as the TATA-box and distal regulatory 
elements such as the enhancer. Binding of enhancer specific transcription factors to their 
consensus binding sites and formation of the enhanceosome plus their interaction with 
poorly-defined “target” proteins of the basal transcriptional machinery promotes the 
positioning and binding of TBP (TFIID) to the TATA-box element (Figure 1.9) (Roeder, 
2005; Green, 2005). The stability of the positioning of TBP in the TATA-box appears to 
be facilitated by TFIIA which enters the complex at the same time as TFIID (Imbalzano 
et al., 1994). Once TBP is bound to the TATA-box, TFIIB is able to bind to the core 
promoter making contact with TBP and the DNA on either side of the TATA-box. The N-
terminal domain of TFIIB extends towards the start site, so the main role of TFIIB 
appears to be the selection of the transcriptional start site (Barberis et al., 1993). After 
binding, TFIIB then helps direct a preformed complex of RNA polymerase II and TFIIF 
to the transcriptional start site (Barberis et al. 1993). TFIIF appears to be involved in the 
suppression of non-specific DNA binding of RNA polymerase II, thus potentially helping 
to ensure the specificity of binding of the enzyme to the transcriptional start site 
(Conaway and Conaway, 1993). Finally, TFIIE enters the forming complex and serves as 
a docking site for TFIIH, which subsequently binds and completes the formation of the 
PIC (Figure 1.9). The helicase function of TFIIH then allows the melting of dsDNA at the 
core promoter and subsequent initiation of transcription by RNA polymerase II (Guzman 
and Lis, 1999). 
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Figure 1.9 Transcription initiation induced by enhancer specific transcription 
factors. Binding of enhancer specific transcription factors to their specific consensus sites 
in the distal regulatory elements (enhancers), promotes their interaction with poorly 
delineated “target” proteins that form part of the GTFs. This interaction promotes the 
binding of TFIID through its TBP subunit to the TATA-box element in the core promoter. 
Binding of TFIIB then occurs and, after recognition of the start site by TFIIB, allows the 
positioning of RNA polymerase to the transcriptional start site (frequently an adenine 
nucleotide for TATA-box containing genes). The PIC is finally completed by the binding 
of TFIIE, which serves as a docking site for TFIIH. Helicase activity of TFIIH melts the 
core promoter allowing the initiation of transcription by polymerase II. The interaction 
and communication of enhancer specific transcription factors with “target” proteins from 
the Mediator complex appear to modulate positively or negatively the transcriptional 
process, although the details of this process are not completely understood. 
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The signalling cascades that initiate the hypertrophic response after haemodynamic-
overload are set into motion by locally-released neurohumoral factors [e.g. autocrine-
paracrine release of ET-1 acting through cognate receptors located at the cell membrane 
of the cardiomyocytes (section 1.2 and 1.3)]. Therefore, ET-1, PE, and many other 
agonists are capable of inducing cardiomyocyte hypertrophy (Sugden and Clerk, 1998; 
Molkentin et al., 2001). The flow of information in these signalling cascades leads to 
activation of several protein kinases including the mitogen-activated protein kinases 
MAPKs, which then phosphorylate target proteins. These target proteins include several 
transcription factors that bind to the promoters of several genes and regulate gene 
expression. Thus, cardiac myocyte hypertrophy is associated with changes in expression 
of IEGs (e.g. c-jun, c-fos), and re-expression of a “foetal pattern” of gene expression (e.g. 
ANP; β-myosin heavy chain), which are often used as markers of hypertrophy (Hoshijima 
and Chien, 2002; Dorn and Force, 2005). Many of the genes that are activated during this 
acute phase are themselves transcription factors that will regulate a second wave of gene 
expression presumably responsible for the sub-acute and chronic changes in phenotype 
leading to cardiac hypertrophy (Hoshijima et al., 2002; Clerk et al., 2005; Clerk et al., 
2007, Cullingford et al., manuscript submitted). Microarray studies from our group, 
comparing the changes in transcriptional profiles induced by H2O2 or ET-1 in neonatal rat 
cardiomyocytes identified ATF3 mRNA as being significantly induced by all these 
agonists (Clerk et al., 2005), and this forms a focus for this thesis. 
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 1.6 Hypothesis 
 
The basic hypothesis is that stimulation of cardiomyocyte hypertrophy or apoptosis 
stimulate intracellular signalling pathways leading to early changes in gene expression 
which propagate the response. One such gene identified by microarrays is ATF3 which is 
induced by hypertrophic or apoptotic stimuli. This thesis explores the regulation and role 
of ATF3 in cardiomyocytes. Further studies examine the effects of inhibitors of protein 
kinase signalling on cardiomyocyte gene expression. 
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Chapter 2 
 
General Methods 
 
 100
2.1 Preparation of primary cultures of neonatal rat cardiomyocytes 
Primary cultures of ventricular cardiomyocytes from neonatal (2-4 days) Sprague-Dawley 
rats (purchased from Harlan) were used for all the experiments and were prepared by Ms. 
Amanda Nercessian. The yield was, on average, 4x106 cells per heart. Myocytes were 
dissociated from the ventricles by a previously described adaptation (Bogoyevitch et al., 
1995) of the method of Iwaki et al. (1990). Neonatal rats were culled by cervical 
dislocation and then decapitated. The hearts were removed immediately under sterile 
conditions. Ventricles were separated from atria, opened and washed in ice-cold sterile 
digest buffer (116 mM NaCl, 20 mM HEPES, 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 
mM KCl and 0.8 mM MgSO4, pH: 7.35). Ventricular tissue was cut into pieces and 
cardiomyocytes were dissociated by serial digestion with 0.4 mg/ml collagenase and 0.6 
mg/ml pancreatin in digest buffer.  
 
Digests were performed in a sterile 100 ml Schott bottle with agitation in a water bath at 
37°C. After the first digest (5 min, 160 cycles/min), the supernatant, containing blood and 
digestion enzymes, was removed and discarded. Following the second digest (20 min, 136 
cycles/min) the cell suspension was transferred to a sterile 50 ml Falcon tube containing 2 
ml of foetal calf serum (FCS) (Invitrogen) to quench the digestion. Cells were centrifuged 
(5 min, 60 × g), resuspended and stored in the incubator. Remaining cardiomyocytes were 
dissociated from heart tissue with 4 sequential digestions (2 × 25 min, 112 cycles/min; 1 
× 20 min, 136 cycles/min; 1 × 10 min, 112 cycles/min). Cells were centrifuged, 
resuspended as described above and added to the cells from the second digest. Pooled 
cells were recovered by centrifugation (5 min, 60 × g) and the cell pellet resuspended in 
plating medium [Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) / Medium 
199 (Invitrogen)  (4:1 v/v), containing 15% (v/v) FCS (Invitrogen), 100 units/ml 
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penicillin and 100 units/ml streptomycin (Invitrogen)]. The resulting cell suspension was 
pre-plated (4 ml per dish) for 30 min (37˚C, 5% CO2) on 60 mm Primaria culture dishes 
to remove non-myocytes (e.g. fibroblasts and endothelial cells), which attach to the 
culture plates and were discarded. Non-adherent cardiomyocytes were collected and 
counted using a haemocytometer [75 μl myocyte suspension, 175 μl plating medium and 
250 μl Trypan blue solution (Invitrogen)] ignoring blue-stained non-viable cells. 
Cardiomyocytes were suspended in plating medium (106 myocytes/ml) and plated (4 ml 
per 60 mm dish) onto Primaria culture dishes which had been pre-coated with sterile 1% 
(w/v) gelatin in water. Myocytes were confluent and beating spontaneously within 18 h. 
After 24 h the plating medium was replaced by serum-free maintenance medium 
[DMEM/Medium 199 (4:1 v/v), containing 100 units/ml penicillin and streptomycin 
(Invitrogen)] for a further 24 h. 
 
 
2.2 Agonists and inhibitors used to treat cardiomyocytes 
Inhibitors (Table 2.1), H2O2 (Sigma) and ET-1 (Sigma) were added directly to the 
cardiomyocytes in serum-free medium. For a full list of reagents and chemicals used in 
the experiments of this thesis see Appendix A. 
 102
 Table 2.1 Inhibitors used to treat cardiomyocytes (all dissolved in dimethyl 
sulphoxide except cycloheximide which was dissolved in H2O). 
 
Inhibitor Supplier Concentration Pre-incubation time Target 
Cycloheximide Sigma 20 μM 10 min Protein translation 
SB203580 Alexis Biochemicals 10 μM 15 min p38-MAPKα/β 
SP600125 Alexis Biochemicals 10 μM 15 min JNKs 
PD98059 Alexis Biochemicals 25 µM 15 MKK1/2 
U0126 Alexis Biochemicals 10 μM 15 min MKK1/2 
LY294002 Alexis Biochemicals 50 µM 15 PI3K 
 
 
2.3 Extraction of total RNA 
Cardiomyocytes (4 x 106 per sample) were scraped into ice-cold RNAzol Bee™ (1000 
µl), incubated with chloroform on ice (200 μl, 5 min) and centrifuged (4°C, 10 min, 
15,300 × g).  The upper phase was incubated with an equal volume of isopropanol on ice 
(1 h).  RNA was pelleted by centrifugation (4°C, 10 min, 15,300 × g), washed (70% 
ethanol) and resuspended in 15 μl Milli-Q filtered water.  RNA concentrations were 
determined by spectrophotometry (λ = 260 nm).  The purity was assessed from A260/A280.  
Values of 1.9–2.1 were considered acceptable. 
 
 
2.4 DNase treatment 
In order to exclude any DNA contamination during RT-PCR reactions, RNA preparations 
were treated with DNase to remove genomic DNA. Total RNA (1 μg) was mixed with 1 
μl of 10X DNase I reaction buffer (200 mM Tris-HCl, pH 8.4, 20 mM MgCl2, 500 mM 
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KCl) (Invitrogen); 1 μl DNase I Amp Grade (1 U/μl) (Invitrogen); and DEPC (diethyl 
pyrocarbonate)-treated water to final volume of 10 μl. Following incubation (room 
temperature, 15 min), the reaction was terminated by addition of 1 μl EDTA (25 mM) and 
heating (65°C, 10 min). 
 
2.5 cDNA synthesis 
RNA (1 μg) was mixed with 0.5 μg random hexamers and dATP, dCTP, dGTP and dTTP 
(0.74 mM each) in a total volume of 13.5 μl.  Following incubation (65°C, 5 min), 6.5 μl 
solution A [15 mM dithiothreitol (DTT), 4 μl commercial 5 × 1st strand buffer 
(Invitrogen), 200 units M-MLV reverse transcriptase (Invitrogen) and 0.5 μl RNaseOut® 
(Invitrogen)] were added and samples were incubated (37˚C, 1 h).  The reaction was 
terminated (65°C, 3 min). 
 
2.6 Reverse transcription-polymerase chain reaction (RT-PCR) 
Primers for semiquantitative (SQ-PCR) and/or quantitative (Q-PCR) were designed for 
established genes using published rat sequences (see Table 2.2). Where possible, these 
were designed across exon boundaries.  
 
Table 2.2 Primers used for Q-PCR and SQ-PCR 
Q-PCR primers 
Gene Accession number Size 
(bp) Forward primer Reverse primer 
ATF3 NM_012912 181 GAGCGAAGACTGGAGCAAAA AAGGTGCTTGTTCTGGATGG 
Ereg NM_021689 113 ACTGCAGATGTGAAGTGGGC  GAGGAAAACGAGAATCACGG  
IL-6 NM_012589 136 CCGGAGAGGAGACTTCACAG CAGAATTGCCATTGCACAAC  
LIF NM_022196 128 TCAACTGGCTCAACTCAACG ACCATCCGATACAGCTCGAC 
c-Jun NM_021835 140 GATCATCCAGTCCAGCAATG TATTCTGGCTATGCAGTTCAG 
CT-1 NM_017129 139 GGAGGGAAGTCTGGAAGACC CTGCACATATTCCTCCAGCA 
GAPDH NM_017008 83 GCTGGCATTGCTCTCAATGACA  TCCACCACCCTGTTGCTGTA  
SQ-PCR primers 
Gene Accession number Size 
(bp) Forward primer Reverse primer 
ATF3 NM_012912 388 GCTGCCAAGTGTCGAAACAAG CAGTTTTCCAATGGCTTCAGG  
IL-6 NM_012589 428 CCGGAGAGGAGACTTCACAG GAGCATTGGAAGTTGGGGTA 
GAPDH NM_017008 452 ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
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2.6.1 Quantitative Real time PCR (Q-PCR) 
Q-PCR was performed using a 7500 Real-Time PCR System (Applied Biosystems). A 
master-mix containing (per reaction) 12.5 μl Sybr-Green Jump Start Taq Readymix 
(Sigma-Aldrich) and 5 μl oligonucleotides (5 pmol each of forward and reverse primers) 
was aliquoted into Optical 96-well reaction-plates (Applied Biosystems), and the cDNA 
template added (7.5 μl, 1/15 dilution in Milli-Q filtered water). PCR conditions for all 
primer pairs were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 
s and 59°C for 60 s. Following Q-PCR, a dissociation curve analysis was performed to 
check for aberrant amplification products (Figure 2.1). Q-PCR analysis of GAPDH was 
performed in each 96-well plate as an endogenous control and the relative quantitation 
protocol was used.  
 
2.6.2 Semi-Quantitative RT-PCR (SQ-PCR) 
PCR reactions were performed in 50 μl  of  1X Buffer IV® (ABgene) containing 0.5-1.0 
ng cDNA, 1 unit Taq polymerase, dATP, dCTP, dGTP and dTTP (0.2 mM each) and 100 
pmol forward and reverse primers (see Table 2.2).  Samples were heated (94°C, 2 min), 
then subjected to 22-32 cycles of denaturation (94°C, 30 s), annealing (59°C, 30 sec), and 
extension (72°C, 30 s), heated again (72°C, 2 min) and finally cooled to 4°C.  Samples 
were mixed with PCR sample buffer [0.25% (w/v) bromophenol blue, 40% (w/v) sucrose] 
at 10% (v/v) and subjected to electrophoresis (90 V, 20 min) on 2% (w/v) agarose gels 
containing 100 μg/l ethidium bromide in 1X TBE (90 mM Tris, 90 mM boric acid, 2 mM 
EDTA).  Bands were detected under UV light.  Band sizes were estimated by comparison 
to a øX174 RF DNA Hae III digest (ABgene) or 100 bp DNA ladder (Invitrogen).  
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Densitometric analysis was performed using Imagemaster 1D Prime, version 3.0 (GE 
Healthcare).  Samples were normalised to the RT-PCR product for the housekeeping 
gene, GAPDH. For genes displaying constitutive expression, it was confirmed that the 
PCRs were semi-quantitative. This was achieved by performing PCR over a range of 
cycles with a single sample, followed by densitometric analysis and construction of 
amplification curves (Figure 2.2). The PCR cycle numbers employed in experiments lay 
within the linear sections of the curves.  
 
 
2.7 Preparation of protein extracts 
2.7.1 Total protein extracts 
Cardiomyocytes (4 × 106 per sample) were rinsed twice in ice-cold phosphate-buffered 
saline (PBS) (Invitrogen). For preparation of total protein extracts, cardiomyocytes were 
scraped into 150 μl ice-cold Buffer G [20 mM glycerophosphate pH 7.5, 50 mM NaF, 2 
mM EDTA, 0.2 mM Na3VO4, 10 mM benzamide, 0.2 mM leupeptin (Sigma), 10 μM 
trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64) (Sigma), 5 mM DTT 
(Sigma), 0.3 mM phenylmethylsulphonyl fluoride (PMSF) (Sigma), 2 μM microcystin 
(Alexis Biochemicals), 1% (v/v) Triton X-100]. Samples were centrifuged (4°C, 5 min, 
10,600 × g) and the supernatants retained. A volume of supernatant (2 μl) was used to 
determine the protein concentration (see below) and the remaining supernatant was boiled 
with 0.33 volume of immunoblotting sample buffer [0.33 M Tris-HCl (pH 6.8), 10% 
(w/v) sodium dodecyl sulphate (SDS), 13% (w/v) glycerol, 133 mM DTT, 0.01% (w/v) 
bromophenol blue]. Immunoblotting samples were stored at -20˚C.  
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Main Product
Tm = 88°C
 
 
 
 
 
 
 
 
 
Figure 2.1 Q-PCR dissociation-curve analysis. Following Q-PCR, optical 96-well 
reaction plates containing the amplified products were subjected to dissociation-curve 
analysis to detect the presence of non-specific amplification. The presence of a uniform 
main product (Tm = 88°C) in the Q-PCR run (as shown here) indicates the absence of 
primer dimers (typical Tm = 75°C) during the Q-PCR reactions. 
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Figure 2.2 Amplification plots of ATF3 and IL-6 genes. PCRs were performed for 
increasing cycle numbers with a single cDNA sample. Plotting of the densitometric 
analysis demonstrated that amplification followed the expected sigmoid curve. The PCR 
cycle numbers used in semi-quantitative RT-PCR lay within the linear sections of the 
curves. The images (upper panels) and the densitometric analysis (lower panels) shown 
are representative of two independent experiments. 
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2.7.2 Nuclear extracts 
Cardiomyocytes (4.0 × 106 cells per sample) were rinsed in PBS  and scraped into 150 µl 
ice-cold buffer A [10 mM Hepes (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.3 mM 
Na3VO4] containing freshly-added protease and phosphatase inhibitors [200 μM 
leupeptin, 10 μM E64, 300 μM PMSF, 2 μM microcystin, 5 mM DTT].  Samples were 
centrifuged (4˚C, 5 min, 10,600 × g) and the pellets washed in 100 µl buffer A containing 
0.1% (v/v) Nonidet P40 (NP40) with added phosphatase and protease inhibitors.  Samples 
were centrifuged (4˚C, 5 min, 10,600 × g) and the pellets resuspended in 50 µl buffer C 
[20 mM Hepes (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) 
glycerol, 0.3 mM Na3VO4] containing phosphatase and protease inhibitors. Suspensions 
were incubated on ice (1 h), centrifuged (4˚C, 5 min, 10,600 × g) and supernatants 
transferred to Eppendorf tubes and stored at -80°C. 
 
2.7.3 Bradford protein assay 
Protein concentrations were determined by Bradford assay (Bradford 1976). BioRad 
Bradford reagent [1/5 dilution in double-deionised water, 1 ml] was added to samples (2 
μl) in a final volume of 100 μl. Absorbance at λ=595 nm was measured and the protein 
concentration determined by comparison to a range of bovine serum albumin (BSA) 
dilutions (1-15 μg). 
 
2.8 Immunoblotting 
Proteins (25 µg) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
using 12% (w/v) polyacrylamide resolving gels and 6% (w/v) stacking gels in BioRad 
Protean II mini-gels (200 V, 45 min) with running buffer [25 mM Tris-HCl, 192 mM 
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glycine, 2% (w/v) SDS].  Proteins were transferred electrophoretically to nitrocellulose 
membranes using BioRad Trans-Blot semi-dry transfer cells (10 V, 1 h) with transfer 
buffer [25 mM Tris-HCl, 192 mM glycine, 20% (v/v) methanol].   Membranes were 
incubated (room temperature, 20 min, with agitation) in blocking buffer [5 % (w/v) non-
fat milk powder in Tris-buffered saline [20 mM Tris-HCl (pH 7.6), 137 mM NaCl] with 
0.1% (v/v) Tween 20 (TBST), washed in TBST (3 × 5 min, with agitation), and washes 
repeated between each step afterwards.  Membranes were incubated (4ºC, overnight) with 
primary antibodies specific for ATF3 (rabbit polyclonal, SC-188, Santa Cruz 
Biotechnology Inc.) and IL-6 (goat polyclonal, SC-1266, Santa Cruz Biotechnology Inc.) 
or ATF2 antibody (rabbit polyclonal, SC-187, Santacruz Biotechnology Inc.) [diluted 
1/1000 in TBST containing 5% (w/v) BSA]. Blots were then incubated (room 
temperature, 60 min) with horseradish peroxidase-conjugated secondary antibodies 
(polyclonal goat anti-rabbit immunoglobulins for ATF3; rabbit anti-goat 
immunoglobulins for IL-6, DakoCytomation) [1/5000 in TBST containing 1% (w/v) non-
fat milk powder]. Immunoreactive bands were detected by enhanced chemiluminescence 
(Santa-Cruz Biotechnology Inc.).  Blots were exposed to Hyperfilm and the bands 
analysed by semi-quantitative scanning densitometry (Imagemaster 1D Prime version 
3.0). 
 
 
2.9 Slot-blotting 
After treatments, the media from cardiomyocyte cultures were collected and loaded (500 
µl) onto a 24-well slot-blot microfiltration manifold (SHM-24, Camlab) preloaded with a 
nitrocellulose membrane pre-soaked in PBS. After filtration of the samples, the slots were 
washed and filtered three times with 250 µl PBS. Membranes were air-dried and then 
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fixed with 25% propanol / 10% acetic acid (room temperature, 2 min), washed once with 
PBS (room temperature, 2 min, with agitation) and air-dried again. Membranes were 
incubated (room temperature, 20 min, with agitation) in blocking buffer (as above, section 
2.8), and washed in TBST (3 × 5 min, with agitation).  Immunodetection of IL-6 was then 
performed as described above (section 2.8). 
 
2.10 Chromatin Immunoprecipitation (ChIP) assay 
After stimulation, cardiomyocytes (4 × 106 per sample; 60 mm dishes) were fixed in 
formaldehyde at a final concentration of 1% (10-12 min at room temperature). Cross-
linking was terminated by the addition of glycine (pH 2.5, 125 mM final concentration). 
After 10 min, cells were washed with ice-cold PBS, scraped into 1 ml PBS supplemented 
with protease and phosphatase inhibitors [0.2 mM leupeptin, 10 μM E64, 5 mM DTT, 0.3 
mM PMSF  and 2 μM microcystin]  and pelleted by centrifugation (3,000 x g, 4ºC, 5 
min).  The supernatants were removed by aspiration and pellets lysed for 15 min in 500 μl 
L1 buffer (50 mM Tris-HCl, pH 8.0, 2 mM EDTA, 0.1% NP40, 10% glycerol) 
supplemented with protease and phosphatase inhibitors.  Resulting nuclei were pelleted 
(3,000 x g, 4ºC, 5 min) and resuspended in 200 μl L2 buffer (50 mM Tris-HCl, pH 8.0, 
1% SDS, 5 mM EDTA). Four samples from each condition were pooled into one 
Eppendorf tube at this stage.  
 
Samples in L2 buffer containing the chromatin were sheared by sonication (4 × 30 s at 
amplitude 30) (Vibracell sonicator).  The lysates were centrifuged (4,000 × g, 4ºC, 5 min), 
and the supernatants (750 μl) transferred to another Eppendorf tube for 
immunoprecipitation. A sample (35 μl) was retained to determine inputs. The samples fro 
immunoprecipitation were diluted 1/10 in RIPA buffer (50 mM Tris-HCl, pH 8.0, 0.5% 
 111
NP40, 0.2 M NaCl, 0.5 mM EDTA). Extracts were precleared for 15 min with 20 µl of a 
50% (v/v) suspension of protein A-Sepharose in RIPA buffer. Immunoprecipitations were 
carried out overnight by incubation with gentle mixing by rotation (4°C overnight) with 
10 μg of anti-ATF3 antibody (rabbit polyclonal, SC-188X, Santa Cruz Biotechnology 
Inc.) or without antibody (control). Immune complexes (antibody-protein-DNA) were 
collected with 100 µl Protein A-Sepharose [50% (v/v) suspension in RIPA buffer 
containing 1 μg/ml sonicated salmon sperm DNA], by incubation with gentle mixing by 
rotation (4°C, 2 h).  
 
Protein A-Sepharose was recovered by centrifugation (1,000 × g, 4˚C, 3 min) and washed 
(4˚C, 3 min, with gentle mixing by rotation) in 1 ml high salt buffer (20 mM Tris, pH 8.0, 
0.1% SDS (w/v), 1% (v/v) NP40, 2 mM EDTA, 500 mM NaCl). Protein A-Sepharose was 
again recovered by centrifugation (4˚C, 1 min, 200 × g) and then washed (4˚C, 3 min, 
with mixing by rotation) in 1 ml low salt buffer [1X Tris-HCl/EDTA (TE)]. Immune 
complexes were extracted in 250 µl elution buffer (1X TE containing 1% (w/v) SDS), 
heated (10 min, 65˚C) then vortex agitated and centrifuged (1 min, room temperature, 200 
× g). Supernatants were transferred to Eppendorfs. The extraction was repeated once more 
in the same manner, and the extracts pooled. 
 
The input samples (made up to 500 μl in TE) and the immunoprecipitated extracts (500 
μl) were uncross-linked by incubation (65˚C, overnight) with 20 μl 5 M NaCl (final 
concentration 0.2 M NaCl). Input and extract samples were then incubated with 500 μl 
phenol:chloroform:isoamyl alcohol (25:24:1, pH 8.0) (Sigma) (on ice, 5 min). Aqueous 
and organic phases were separated by centrifugation (15,300 × g, 4˚C, 10 min). The upper 
aqueous phase was transferred to an Eppendorf tube and incubated with 500 μl 
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isopropanol (-80˚C, 3 h). DNA was pelleted by centrifugation (15,300 × g, 4˚C, 10 min), 
precipitated by addition of 70% (v/v) ethanol and pelleted by centrifugation (15,300 × g, 
4˚C, 10 min). The DNA was air-dried (4˚C) and resuspended in 25 μl Milli-Q filtered 
water. 
 
PCR amplification was performed as described for RT-PCR (see above) in a final volume 
of 20 μl to which 2 μl of DNA were added. Promoter-specific primers were used for rat 
IL-6 (sense 5’- TGC TCA AGT GCT GAG TCA CT -3’; antisense: 5’- AGA CTC ATG 
GGA AAA TCC CA -3’). The number of cycles used for each primer set was 32. The 
conditions for PCR amplification were as follows: denaturing at 95oC for 45 s, annealing 
at 52°C for 45 s, and extension at 72oC for 1 min. For semi-quantitative analysis PCR was 
also performed with genomic DNA obtained from input samples. Samples were mixed 
with PCR sample buffer [0.25%  (w/v) bromophenol blue, 40% (w/v) sucrose] at 10% 
(v/v) and subjected to electrophoresis (90 V, 20 min) on 2% (w/v) agarose gels containing 
100 μg/l ethidium bromide in 1X TBE (90 mM Tris-HCl, 90 mM boric acid, 2 mM 
EDTA).  Bands were detected under UV light. 
 
2.11 Replication-deficient adenovirus  
2.11.1 Cloning strategy and production of ATF3 adenoviral vectors 
Replication-deficient adenoviruses expressing either full-length wild-type rat ATF3 (WT-
ATF3) or full-length rat ATF3 antisense (AS-ATF3), were prepared using the AdEasy™ 
XL Adenoviral Vector System (Stratagene). Both adenovirus constructs were made and 
amplified by Dr Stephen Fuller in our laboratory. Constructs were cloned into a shuttle 
vector (pShuttle-CMV, see Figures 2.3 and 2.4A) which was then linearized with 
restriction enzyme Pme 1 and transformed into BJ5183-AD-1 competent cells (see Figure 
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2.4A).  These cells are pre-transformed with the pAdEasy-1 plasmid which contains most 
of the human adenovirus serotype 5 (Ad5) genome but with genes E1 and E3 deleted, and 
possess the machinery necessary for homologous recombination between the shuttle 
vector and pAdEasy-1 (see Figures 2.4B and 2.5). The removal of the E1 and E3 viral 
genes creates space for foreign DNA (up to 7.5 kb) and eliminates self-replication 
capabilities. After recombination the ampicillin resistance gene of pAdEasy-1 is 
exchanged for the kanamycin resistance gene of pShuttle-CMV, enabling antibiotic 
selection of recombinants for kanamycin resistance which were then screened by 
restriction digestion with Pac1 (see Figures 2.4B and 2.6A).  After identification, the 
recombinant pAdEasy-1 was produced in bulk in a recombination-deficient bacterial cell 
line (e.g. XL10-Gold®).  Purified recombinant pAdEasy-1 plasmid DNA was linearised 
by digestion with Pac1 to expose the inverted terminal repeats (ITRs) and used to 
transfect human embryonic kidney cells HEK293 cells (see Figure 2.4C). Recombinant 
adenoviruses were then generated within 7-10 days.  
 
To facilitate the identification, intracellular location and isolation of virally infected 
proteins, the WT-ATF3 construct was tagged with a FLAG sequence (DYKDDDDK) at 
its N-terminus (See Figure 2.6B).  The FLAG sequence was introduced between the BglII 
and KpnI restriction sites of the multiple cloning site (MCS) of the pShuttle-CMV vector 
by synthesis of an oligonucleotide cassette containing the FLAG sequence preceded by an 
ATG start codon and flanked by appropriate restriction sites (see Figure 2.6B). The ATF3 
coding sequences were isolated by PCR from rat cDNA using Pfu polymerase and 
primers designed to the 5’ ATG start site and 3’ stop codon regions (See Figure 2.6A).  
Primers were designed to include restriction enzyme sites to facilitate insertion into the 
multiple cloning site (MCS) downstream to and in-frame with the inserted FLAG 
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sequence (see Figure 2.6B). A similar strategy was used for AS-ATF3 constructs, using 
ATF3-FLAGpShuttle as a template for PCR and inserting the product into pShuttle-CMV 
vector (see Figure 2.3) but without the FLAG sequence. 
 
2.11.2 Adenoviral infections 
WT-ATF3 recombinants were tested for appropriate expression in neonatal 
cardiomyocytes by western blotting using ant-ATF3 antibody (SC-188, Santa Cruz 
Biotechnology) and anti-FLAG antibody (SC-807, Santa Cruz Biotechnology). 
Adenoviral infection of cardiomyocytes was performed at a multiplicity of infection (moi) 
of 10-100 in 4 ml (60 mm culture dishes) of serum-free maintenance medium 
[DMEM/Medium 199 (4:1 v/v) overnight at 37 ºC in a humidified, 5 % CO2 incubator]. 
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Figure 2.3 pShuttle-CMV vector map. The vector pShuttle-CMV contains a multiple 
cloning site (MCS) sandwiched between the CMV promoter and the SV40 
polyadenylation signal and is suitable for insertion of a large cDNA (up to 6.6 kb). The 
regions indicated as arms are the stretches of sequence homology with pAdEasy-1 where 
the homologous recombination occurs. The R-ITR and L-ITR regions are short inverted 
terminal repeats (Left and Right) which have a role in replication of the viral DNA. Taken 
from instruction manual AdEasy™ Adenoviral vector system (Stratagene). 
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Figure 2.4 Schematic representation of the generation of recombinant adenovirus. 
(A) Cloning of the gene of interest into a Shuttle Vector (e.g. pShuttle-CMV). (B) 
Resultant plasmid is linearized with restriction endonuclease Pme I, and subsequently co-
transformed into E. coli BJ5183-AD-1 cells with an adenoviral backbone plasmid (e.g. 
pAdEasy-1). Recombinants are selected for kanamycin resistance. (C) The linearized 
recombinant plasmid was transfected into adenovirus packaging cell lines (e.g. HEK293 
cells). Recombinant adenoviruses were then generated. Adapted from instruction manual 
AdEasy™ Adenoviral vector system (Stratagene). 
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Figure 2.5 pAdEasy-1 vector map. The plasmid pAdEasy-1, containing most of the 
human adenovirus serotype 5 (Ad5) genome, is deleted for the genes E1 and E3. The 
removal of these two viral genes creates space for foreign DNA (up to 7.5 kb) and 
eliminates self-replication capabilities. pAdEasy-1 carries the ampicillin resistance gene, 
which is lost after recombination with a shuttle vector. Taken from instruction manual 
AdEasy™ Adenoviral vector system (Stratagene). 
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 (A)      
Rat ATF3 (coding sequence 546 bp) 
CCCTGGCCGCCCCGAGCGAAGACTGGAGCAAAATGATGCTTCAACATCCAGGCCAGGTCTCTGCCTCAGAAG
TCAGCGCGACCGCCATCGTCCCCTGCCTCTCACCTCCTGGGTCACTGGTGTTTGAGGATTTTGCTAACCTGA
CACCTTTTGTCAAGGAAGAGCTGAGATTCGCCATCCAGAACAAGCACCTTTGCCATCGGATGTCCTCTGCGC
TGGAGTCAGTCACCATCAACAACAGACCTCTGGAGATGTCAGTCACCAAGTCTGAGGTGGCCCCTGAAGAAG
ATGAGAGAAAAAGGAGGCGGCGGGAAAGAAACAAAATTGCTGCTGCCAAGTGTCGAAACAAGAAAAAAGAGA
AGACAGAGTGCCTGCAGAAGGAGTCAGAGAAACTGGAGAGTGTGAATGCCGAACTGAAGGCCCAGATCGAGG
AGCTGAAGAATGAGAAGCAGCATCTGATTTACATGCTCAACCTGCACCGGCCCACGTGTATCGTCCGGGCTC
AGAACGGGCGGACGCCGGAAGACGAGAGGAACCTTTTTATCCAACAGATAAAAGAAGGAACATTGCAGAGCT
AAGCAGAGGTGGCATGGGGGCAAT  
 
Sense primer   5’- ATGATGCTTCAACATCCAGGC -3’ 
Antisense primer  5’- TTAGCTCTGCAATGTTCCTTC -3’ 
 
 
 (B) 
                            KpnI   
5’- GACGACAAGGGTACCATGATGCTTCAACATCCAGGC -3’  ATF3FwdKpnI 
      Asp.Asp.Lys.Gly.Thr…   = end of FLAG sequence 
 
5’- CTTATCTAGAAGCTTTTAGCTCTGCAATGTTCCTTC -3’  ATF3RevHindIII 
     .……………....HindIII..   = reverse MCS in pShuttle 
 
Figure 2.6 Rat ATF3 cloning strategy. (A) PCR was performed using rat cDNA with 
fully complementary primers (location of primers within ATF3 sequence is shown in bold 
underlined text) for the coding region. Start and termination codons are shown in red. A 
PstI restriction site is shown in blue, which gives products of 342 and 204 bp to help 
confirm the identity of the PCR product. (B) PCR was performed from rat cDNA with 
ATF3FwdKpn1 and ATF3RevHindIII primers and the product was then cut with Kpn1 / 
HindIII and ligated into pShuttleFLAG. 
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Chapter 3 
 
Expression of ATF3 in cardiomyocytes in response to  
endothelin-1 or oxidative stress 
 120
3.1 Introduction 
 
3.1.1 Activating transcription factor 3 (ATF3)  
As previously discussed (section 1.5), the induced expression of protein-coding genes is 
regulated by transcription factors that bind to specific consensus binding sites in the 
promoters of target genes. The response of cardiomyocytes to hypertrophic agonists such 
as ET-1 and stress stimuli such as oxidative stress is likely to cause alterations in their 
phenotype (e.g. hypertrophy or cell death) by inducing changes in the patterns of gene 
expression that regulates these processes in the cell. Microarray studies from our 
laboratory identified ATF3 as one of the most potently induced transcription factors 
following stimulation of cardiomyocytes with ET-1 or H2O2 (Clerk et al., 2005) (Table 
3.1).  ATF3 is a member of the ATF/CREB (cyclic AMP-responsive element binding 
protein) family of basic leucine zipper-type transcription factors (section 1.5.1.3).  
 
ATF3 is upregulated rapidly (usually within 2 h) and transiently after many stress-
inducing stimuli. These stimuli include ischaemia alone and ischaemia/reperfusion in the 
heart (Yin et al., 1997), ischaemia/reperfusion in the kidney (Yin et al., 1997), partial 
hepatectomy (Hsu et al., 1991), seizure in the brain (Hai et al., 1999), axotomy of 
peripheral nerves (Tsujino et al., 2000), cycloheximide and FGF in hepatocytes (Weir et 
al., 1994), the antineoplastic drug doxorubicin and TNFα in cardiomyocytes and 
endothelial cells respectively (Nobori et al., 2002; Kawauchi et al., 2002), along with 
many other stimuli in many tissues and cells (reviewed in Hai et al., 1999). The transient 
induction of ATF3 by many stress signals has led to the conclusion that this transcription 
factor is important for the cells to cope with stress in the early stages of the stress 
response (Hai et al., 2001). However, the biological consequences of ATF3 induction in 
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these systems are still incompletely understood. Overexpression studies intended to 
mimic the upregulation of ATF3 in cells suggest that ATF3 could be involved in 
preventing cellular damage in neurons (Nakagomi et al., 2003) or cardiomyocytes 
(Nobori et al., 2002) (see below), or in the removal of damaged cells (Yan et al., 2005). 
However, unregulated overexpression of ATF3 in the pancreas (Hartman et al., 2004) or 
heart (Nobori et al., 2002) contributes to the dysfunction of these organs. Thus, despite 
cumulative evidence suggest that ATF3 plays an important role in the cellular response to 
stress, in general, its role in cell biology is not well understood and there is very little 
information about its physiological function in cardiomyocytes and the heart.  
 
Table 3.1 Upregulation of ATF3 in cardiomyocytes by ET-1 or H2O2 (microarray 
analysis). 
 
 
ET-1 (100 nM)
Time            Fold stimulation
30 min 3.9
1 h 6.2
2 h 3.2
4 h 0.9
24 h 1.1
ATF3
H2O2 (0.2 mM)
Time             Fold stimulation
2 h 20.9
4 h 6.6
24 h 1.8
Affymetrix probe set 1369268_at
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiomyocytes were exposed to ET-1 or H2O2 for the indicated times. RNA was 
extracted, cRNA was prepared and samples hybridized to Affymetrix Rat Genome 230 
2.0 arrays.  Array data were analysed by MicroArray Suite 5.0 followed by Genespring 
7.31.  Results are expressed as fold stimulation relative to unstimulated control (n = 3). 
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 3.1.1.2 Structure, function and isoforms of ATF3 
ATF3 was initially isolated from HeLa cells treated with PMA, as one of eight cDNA 
clones which encoded transcription factors that were able to bind to the ATF consensus 
sequence (5’-TGACGTCA-3’) (Hai et al., 1989). ATF3 is a protein of 181 amino acids 
which contains a basic leucine zipper (b-Zip) DNA binding domain (residues 88–142) 
(Figure 3.1) responsible for homo- and heterodimer formation with other members of the 
b-Zip family (Figure 3.2). This domain also contains the basic amino acids which interact 
with ATF/CRE (5’-TGACGTCA-3’) and activated protein-1 (AP-1) consensus sequences 
(5'-TGAGTCA-3') on target genes (Hai et al., 1999). In vitro studies have shown that 
ATF3 can form homodimers (ATF3/ATF3) or heterodimers with Jun family proteins. 
ATF3 homodimers are negative regulators of transcription of its own promoter (Chen et 
al., 1994; Wolfgang et al., 2000), and the promoters of other genes such as the 
proapoptotic transcription factor CHOP [C/EBP (CCAAT/enhancer binding protein) 
homologous protein] (Wolfgang et al., 1997), and the Ca2+ regulatory protein PLB among 
others (Gao et al., 2004). Heterodimers such as c-Jun/ATF3 or JunD/ATF3 activate 
transcription from promoters containing ATF/CRE, AP-1 and related transcription factor 
binding sites (Hsu et al., 1992; Chu et al., 1994), whereas the JunB/ATF3 heterodimer can 
either activate or repress transcription depending on the promoter context (Hsu et al., 
1992). 
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A B C D E
Human
ATF3 Spliced mRNA
DNA
Protein
1
Basic Zip
167 411 519 717 1914
Spliced mRNA
Protein
1
Basic
167 411 516 717 2056
ATF3ΔZip
1 80 116 181
1 80 115
L L L L
Spliced mRNA
Protein
1
Basic Zip
167 295 519 717 1914
1 80 116 181
L L L L
ATF3b
57
(A)
(B)
(C)
661
UAA
*
UAG
*
UAA
*
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Human ATF3 and the alternatively-spliced ATF3ΔZip and ATF3b 
isoforms. (A) The human ATF3 gene has 5 exons (A-E) some of which are spliced into 
mRNA encoding the full-length ATF3. Exon A corresponds to the 5’ untranslated region, 
exon B encodes the 80 N-terminal region, exon C encodes the basic region, and exon E 
encodes the leucine zipper domain. (B) Alternative-splicing of ATF3 containing all 5 
exons results in an in-frame termination codon after the initial leucine of the leucine 
zipper domain. This leads to a 115 amino acid protein known as ATF3ΔZip, which is 
incapable of DNA binding as a consequence of lacking the leucine zipper domain. (C) 
The ATF3b isoform is formed as a consequence of an intron-like deletion of 116 bases 
from exon B, producing a shorter protein lacking 39 amino acids of the weak activation 
region (1–39 amino acids) and 18 amino acids of the repression region (40–84 amino 
acids). This protein retains DNA binding capabilities as the basic and leucine zipper 
regions are preserved. (A) and (B) adapted from Liang et at. (1996); (C) adapted from 
Wang et al. (2003). 
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* * * * *
Basic Leucine rep
  
Figure 3.2 ATF3 shares significant homology with other ATF/CRE transcription 
factors. ATF3 has significant homology with ATF1 and ATF2 predominantly in the basic 
region (Basic) and the leucine zipper domain (leucine repeat) as indicated in boxed 
sequences. Like most leucine zipper transcription factors, leucine amino acids of the 
zipper domain are repeated every 7 amino acids as indicated by (*). Human ATF3: 
NP_001025458; Human ATF1: NP_005162; Human ATF2: NP_001871; graphic was 
generated using MultiAlin tool (Corpet, 1988) http://bioinfo.genopole-
toulouse.prd.fr/multalin/multalin.html 
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The amino acid sequence homology of mouse ATF3 protein is 99% and 98% with that of 
rat and human proteins respectively (Drysdale et al., 1996). The human ATF3 gene 
contains 5 exons (exons A-E) which encodes a protein of 181 amino acids following 
splicing of the RNA and removal of exon D (Liang et al., 1996) (Figure 3.1A). Thus, 
exon A encodes the 5’ untranslated region, exon B encodes the N-terminal 80 amino 
acids, exon C encodes 36 amino acids which corresponds to the basic region, and exon E 
encodes the C-terminal 65 amino acids which contain the leucine zipper residues (Liang 
et al., 1996) (Figure 3.1A). The rat ATF3 was initially designated liver regenerating factor 
1 (LRF1) and also contains 5 exons. In a similar manner to the human orthologue, rat 
ATF3 mRNA encodes a protein of 181 amino acids which is also a product of exons B, C, 
and E (Hsu et al., 1991; Chen et al., 1994). Several isoforms of ATF3 have been 
described in humans, which are the result of alternative-splicing of the transcribed RNA. 
However, to date such isoforms have not been described in rodents. The ATF3Δzip splice 
variant contains an additional 145 bases (exon D) between exons C and E (Figure 3.1B) 
(Chen et al., 1994). This replacement results in an in-frame termination codon 
immediately after the first leucine residue in the leucine zipper domain. The protein is 
therefore devoid of the leucine zipper dimerization domain and is incapable of binding to 
DNA (Figure 3.1B) (Chen et al., 1994). Recently two alternatively-spliced isoforms 
ATF3Δzip2a/b encoding the same protein of 135 amino acids were also described 
(Hashimoto et al., 2002). These isoforms also lack the leucine zipper domain and are 
unable to form dimers or bind to DNA consensus. Another isoform is ATF3b (Figure 
3.1C) which lacks 39 amino acids of the weak activation region (1–39 amino acids) and 
18 amino acids of the repression region (40–84 amino acids), as a consequence of an 
intron-like deletion of 106 bases from exon B. This isoform retains the intact bZip DNA 
binding domain and therefore has the ability to form dimers with other bZip family 
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members. Interestingly, ATF3b has a higher binding affinity for the ATF/CRE consensus 
than the long isoform (Wang et al., 2003). 
 
3.1.2 ATF3 in cancer 
Accumulating evidence suggests that ATF3 is an important adaptive response of the cell 
to genotoxic agents and that its function in this context may be related to the prevention 
of cell transformation and carcinogenesis. Thus, ATF3 is known to induce or accelerate 
apoptosis in tumour cells treated with chemotherapeutic agents (Yu et al., 1996; Mashima 
et al., 2001; Yan et al., 2005). As discussed in section 1.4.2, the PKB/Akt signalling 
pathway has an important role in regulating cell growth in several cell systems and has 
been proposed as a mediator of cardiac hypertrophy. However, activation of several 
components of this pathway correlates with the development of several forms of cancer, 
including breast cancer (Hutchinson et al., 2001) thyroid carcinoma (Ringel et al., 2001) 
and colon adenocarcimona (Khaleghpour et al., 2004). Therefore, the blockade of this 
pathway is actively being considered as an important target for the development of novel 
antineoplastic drugs (reviewed in Kim et al., 2005). The PI3K inhibitor LY294002 exerts 
antitumorigenic effects and induction of apoptosis in human colon cancer cells both in 
vitro and in vivo (Semba et al., 2002). Interestingly, treatment of colorectal cancer cells 
with the PI3K inhibitor LY294002, leads to ATF3 upregulation secondary to 
phosphorylation of the transcription factor, early growth response 1 (EGR-1). 
Knockdown of the ATF3 gene using small interference RNA (siRNA) suppresses 
LY294002-induced apoptosis in colorectal cancer cells (Yamaguchi et al., 2006). This 
suggests that ATF3 could be responsible for some of the antineoplastic effects of 
LY294002 (Yamaguchi et al., 2006). One important observation derived from several 
microarray studies is that ATF3 expression levels appear to be downregulated in many 
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human cancers, including cancers of colon (Notterman et al., 2001), liver (Chen et al., 
2002), kidney (Higgins et al., 2003), lung (Beer et al., 2002), breast (Sorlie et al., 2001) 
and prostate (Lappointe et al., 2001). Using a cancer profiling array, ATF3 expression 
levels were found to be downregulated by more than 50% in kidney, lung, breast, bladder, 
cervical and ovarian cancers (Yan and Boyd, 2006).  
 
Recently a link between ATF3 and the tumour suppressor p53 was described that has 
shed some light on the possible role of ATF3 in cancer. The transcription factor p53 is an 
important regulator of cell fate and regulates cell cycle arrest and apoptosis (Levine, 
1997). In normal cells, the protein levels of p53 are low as a consequence of a rapid 
turnover (half-life ~20 min) through the ubiquitin proteasome system that quickly 
degrades the protein (Horn and Vousden, 2007). Upon cellular stress by, for example, 
genotoxic agents or oxidative stress, the protein levels of p53 are upregulated via an 
increase in the stability of the protein. This leads to upregulation of p53-dependent genes 
which will promote cell cycle arrest to allow DNA repair, or commit the cells to apoptosis 
to eliminate damaged cells (Horn and Vousden, 2007). The importance of p53 as an 
antitumor gene is highlighted by the finding of mutations of the p53 gene in almost 50% 
of human cancers (Levine, 1997). One of the main regulators of p53 is the MDM2 (mouse 
double minute 2) protein (also known as HDM2 in humans), which binds to the N-
terminal domain of p53 and acts as an ubiquitin ligase, thus adding ubiquitin moieties to 
several lysine residues of the C-terminal domain of the protein (Fang et al., 2000). This 
promotes p53 shuttling from the nucleus to the cytoplasm and its degradation by 
proteasomes (Lohrum et al., 2001). Recently, ATF3 was shown to be induced by the same 
genotoxic stress stimuli that also upregulate p53 (e.g. doxorubicin, camptothecin and 
actinomycin D) (Yan et al., 2005). Under these conditions, ATF3 binds to the C-terminal 
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domain of p53 and this binding leads to concealment of the lysine residues that are 
targeted by MDM2 for the addition of ubiquitin moieties, suggesting that ATF3 prevents 
degradation and increases the stability and activity of p53 by interfering with MDM2 
(Yan et al., 2005). Thus, ATF3 appears to be a regulator of the stability and activity of 
p53, and in this way protect cells from transformation.   
 
 
A dual role for ATF3 in cancer cells has been recently described whereby ATF3 
overexpression enhances apoptosis of untransformed mammary epithelial cells 
(MCF10A). However, ATF3 protects the aggressive MCF10CA1a cancer cells, from 
apoptosis and even increases their motility, thus increasing cell viability and metastatic 
potential (Yin et al., 2007). This correlates with the finding of more than two copies of the 
ATF3 gene in up to 80% of breast tumours with increased expression of ATF3 in 50% of 
tumours evaluated (Yin et al., 2007). This suggests that ATF3 may have both protective 
activities against cell transformation and possible permissive effects in the setting of 
cancer metastasis at least for some types of tumours. 
 
3.1.3 Role of ATF3 in the cardiovascular system  
The physiological functions of ATF3 in the cardiovascular system are not entirely clear, 
and protective as well as harmful effects have been described. ROS production is 
increased during ischaemia or ischaemia/reperfusion, and this plays an important role in 
the development of cardiovascular pathologies because of the increased cellular damage 
to cardiomyocytes secondary to necrosis and/or apoptosis (Clerk et al., 2003). Using 
microarray analysis, ATF3 was shown to be upregulated in rat hearts subjected to 
ischemia/reperfusion, suggesting a possible cytoprotective role during oxidative stress 
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(Simkhovich et al., 2003). Ischaemic preconditioning is a natural phenomenon that occurs 
in the heart and other organs whereby after several brief periods of ischaemia followed by 
reperfusion there is increased resistance to cellular damage when further episodes of 
ischaemia of longer duration are applied (reviewed in Eisen et al., 2004). Recently, one 
study using microarray analysis confirmed that ATF3 is upregulated by 
ischaemia/reperfusion (Canatan, 2007). However, after the induction of ischaemic 
preconditioning by brief periods of ischaemia/reperfusion [3 x (5 min ischaemia followed 
of 10 minutes reperfusion)], ATF3 levels were downregulated during a lethal period of 
ischaemia/reperfusion (Canatan, 2007). The significance of the downregulation of ATF3 
after ischaemic preconditioning in the heart is not clear, but suggests that under these 
conditions of limited cellular damage, ATF3 upregulation is probably not required by the 
cell. ATF3 expression is also increased in the heart by ischaemia alone and ischaemia 
coupled to reperfusion, which appears to depend on JNK activation (Yin et al., 1997). 
 
Increased ROS production has also been associated with the proapoptotic effects of the 
chemotherapeutic drug doxorubicin in cardiomyocytes (Kumar et al., 2002). Under these 
conditions, ATF3 appears to play a cytoprotective role in the cardiovascular system. 
Thus, ATF3 mRNA and protein is upregulated by doxorubicin and adenovirus-mediated 
overexpression of ATF3 protects cardiomyocytes from doxorubicin-induced apoptosis by 
downregulating the transcription factor p53 (Nobori et al., 2002). Adenovirus-mediated 
overexpression of ATF3 in endothelial cells represses the transcription of the p53 gene 
and protects these cells from TNFα induced apoptosis (Kawauchi et al., 2002).  
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Although some of the above evidence suggest that ATF3 is cytoprotective in the 
cardiovascular system, unregulated expression of ATF3 also appears to be harmful. Thus, 
cardiospecific overexpression of ATF3 in mice induces some degree of cardiac 
hypertrophy (which is more prominent in the atria than the ventricles, suggesting diastolic 
dysfunction, which correlates with a reduced relaxation rate), increases myocardial 
fibrosis, reduces cardiac contractility and increases arrhythmogenesis (Okamoto et al., 
2001). Some in vivo studies have also suggested an important but ill-defined role for 
ATF3 in the heart. Microarray studies of the gene expression profiles induced in a model 
of myocardial infarction in rats found that among the genes expressed after 24 h of 
coronary artery ligation, ATF3 is induced in the area remote to the infarct but not within 
the necrotic area (LaFramboise et al., 2005). In contrast, 28 days after the occlusion, 
ATF3 is expressed in both the necrotic and remote areas of the affected heart 
(LaFramboise et al., 2005). Microarrays were also used to evaluate the transcriptional 
profiles of end-stage ischaemic and non-ischaemic cardiomyopathy in humans, and 
demonstrated that ATF3 is downregulated in the ischaemic group (Kittleson et al., 2005). 
However, the specific role of ATF3 was not further investigated in these studies. 
Nevertheless, all the above evidence suggests that ATF3 may be cytoprotective or 
harmful in the cardiovascular system depending on the precise circumstances.  
 
Microarray studies in cardiomyocytes, comparing the changes in the transcriptional 
profile induced by H2O2, and the GqPCR agonist ET-1 (Table 3.1), identified ATF3 as 
one of the genes most potently induced by all these stimuli (Clerk et al., 2005). In this 
chapter, I have characterized the time course of ATF3 mRNA and protein expression in 
cardiomyocytes exposed to the hypertrophic agonist ET-1, or stress-inducing stimuli such 
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as H2O2 or doxorubicin). The signalling pathways involved in ATF3 expression were also 
explored in the setting of stimulation by ET-1. 
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3.2 Methods 
 
3.2.1 RT-PCR 
Cardiomyocytes were exposed to ET-1 (100 nM for 0-6 h or 0-100 nM for 30 min), or to 
H2O2 (0.2 mM for 0-6 h or 0-1 mM for 30 min), or to doxorubicin (3 μM for 0-6 h or 0-10 
μM for 30 min). In some experiments, cardiomyocytes were preincubated for 10 min with 
20 μM cycloheximide before the addition of ET-1, or preincubated for 15 min with 10 
μM U0126, 10 μM SP600125 or 10 μM SB203580 prior to the addition of ET-1. Total 
RNA was extracted and cDNA synthesized (sections 2.3 and 2.5). SQ-PCR and Q-PCR 
were performed (section 2.6) to assess expression of Atf3 or Gapdh mRNA, using primers 
designed across exon boundaries (see Table 2.2). For SQ-PCR 28 cycles of amplification 
for ATF3 and 22 cycles for GAPDH were performed.  
 
 
3.2.2 Immunoblotting 
Cardiomyocytes were exposed to 100 nM ET-1 or 0.2 mM H2O2 for 0-6 h. Nuclear 
proteins were extracted and immunoblotting was then perfomed (sections 2.8.2 and 2.9). 
Briefly, proteins (25 μg) were subjected to SDS-PAGE with a 12% polyacrylamide 
resolving gel and 6% stacking gel. Proteins were transferred to nitrocellulose membranes 
and probed with primary antibody to ATF3 (SC-188, Santa Cruz Biotechnology Inc.). 
Immunoreactive bands were detected by enhanced chemiluminescence and analysed 
semi-quantitatively by scanning densitometry. Values are expressed as arbitrary units. 
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3.3 Results 
 
3.3.1 ATF3 mRNA is upregulated by endothelin-1 
Using microarrays, ATF3 was identified as one of the genes most potently induced in 
cardiomyocytes by H2O2 or ET-1 (Table 3.1) (Clerk et al., 2005). To confirm these data 
and examine the time course of induction in more detail, ATF3 mRNA expression was 
evaluated in cardiomyocytes exposed to 100 nM ET-1 using SQ-PCR. ATF3 mRNA was 
expressed under basal conditions, but was significantly induced in response to ET-1 
(Figure 3.3A). The maximal expression of ATF3 mRNA was at 30 min and rapidly 
returned to near basal levels within 2 h. These results were also validated for 100 nM ET-
1 (0-8 h) using Q-PCR. A similar time course of expression with peak levels of mRNA at 
30 min was observed (Figure 3.3B). The amplification plots (product vs number of 
cycles) for both ATF3 and GAPDH are shown in Figure 3.4. These demonstrate clearly 
the changes in the amount of ATF3 mRNA as a result of the different expression levels at 
different time points, with homogeneous amplification of GAPDH. 
 
The effects of concentrations of ET-1 (30 min) on the expression levels of ATF3, were 
examined. ET-1 caused an increase in ATF3 mRNA expression at concentrations between 
10 nM to 100 nM, whereas concentrations bellow 10 nM did not cause significant 
induction (Figure 3.4). 
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Figure 3.3 ET-1 promotes up-regulation of ATF3 mRNA in cardiocardiomyocytes.  
Cardiomyocytes were unstimulated (controls, zero time) or exposed to ET-1 (100 nM), 
for the indicated periods of time. In (A), the expression of ATF3 mRNA was analysed by 
SQ-PCR and representative images from a single experiment are shown in the upper 
panels. Control PCR reactions were carried out in the absence of reverse transcriptase (-
RT). Densitometric analysis of the data is provided in the lower panel and expressed 
relative to controls after normalization with the housekeeping gene GAPDH. In (B), the 
expression of ATF3 mRNA was analysed by Q-PCR. Results are means ± S.E.M. for four 
independent cardiomyocyte preparations. (* p< 0.05; # p< 0.01, relative to control, one-
way ANOVA with Tukey post test). 
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ATF3
GAPDH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Q-PCR amplification plots for ATF3 and GAPDH. Expression of ATF3 
(top panel) was analysed by Q-PCR, with simultaneous analysis of the housekeeping gene 
GAPDH (lower panel) in each 96-well optical plate as an endogenous control. Notice the 
variance of the amplification plot (product vs number of cycles) for ATF3 compared with 
the homogeneity of the amplification plot for GAPDH, indicating the homogeneous levels 
of housekeeping gene GAPDH, and the different levels of ATF3 expression that are 
quantified with the different treatment conditions. 
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Figure 3.5 Effects of ET-1 concentration on the expression of ATF3 mRNA. 
Cardiomyocytes were unstimulated (controls, zero time) or exposed to ET-1 for 30 min 
with the concentrations indicated. The expression of ATF3 mRNA was analysed by SQ-
PCR and a representative image from a single experiment is shown in the upper panel. 
Control PCR reactions were carried out in the absence of reverse transcriptase (-RT). 
Densitometric analysis of the data is provided in the lower panels and expressed relative 
to controls after normalization with the housekeeping gene GAPDH. Results are means ± 
S.E.M. for three independent cardiomyocyte preparations (* p< 0.01; # p< 0.001, one way 
ANOVA with Tukey post test). 
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3.3.2 ATF3 is an immediate-early gene upregulated by endothelin-1 through the 
ERK1/2 cascade 
The induction of IEGs occurs in the absence of de novo protein synthesis and thus cannot 
be blocked by protein synthesis inhibitors (e.g. cycloheximide) (Woodget et al., 1989; 
Platenik et al., 2000). Given the transient expression of ATF3 in cardiomyocytes in 
response to ET-1 and that activation of the ERK1/2 pathway by GqPCR agonists such as 
ET-1 plays an important role in the development of cardiomyocyte hypertrophy (sections 
1.3.1.5 and 1.3.1.6)  (Bogoyevitch et al., 1993; Bogoyevitch et al., 1994; Bogoyevitch et 
al., 1995a; Gillespie-Brown et al., 1995; Bogoyevitch et al., 1996; Glennon et al., 1996; 
Clerk et al., 1998a; Yue et al., 2000), I then examined whether ATF3 is an IEG, and 
whether or not this was mediated through the ERK1/2 cascade. 
 
Incubation of cardiomyocytes for 30 min with ET-1 in the presence of the protein 
synthesis inhibitor cycloheximide did not reduce the expression levels of ATF3 mRNA 
(Figure 3.6). Indeed, on the contrary, cycloheximide caused superinduction of ATF3 
mRNA expression compared with ET-1 alone (Figure 3.6), suggesting that protein 
synthesis is not involved in ATF3 mRNA upregulation. This confirms that ATF3 is an 
IEG upregulated in cardiomyocytes in response to ET-1. Preincubation of cardiomyocytes 
with the MEK1/2 inhibitor U0126 significantly attenuated the expression of ATF3 mRNA 
induced by ET-1 (Figures 3.6 and 3.7), indicating that the ERK1/2 pathway is involved in 
the upregulation of ATF3 mRNA by ET-1. 
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Figure 3.6 ATF3 is an IEG upregulated in cardiomyocytes by ET-1 through the 
ERK1/2 pathway. Cardiomyocytes were unstimulated (control) or exposed to ET-1 (100 
nM) for 30 min, in the absence or presence of cycloheximide (20 μM), or U0126 (10 
μM). The expression of ATF3 mRNA was analysed by SQ-PCR and representative 
images from a single experiment are shown in the upper panel. Control PCR reactions 
were carried out in the absence of reverse transcriptase (-RT). Densitometric analysis of 
the data is provided in the lower panel and expressed relative to controls after 
normalization with the housekeeping gene GAPDH. Results are means ± S.E.M. for five 
independent cardiomyocyte preparations (# p< 0.001 relative to ET-1, one way ANOVA 
with Tukey post test) (CH= cycloheximide; CONT= control; U0= U0126). 
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3.3.3 JNKs but not p38-MAPKs are also implicated in ATF3 mRNA upregulation in 
response to ET-1 
Previous studies have shown that ATF3 upregulation by the doxorubicin in 
cardiomyocytes could be regulated, at least in part, by the JNK pathway (Nobori et al., 
2002). In other cell systems, p38-MAPK appears to be the main MAPK pathway 
responsible for ATF3 upregulation by agonists such as the protein synthesis inhibitor 
anisomycin, cytokines such as IL-1β, and TNFα and oxidative stress in the form of H2O2 
(Lu et al ., 2007). Therefore, I examined whether p38-MAPK or JNK were involved in 
ATF3 mRNA upregulation in response to ET-1 in cardiomyocytes. 
 
Preincubation of cardiomyocytes for 15 min with 10 μM SB203580, which inhibits p38-
MAPKs in cardiomyocytes (Clerk et al., 2002), did not significantly affect the induction 
of ATF3 mRNA by ET-1, suggesting that this pathway is not necessary for the 
upregulation of ATF3 by ET-1 (Figure 3.7). In contrast, pretreatment of cardiomyocytes 
with 10 μM SP600125 which inhibits JNKs in cardiomyocytes (Clerk et al., 2002), or 
with U0126, an inhibitor of the ERK1/2 pathway, significantly blunted the upregulation 
of ATF3 mRNA induced by ET-1 (Figure 3.7). 
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Figure 3.7 ERK1/2 and JNKs but not p38-MAPKs, are involved in the upregulation 
of ATF3 mRNA in cardiomyocytes in response to ET-1. Cardiomyocytes were 
unstimulated (Control) or exposed to 100 nM ET-1 for 30 min in the absence or presence 
of 10 μM U0126, 10 μM SP600125 or 10 μM SB203580. Cardiomyocytes were also 
exposed to inhibitors alone. The expression of ATF3 mRNA was analysed by SQ-PCR 
and representative images from a single experiment are shown in the upper panel. Control 
PCR reactions were carried out in the absence of reverse transcriptase (-RT). 
Densitometric analysis of the data is provided in the lower panel and expressed relative to 
controls after normalization with the housekeeping gene GAPDH. Results are means ± 
S.E.M. for three independent cardiomyocyte preparations (* p< 0.05; # p< 0.001, relative 
to ET-1, one way ANOVA with Tukey post test). 
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3.3.4 ATF3 protein is upregulated by ET-1 in cardiomyocytes 
To confirm that the increase in ATF3 mRNA was reflected by an increase in ATF3 
protein, the time course of expression of ATF3 protein was studied by western blotting of 
cardiomyocyte nuclear extracts. ATF3 was detected mainly as a band of 21 kDa but also 
as an additional fainter band of slower mobility (~23 kDa) on some occasions. This latter 
band may correspond with a phosphorylated form of ATF3. Consistent with the 
expression of ATF3 mRNA, ATF3 protein was present at low abundance under basal 
conditions and its expression was increased in response to ET-1 (Figure 3.8A). Maximal 
expression was at 1 h. Although the protein levels remained elevated for over 2 h with 
ET-1, expression of ATF3 had declined significantly by 4 h, and levels returned to basal  
by 6 h (Figure 3.8A). To confirm that the input from the ERK1/2 cascade on mRNA 
levels of ATF3 in response to ET-1 was also reflected at the protein level, I examined the 
effect of U0126 on the induction of ATF3 by ET-1. Preincubation of cardiomyocytes for 
15 min with 10 μM U0126 significantly attenuated the expression of ATF3 protein 
induced by 100 nM ET-1 (1 h) (Figure 3.8B). 
 
3.3.5 ATF3 mRNA is upregulated by H2O2 
I then investigated the time course of expression of ATF3 mRNA by H2O2, another 
stimulus that in previous microarray studies from our laboratory was shown to potently 
induce ATF3 (Clerk et al., 2005). ATF3 mRNA expression was evaluated in 
cardiomyocytes exposed to 0.2 mM H2O2 using SQ-PCR. ATF3 mRNA was expressed 
under basal conditions, but was induced in response to H2O2 (Figure 3.9A). The peak of 
expression of ATF3 mRNA was at 1-2 h (Figure 3.9A) and levels returned to basal after 6 
hours. 
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Figure 3.8 ATF3 protein expression is upregulated by ET-1 through the ERK1/2 
cascade. In (A), cardiomyocytes were unstimulated (control, zero time), exposed to 100 
nM ET-1 for the indicated times. In (B), cardiomyocytes were unstimulated (control) or 
exposed to ET-1 (100 nM) for 1 h, in the absence or presence of U0126 (10 μM), or 
exposed to U0126 alone. Nuclear extracts (25 μg) were immunoblotted with antibodies to 
ATF3 and representative images are shown in the upper panels. The blots were analysed 
by scanning densitometry and the combined data are shown in the lower panels as means 
± S.E.M. for three independent preparations of cardiomyocytes. (In (A) # p< 0.001 
relative to control; in (B) # p< 0.001 relative to ET-1, one-way ANOVA with Tukey post 
test). 
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 The effects of H2O2 concentration (1 h) on the expression levels of ATF3 were also 
examined. H2O2 caused an increase in ATF3 mRNA expression at a concentration of 0.1 
mM with a similar level of induction up to at least 1 mM (Figure 3.9B). In contrast, 
concentrations below 0.1 mM did not cause any significant increase in ATF3 mRNA 
expression (Figure 3.9B). 
 
3.3.6 ATF3 protein is upregulated by H2O2 
I also confirmed that the increase in ATF3 mRNA was reflected by an increase in protein, 
and explored the time course of expression of ATF3 protein by immunoblotting of 
cardiomyocyte nuclear extracts. Consistent with the expression of ATF3 mRNA (Figure 
3.9A), ATF3 protein was present at low abundance under basal conditions and was 
rapidly induced from 1 h with maximal expression at 2 h (Figure 3.10). The protein levels 
then declined by 4 h returning to near basal levels at 6 h (Figure 3.10). 
 
3.3.7 ATF3 mRNA is downregulated by doxorubicin in cardiomyocytes 
Doxorubicin is a very effective anticancer drug that is associated with high incidence of 
cardiomyopathy, probably as a consequence of increased production of reactive oxygen 
species and apoptosis of cardiac cardiomyocytes (Kumar et al., 2002). A previous study 
has shown that doxorubicin induces the expression of ATF3 at both mRNA and protein 
levels in cardiomyocytes (Nobori et al., 2002). I sought to confirm the effects of 
doxorubicin on the expression of ATF3. ATF3 mRNA expression was evaluated in 
cardiomyocytes exposed to 3 μM doxorubicin using SQ-PCR. ATF3 mRNA was 
expressed under basal conditions but, although there was a tendency towards increased 
expression by 30 min, this was not statistically significant (Figure 3.11A). In contrast,  
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Figure 3.9 ATF3 mRNA expression is upregulated by H2O2 in cardiomyocytes. In 
(A), cardiomyocytes were unstimulated (control, zero time) or exposed to 0.2 mM H2O2 
for the indicated periods of time. In (B), cardiomyocytes were unstimulated (Control) or 
exposed to H2O2 for 1 h at the concentrations indicated. The expression of ATF3 mRNA 
was analysed by SQ-PCR and representative images from a single experiment are shown 
in the upper panels. Control PCR reactions were carried out in the absence of reverse 
transcriptase (-RT). Densitometric analysis of the data is provided in the lower panels and 
expressed relative to controls after normalization with the housekeeping gene GAPDH. 
Results are means ± S.E.M. for three independent cardiomyocyte preparations (* p< 0.01; 
and # p< 0.001, one way ANOVA with Tukey post test). 
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Figure 3.10 ATF3 protein expression is upregulated by H2O2. Cardiomyocytes were 
unstimulated (control, zero time) or exposed to 0.2 mM H2O2 for the indicated times. 
Nuclear extracts (25 μg) were immunoblotted with antibodies to ATF3 and a 
representative image are shown in the upper panel. The blots were analysed by scanning 
densitometry and the combined data are shown in the lower panel as means ± S.E.M. for 
three independent preparations of cardiomyocytes. (# p< 0.001 relative to control, one-
way ANOVA with Tukey post test). 
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ATF3 mRNA expression not only declined after 1 h, but the mRNA was significantly 
downregulated within 3 hours and remained downregulated for 6 h following doxorubicin 
exposure (Figure 3.11A). I then explored the effects of different concentrations of 
doxorubicin on the expression levels of ATF3 mRNA (30 min). Doxorubicin had a 
tendency towards induction of ATF3 mRNA levels only at a concentration of 3 μM, 
however this effect was not statistically significant (Figure 3.11B). 
 
3.3.8 ATF3 protein levels are transiently upregulated and then downregulated below 
basal levels by doxorubicin in cardiomyocytes 
I then evaluated the time course of ATF3 protein expression by doxorubicin using 
immunoblotting. As in other experiments (see sections 3.3.4 and 33.6), ATF3 protein was 
present at low abundance under basal conditions, and was significantly induced at 30 min 
(Figure 3.12). Interestingly, as with the mRNA levels of ATF3 (see above) the protein 
levels quickly declined and were downregulated below basal levels after 1 h and this was 
significant at the 6 h time point (Figure 3.12). 
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Figure 3.11 Doxorubicin downregulates the expression of ATF3 mRNA in 
cardiomyocytes. In (A), cardiomyocytes were unstimulated (control, zero time) or 
exposed to 3 μM doxorubicin for the indicated periods of time. In (B), cardiomyocytes 
were unstimulated (Control) or exposed to doxorubicin for 30 min at the concentrations 
indicated. The expression of ATF3 mRNA was analysed by SQ-PCR and representative 
images from a single experiment are shown in the upper panels. Control PCR reactions 
were carried out in the absence of reverse transcriptase (-RT). Densitometric analysis of 
the data is provided in the lower panels and expressed relative to controls after 
normalization with the housekeeping gene GAPDH. Results are means ± S.E.M. for three 
independent cardiomyocyte. (* p< 0.05 relative to control, one-way ANOVA with Tukey 
post test). 
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Figure 3.12 Doxorubicin transiently upregulates ATF3 protein levels, and then 
downregulates its expression below basal levels. Cardiomyocytes were unstimulated 
(control, zero time) or exposed to 3 μM doxorubicin for the indicated periods of time. 
Nuclear extracts (25 μg) were immunoblotted with antibodies to ATF3 and a 
representative image is shown in the upper panel. The blots were analysed by scanning 
densitometry and the combined data are shown in the lower panel as means ± S.E.M. for 
three independent preparations of cardiomyocytes. (* p< 0.05 relative to control, one-way 
ANOVA with Tukey post test). 
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3.4 Discussion 
3.4.1 Expression of ATF3 mRNA and protein in cardiomyocytes 
ATF3 is upregulated in response to many stress stimuli in several tissues and cell systems 
(Hai et al., 1999). It has been postulated that one of the main functions of this 
transcription factor is to provide the cell with the means to cope with stress during the 
early stages of the response (reviewed in Hai et al., 2001). Previous studies in 
cardiomyocytes have documented acute upregulation of ATF3 mRNA and protein levels 
in response to the anticancer drug doxorubicin, which appears to be cytoprotective under 
these conditions (Nobori et al., 2002). However, the effects on ATF3 gene expression 
caused by stimuli also associated with cardiac pathologies such as hypertrophic 
stimulation by GqPCR agonists (e.g. ET-1, PE) or oxidative stress in the form of H2O2 
has not been studied in these cells.  
 
The experiments in this chapter demonstrate that ATF3 mRNA and protein abundance are 
increased in cardiomyocytes in response to ET-1 or H2O2 (Figures 3.3-3.9).  As assessed 
by SQ-PCR and Q-PCR, the expression of ATF3 mRNA was potently induced by either 
H2O2 or ET-1 (Figures 3.3, 3.5 and 3.9), in agreement with previous microarray studies 
from our laboratory (Clerk et al., 2005).  The effects of either agonist on the expression of 
ATF3 mRNA in cardiomyocytes were concentration-dependent (Figures 3.5 and 3.9). At 
the range of concentrations which induce ATF3 mRNA expression (10-100 nM), ET-1 
promotes cardiomyocyte hypertrophy and this is mediated through signalling events 
dependent on the ERK1/2 pathway, a signalling cascade which also appears to be 
cytoprotective in cardiomyocytes (Yue et al., 2000). However, the concentrations of H2O2 
which induce ATF3 expression (0.1-1 mM) (Figure 3.9) cause apoptosis (0.1-0.3 mM) or 
necrosis (> 0.5 mM) of cardiomyocytes (Cook et al. 1999; Kwon et al., 2003). 
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 In addition to increasing the abundance of ATF3 mRNA, ET-1 or H2O2 also caused an 
increase in the expression of ATF3 protein (Figures 3.8 and 3.10). The induction of ATF3 
mRNA and protein by ET-1 in cardiomyocytes was statistically significant. Although 
there are no previous reports of ET-1 induction of ATF3 in this or other cell systems, it 
has been reported that peptide growth factors or PMA, do induce such a response in other 
cell systems. Thus, treatment of the RAW 264.7 mouse macrophage cell line with PMA 
(3 h) induces the expression of ATF3 mRNA (Farber, 1992). In addition, EGF or hepatic 
growth factor potently induce the expression of ATF3 mRNA in rat hepatocytes (maximal 
at 1 h) (Weir et al., 1994). Similarly, FGF induces the expression of ATF3 (4 h) in 
neuroblastoma cells (Tan et a., 1994). 
  
The effect of H2O2 on ATF3 induction was also statistically significant and in agreement 
with previous studies in other cell systems and in cardiomyocytes. Thus, direct exposure 
of rat (r-RIN) and mouse (β TC6) pancreatic islet cells to 0.1 mM H2O2 for 1 h leads to 
increased expression of ATF3 mRNA (Allen-Jennings et al., 2001) However, the time 
course of expression was not explored in this study. The anticancer drug doxorubicin, 
appears to cause apoptosis, at least in part as a consequence of increased ROS production 
(Bachur et al., 1979; Yu et al., 1996). In human H9 leukaemia cell line treated with 
doxorubicin the expression of ATF3 was upregulated within 1 h and remained elevated 
over 6 h (Bachur et al., 1996). This induction of ATF3 expression correlated with JNK 
activation, increased c-jun mRNA expression and induction of apoptosis, suggesting that 
ATF3 may be involved in the elimination of cancer cells by cytotoxic agents like 
doxorubicin. 
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Importantly, the adverse effects of doxorubicin and related compounds in the heart 
frequently cause a severe form of cardiomyopathy. This cardiomyopathy is dependent on 
the cumulative dose administered to the patient (Minotti et al., 2004), and also appears to 
be mediated through the increased production of superoxide radical anion (O2˙¯), which is 
quickly converted into H2O2 or peroxynitrite (Dorr, 1996; Kumar et al., 2002). Consistent 
with this, doxorubicin and related compounds such as daunorubicin cause apoptosis of 
cardiomyocytes secondary to increased production of ROS (Sawyer et al. 1999; reviewed 
in Minotti et al., 2004). Interestingly, previous reports have shown that doxorubicin 
induces the expression of ATF3 mRNA and protein in cardiomyocytes, with maximal 
expression at 1 h and 2 h, respectively (Nobori et al., 2002). In these settings, increased 
expression of ATF3 has been postulated to be cytoprotective. Thus, adenovirally-
mediated overexpression of ATF3 in these cells prevents doxorubicin-induced apoptosis 
(Nobori et al., 2002). Using SQ-PCR, I also observed that ATF3 mRNA abundance tends 
to increase in cardiomyocytes exposed to doxorubicin for 30 min, but this does not appear 
to be statistically significant. However, subsequent downregulation of the expression of 
ATF3 mRNA below basal levels is statistically significant (Figure 3.9). Our studies also 
show a significant (though small) increase in expression of ATF3 protein levels following 
doxorubicin stimulation (Figure 3.10). However, this was followed by significant 
downregulation of ATF3 protein below basal levels. Although the reasons for these 
discrepancies between the data presented here and those of Nobori et al. (2002) are not 
clear, it is possible that the methodology employed (Northern blot (Nobori et al., 2002) vs 
SQ-PCR here) or doxorubicin concentration (1 μM (Nobori et al., 2002) vs 3 μM here) 
may have influenced these observations. However, the concentration dependence suggests 
that this is not the case, because at the 1 μM concentration I still did not observe any 
increase in the transcript levels of ATF3 (Figure 3.9). 
 152
 3.4.2 ATF3 is an IEG 
My experiments show that ATF3 is an IEG which is rapidly and transiently induced by 
ET-1 in a process that does not require de novo protein synthesis (Figure 3.5). Although 
this has not been previously shown in cardiomyocytes, previous studies in other cell 
systems and tissues have suggested that ATF3 is indeed an IEG which may be activated 
by growth or stress signals. Thus, ATF3 mRNA levels are low under basal conditions, but 
dramatically increase upon stimulation by serum (Mohn et al., 1991; Chen et al., 1994). 
The 3’ untranslated region (3’ UTR) of the ATF3 mRNA contains several AU-rich 
sequences, which is a characteristic of many IEGs (Chen et al., 1994; Hsu et al., 1994), 
and this also appears to be responsible for the short half life of these so called “labile 
mRNAs” (Zubiaga et al., 1995; Barreau et al., 2006). In fact, this may also explain at least 
in part the transient expression of ATF3 observed upon ET-1 and H2O2 (Figures 3.3, 3.8, 
3.9, and 3.10). It was also evident from experiments from Figure 3.6 that cycloheximide 
alone induces the expression of ATF3 mRNA which correlates with the induced 
expression of ATF3 previously reported in hepatocytes (Weir et al., 1994). A common 
characteristic of many IEGs is the superinduction of their expression in the presence of 
cycloheximide (Woodgett, 1989), and this was also observed in our experiments (Figure 
3.5), although this was not statistically significant. 
 
ATF3 has been previously described as a negative regulator of transcription (Chen et al., 
1994). Thus, another potential explanation for the transient expression of ATF3 in these 
experiments is that once ATF3 message is translated into protein, the active ATF3 may 
feedback into its own promoter and cause transcriptional repression of the message. In 
agreement with this hypothesis, there also is evidence that ATF3 causes autorepression of 
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its own transcription and several ATF/CRE consensus sequences located in the promoter 
of ATF3 are required for efficient repression (Wolfgang et al., 2000). 
 
3.4.3 Regulation of ATF3 expression by ET-1 is mediated through the ERK1/2 and 
JNK signalling pathways 
There are suggestions in the literature that ATF3 activity and/or expression is regulated 
by protein kinases, but how this occurs is not yet completely understood. Of the different 
kinase superfamilies, MAPKs are the most likely. Thus, many stress responses that are 
implicated in ATF3 expression are known to activate one or more of the MAPKs. For 
example, ischaemia or ischaemia/reperfusion cause increased expression of ATF3 in the 
heart and the kidney (Yin et al., 1997), and this same stress causes activation of all 
MAPK cascades in the heart, although most prominently JNKs and p38-MAPKs 
(Bogoyevitch et al., 1996; Clerk et al., 1998). Recently, ATF3 gene and protein 
expression was shown to be induced in cardiomyocytes by doxorubicin, and the 
phosphorylation of JNK, (but not p38-MAPKs or ERK1/2) was documented as emulating 
the time course of expression of ATF3, which was interpreted as indirect evidence for a 
role of JNK in ATF3 regulation (Nobori et al., 2002).  
 
A recent report studied the involvement of the MAPKs cascades on the expression of 
ATF3 in several transformed cells lines. Using a variety of agonists (anisomycin, IL-1β, 
TNFα or H2O2) appear to promote ATF3 mRNA and protein expression via the p38-
MAPK signalling cascade (Lu et al., 2007). In contrast, neither ERK1/2 nor JNKs seem to 
be necessary or sufficient for ATF3 induction by these agonists (Lu et al., 2007). 
However, studies in other systems have led to different conclusions. Thus, induction of 
ATF3 expression by the non-steroidal anti-inflammatory drug sulindac in colon cancer 
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cells is mediated through the increase in the transcriptional activity of Egr-1 on the ATF3 
promoter (Bottone et al., 2005). This effect was inhibited by overexpression of a 
dominant negative ERK1 (dn-ERK1) and by the ERK1/2 cascade inhibitor PD98059, 
indicating the importance of this pathway in regulating ATF3 expression in this system 
(Bottone et al., 2005). In endothelial cells, JNKs play an important role in upregulation of 
ATF3 by homocysteine (Cai et al., 2000) or by TNFα (Inoue et al., 2004). In contrast, 
activation of the ERK1/2 pathway by TNFα may downregulate ATF3 levels in this same 
system (Inoue et al., 2004). This suggests that upregulation of ATF3 by a particular 
MAPK cascade may depend on the cellular context. 
 
ET-1 and other GqPCR agonists potently activate the ERK1/2 cascade and this signalling 
cascade plays a major role in cardiac hypertrophy both in vitro and in vivo (sections 
1.3.1.5, 1.3.1.6) (Bogoyevitch et al., 1993; Bogoyevitch et al., 1994; Bogoyevitch et al., 
1995a; Gillespie-Brown et al., 1995; Bogoyevitch et al., 1996; Glennon et al., 1996; Clerk 
et al., 1998a; Bueno et al., 2000; Yue et al., 2000). Given the importance of the ERK1/2 
pathway in cardiac hypertrophy, and the potency of GqPCR in activating this pathway, I 
explored the role of the 3 major subfamilies of MAPKs in the regulation of ATF3 
expression in response to ET-1. My experiments demonstrated that ATF3 is not only an 
IEG induced by ET-1 (see above), but also the upregulation of this IEG is mediated 
particularly through the ERK1/2 cascade (Figure 3.6). Thus, the upregulation of ATF3 
mRNA and protein in response to ET-1 was significantly inhibited by the ERK1/2 
inhibitor U0126 (Figure 3.7 and 3.8B) and to a lesser extent but also significant ATF3 
mRNA levels by the JNK inhibitor SP600125 (Figure 3.7). This suggests that ATF3 
upregulation by ET-1 in cardiomyocytes is mediated mainly through the ERK1/2 cascade 
with some input from the JNKs, although the relative lack specificity of SP600125 for 
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inhibition of the JNK cascade may be partially responsible for the effect observed on 
ATF3 upon ET-1 stimulation (Figure 3.7) (Bain et al., 2007). However, in contrast to 
other studies that suggests p38-MAPK is the main regulator of ATF3 mRNA and protein 
in several cell lines (Lu et al., 2007), the p38-MAPK pathway does not appear to have a 
significant involvement in the regulation of ATF3 in cardiomyocytes following 
stimulation by ET-1 (Figure 3.7). 
 
ATF3 is a basic leucine zipper member and similarity with other members of this family 
of transcription factors has been described. Thus, ATF3 and c-Fos (another IEG) share 
homology in the b-Zip region and some authors have proposed that they probably evolved 
from a common ancestor (Meyer and Habener, 1993). In addition, human ATF3 and c-
Jun dimerization protein 2 (JDP2) have 90% homology at the b-Zip motif (Katz and 
Aronheim, 2002). However, despite the fact that the conserved b-Zip region of ATF3 
derived from several species possesses an identical putative phosphoacceptor site to JDP2 
(Thr-148), ATF3 does not appear to be phosphorylated by any of the MAPKs, whereas 
phosphorylation of this site is crucial for JDP2 phosphorylation by JNKs (Katz and 
Aronheim, 2002). Therefore it is unlikely, that ERK1/2 or JNKs may influence the 
transactivating activity of ATF3, and probably their role in the regulation of ATF3 in 
cardiomyocytes is restricted to influence the signalling events leading to the upregulation 
of this IEG. 
 
Interestingly, although it may be coincidental, JNKs, p38-MAPK or ATF3 cardiospecific 
over-expressing transgenic mice produce similar phenotypes, consisting of conduction 
disturbances, myocardial fibrosis and heart failure (Liao et al., 2001; Okamoto et al., 
2001; Petrich et al., 2002; Liang and Molkentin 2003; Petrich et al., 2003; Petrich et al., 
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2004). The cardiac hypertrophic phenotype in these transgenic mice is not as marked as in 
other models [e.g. MKK1 overexpression (Bueno et al., 2000)], and all these studies 
describe bilateral atrial enlargement after MKK7, MKK3, MKK6 or ATF3 
overexpression. An additional finding common to the phenotypes derived from cardiac 
overexpression of ATF3, p38-MAPKs and JNKs is that most studies are inconclusive 
with respect to their apoptotic effects, with both pro- and anti-apoptotic effects described, 
suggesting a context dependent outcome for their effects on apoptosis (Liao et al., 2001; 
Okamoto et al., 2001; Petrich et al., 2002; Liang and Molkentin 2003; Petrich et al., 2003; 
Petrich et al., 2004; Mitchell et al., 2006). 
 
Upregulation of ATF3 in cardiomyocytes in response to doxorubicin appears to be 
cytoprotective (Nobori et al., 2002). It is possible that technical differences (e.g. 
concentration used) prevented me from replicating the previously described upregulation 
of ATF3 with doxorubicin. Nevertheless, the data of Nobori et al. (2002) suggest that 
ATF3 induction in response to oxidative stress in the form of doxorubicin is 
cytoprotective. The experiments presented here suggest that ATF3 may play an important 
role in the regulation of the cellular response to oxidative stress and hypertrophic 
stimulation. However, the specific role of ATF3 in response to ET-1 or H2O2 remains to 
be established. Further experiments will evaluate the physiological consequences of 
ATF3 induction in cardiomyocytes in response to oxidative stress and ET-1. 
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Chapter 4 
 
Regulation of interleukin 6 expression by ATF3 in 
cardiomyocytes 
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4.1 Introduction 
In chapter 3, I have demonstrated that the transcription factor ATF3 is an IEG that may play 
an important role in the hypertrophic or stress response of cardiomyocytes as indicated by the 
potent induction of its mRNA and protein by ET-1 or H2O2. The availability of the complete 
sequence of the human genome and several others such as the rat and mouse, has led to the 
cataloguing of thousands of genes (~25,000) which are protein-coding genes (International 
Human Genome Sequencing Consortium, 2004). The major task now is to understand how 
the changes in the expression of genes in different cells and tissues lead to alterations in the 
structure and function of organs such as the heart during adaptive responses such as cardiac 
hypertrophy or in pathological ventricular remodelling following myocardial infarction. 
Accordingly, to characterize further the physiological function of ATF3 in cardiomyocytes 
exposed to ET-1 or H2O2, it is important to identify the potential downstream targets. 
 
As discussed in chapter 1 the gp130 cytokines (also known as IL-6 family of cytokines) 
appears to play an important role in disease states such as heart failure (section 1.3.3). The 
most studied members of this family in the heart include CT-1, LIF and IL-6 (Pennica et al., 
1996; Wollert et al., 1996). It is well-established that this family of cytokines acting on their 
cognate receptors activate several signalling pathways including the ERK5 signalling 
cascade, which cause elongation of cardiomyocytes by directing sarcomeric assembly in 
series (Wollert et al., 1996). Due to the circumferential disposition of cardiomyocytes in the 
ventricle, myocyte elongation may ultimately translate into eccentric hypertrophy and 
ventricular dilatation (section 1.1) (Grossman, 1975). It is for this reason that, since the 
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discovery of cardiotrophin-1, this and other members of the gp130 cytokines have been 
postulated as direct mediators of the alterations in the dilatation of the heart observed in the 
progression to heart failure (Wollert et al., 1996; Hunter and Chien, 1999). Other signalling 
cascades activated by the IL-6 family upon binding to their receptors are the ERK1/2 
cascade, the PKB/Akt pathway and the JAK/STAT pathway, all of which are probably 
involved in cytoprotection and prevention of apoptosis in the cardiomyocyte following 
oxidative stress (reviewed in Hilfiker-Kleiner et al., 2006).  
 
IL-6 has an important role in the regulation of the immune response defence of the organism. 
Thus, upon stimulation with foreign antigens from invading bacteria, such as bacterial 
lipopolysaccharide (LPS), the activation of receptors (e.g. Toll-like receptors) in the cells of 
the innate immune system (e.g. monocytes, the first line of defence of the organism) leads to 
their activation and removal of the invader (Royet et al., 2005). Under these conditions, the 
mounting of a proper defence response not only involves destruction and removal of the 
pathogenic agents (e.g. bacteria), but also the preservation of the integrity of the organism by 
avoiding excessive inflammation and tissue damage. This process is positively regulated, at 
least in part, by cytokines such as IL-6 secreted by activated monocytes, and there is 
evidence that increased expression of IL-6 leads to chronic inflammation and autoimmune 
diseases (reviewed in Rose-John et al., 2007). Recently, IL-6 was identified as one of the 
direct targets of ATF3 in monocytes activated with LPS. Thus, during the initial phase of the 
response, LPS induces the expression of IL-6 within a period of 2 h, and this correlates with 
the activation of monocytes into cytotoxic macrophages. However, after more prolonged 
exposure, ATF3 is upregulated and this correlates with a reduction in the expression levels of 
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IL-6 4-6 h following stimulation (Gilchrist et al., 2006). This suggests that ATF3 may 
contribute to the modulation of the immune response. In agreement with this hypothesis, 
using chromatin immunoprecipitation (ChIP), ATF3 can be identified as being bound to the 
promoter of IL-6 within 4 h of stimulation of monocytes with LPS. Injection of LPS into 
ATF3 -/- mice, leads to sustained inflammation and increased mortality, which correlates 
with significantly increased levels of IL-6 in the serum of ATF3-deficient mice compared 
with wild-type animals. This suggests that ATF3 is involved in the regulation of the LPS-
Toll-like receptor-stimulated inflammatory response in a negative feedback loop (Gilchrist et 
al., 2006). 
 
Parallel studies from our laboratory indicate that IL-6 is a gene whose expression is 
significantly induced upon stimulation with ET-1 or H2O2 in cardiomyocytes at different time 
points (Table 4.1) (Cullingford et al., manuscript submitted). Because IL-6 and other 
members of the family may play an important role in cardiac pathologies, I further 
characterized the expression of IL-6 mRNA and protein, and evaluated the binding of ATF3 
to the rat IL-6 promoter using ChIP assays in cardiomyocytes stimulated with ET-1 or H2O2. 
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 Table 4.1 Upregulation of IL-6 in cardiomyocytes by ET-1 or H2O2 (microarray analysis). 
 
 
 
 
 
 
 
 
IL-6
H2O2 (0.2 mM)
Time             Fold stimulation
2 h 15.2
4 h 7.4
24 h 6.4
ET-1 (100 nM)
Time Fold stimulation
30 min 4.6
1 h 2.2
2 h 1.0
4 h 1.1
24 h  1.5
Affymetrix probe set 1369191_at
Myocytes were exposed to ET-1 or H2O2 for the indicated times. RNA was extracted, cRNA 
was prepared and samples hybridized to Affymetrix Rat Genome 230 2.0 arrays.  Array data 
were analysed by MicroArray Suite 5.0 followed by Genespring 7.31.  Results are expressed 
as fold stimulation relative to control (n = 3). 
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4.2 Methods 
4.2.1 RT-PCR 
Cardiomyocytes were exposed to ET-1 (100 nM for 0-6 h), or to H2O2 (0.2 mM for 0-6 h). In 
some experiments, cardiomyocytes were preincubated for 10 min with 20 μM cycloheximide 
or for 15 min with 10 μM U0126, prior to the addition of ET-1. Total RNA was extracted and 
cDNA synthesized (Sections 2.3 and 2.5). SQ-PCR and Q-PCR were performed (Section 2.6) 
to assess expression of IL-6 and Gapdh mRNA. For SQ-PCR 29 cycles of amplification for 
IL-6 and 22 cycles for GAPDH were performed. 
 
4.2.2 Immunoblotting 
Cardiomyocytes were exposed to 100 nM ET-1 or 0.2 mM H2O2 (0-4 h) and then 
immunoblotting of total protein extracts (10 μg) performed (Sections 2.8.1 and 2.9). The 
primary antibodies used were to IL-6 (SC-1266, Santa Cruz Biotechnology). Bands were 
analysed by semi-quantitative scanning densitometry.  
 
4.2.3 Slot-blotting 
Cardiomyocytes were exposed to 100 nM ET-1 or 0.2 mM H2O2 (0-4 h), conditioned media 
was collected and slot-blotting performed (section 2.10). Immuno-detection of IL-6 was then 
performed as described in section 2.9. The primary antibody used was to IL-6 (SC-1266, 
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Santa Cruz Biotechnology Inc.). Bands were analysed by semi-quantitative scanning 
densitometry. 
 
4.2.4 Promoter analysis 
The analysis of the promoter sequence of IL-6 was performed using the tool TRANSFAC 4.0 
available at the website address: 
http://www.gene-regulation.com/pub/programs/alibaba2/index.html?  
 
4.2.5 Chromatin immunoprecipitation (ChIP) assay 
Cardiac myocytes were unstimulated or exposed to 100 nM ET-1 (1 h) or 0.2 mM H2O2 (2 h) 
and ChIP assays were performed (Section 2.11). The ATF3 antibody (10 μg) used in the 
immunoprecipitation was from Santa Cruz Biotechnology Inc (SC-188X). The primers used 
for PCR were specific to the IL-6 promoter at the boundaries of the ATF/CRE consensus 
(Sense 5’- TGC TCA AGT GCT GAG TCA CT -3’; Antisense 5’- AGA CTC ATG GGA 
AAA TCC CA -3’) (see also section 4.3.4), or to an arbitrary downstream sequence lying 
2000 bp 3’ to the IL-6 promoter (Sense 5'- CAC CTC TCC ACC CTG ACA TT -3'; 
Antisense 5'- CCA ACT AGA CAG CCC AGA GC -3'). PCR products were analysed by 
scanning densitometry. 
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4.3 Results 
4.3.1 IL-6 mRNA is upregulated in response to ET-1 
Using microarray analysis parallel studies from our laboratory indicated that IL-6 is one of 
the genes upregulated by ET-1 or H2O2 in cardiomyocytes (Table 4.1) (Cullingford et al., 
manuscript submitted). Recent studies have identified IL-6 as a downstream target of ATF3 
in other systems (Gilchrist et al., 2006). To confirm the microarray data and delineate the 
time course of induction of IL-6 mRNA in more detail, I evaluated the expression of IL-6 in 
cardiomyocytes in response to ET-1 using SQ-PCR. As shown in Figure 4.1A, IL-6 
transcripts are present at low abundance under basal conditions, but after stimulation of 
cardiomyocytes with ET-1 there is a potent induction from as early as 15 min. This is 
followed by a peak of expression at 30 min, and then a significant decline in the mRNA 
abundance within 1 h post-stimulation, with return to near basal levels by 2 h (Figure 4.1A). 
These results were also confirmed by Q-PCR. A similar time course of expression of IL-6 
with peak of mRNA at 30 min was observed (Figure 4.1B). 
 
4.3.2 IL-6 is an IEG upregulated by ET-1 through the ERK1/2 cascade 
Given the transient nature of the expression of IL-6 following stimulation with ET-1 and the 
importance of the ERK1/2 cascade in the signalling events activated by GqPCR agonists such 
as ET-1 during cardiomyocyte hypertrophy (Bogoyevitch et al., 1993; Bogoyevitch et al., 
1994; Bogoyevitch et al., 1995a; Gillespie-Brown et al., 1995; Bogoyevitch et al., 1996; 
Glennon et al., 1996; Clerk et al., 1998a; Yue et al., 2000), I further evaluated whether IL-6 
was an IEG and whether or not upregulation or IL-6 mRNA was mediated via the ERK1/2 
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pathway. Incubation of cardiomyocytes with the protein synthesis inhibitor cycloheximide 
and ET-1 did not cause a decrease in the expression of IL-6 mRNA abundance at 30 min. On 
the contrary, this treatment caused a superinduction of IL-6 expression compared with ET-1 
alone (Figure 4.2). Even in the absence of ET-1, cycloheximide caused significant induction 
of IL-6 (Figure 4.2). This confirmed that IL-6 expression does not require de novo protein 
synthesis and therefore exhibits the characteristic pattern of expression of an IEG: acute and 
transient induction in the absence of de novo protein synthesis (Woodget et al., 1989; 
Platenik et al., 2000). Preincubation of cardiomyocytes with the MEK1/2 inhibitor U0126 
significantly attenuated the expression of IL-6 mRNA induced by ET-1 (Figure 4.2), 
indicating that the ERK1/2 pathway is involved in the upregulation of IL-6 mRNA by ET-1 
in cardiomyocytes. 
 
4.3.3 IL-6 protein expression is upregulated in response to ET-1 
To confirm that IL-6 mRNA was translated into protein, I evaluated the expression of IL-6 
protein by immunoblotting of total protein extracts from cardiomyocytes and also using slot-
blotting of the conditioned media from cardiomyocytes in culture since IL-6 should be 
secreted. IL-6 protein was detected by immunoblotting of cardiomyocyte extracts as one 
band of 25 kDa. Consistent with the expression of IL-6 mRNA, the protein abundance of IL-
6 was low under basal conditions and was induced by ET-1 stimulation (Figure 4.3). 
Maximal expression of IL-6 protein was at 1 to 2 h and levels then declined after 4 h (Figure 
4.3A). 
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Figure 4.1 Upregulation of IL-6 mRNA by ET-1 in cardiomyocytes. Cardiomyocytes 
were unstimulated (controls, zero time) or exposed to 100 nM ET-1 for the indicated period 
of time. In (A), the expression of IL-6 mRNA was analysed by SQ-PCR and representative 
images from a single experiment is shown in the upper panel. Densitometric analysis of the 
data is provided in the lower panel and expressed relative to controls after normalization with 
the housekeeping gene GAPDH for three independent cardiomyocyte preparations. In (B), 
the expression of IL-6 mRNA was analysed by Q-PCR with simultaneous analysis of 
GAPDH in each 96-well plate as an endogenous control using the relative quantification 
protocol. Results are means ± S.E.M. for four independent cardiomyocyte preparations. (* p< 
0.01; # p< 0.001 relative to control, one way ANOVA with Tukey post test).
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Figure 4.2 IL-6 is an IEG upregulated by ET-1 through the ERK1/2 signalling pathway 
in cardiomyocytes. Myocytes were unstimulated (control) or exposed to ET-1 (100 nM) for 
30 min, in the absence or presence of cycloheximide (CHX) (20 μM), or U0126 (10 μM). 
The expression of IL-6 mRNA was analysed by SQ-PCR and representative images from a 
single experiment are shown in the upper panel. Densitometric analysis of the data is 
provided in the lower panel and expressed relative to controls after normalization with the 
housekeeping gene GAPDH. Results are means ± S.E.M. for five independent cardiomyocyte 
preparations (* p< 0.01 relative to ET-1, one way ANOVA with Tukey post test). 
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Figure 4.3 IL-6 protein is upregulated by ET-1 in cardiomyocytes. Cardiomyocytes were 
unstimulated (controls) or exposed to 100 nM ET-1 for the indicated periods of time. In (A), 
total protein extracts were immunoblotted with antibodies to IL-6 and a representative image 
is shown in the upper panel. In (B), conditioned media was collected, slot-blotted and then 
probed with antibodies against IL-6 and a representative image is shown in the upper panel. 
The blots were analysed by scanning densitometry and the combined data are shown in the 
lower panels as means ± S.E.M. for three independent preparations of cardiomyocytes. (* 
p<0.05; # p< 0.01 relative to controls, one way ANOVA with Tukey post test). 
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In the slot-blotting experiments, there was induction (secretion) of IL-6 protein from 1 h that 
remained elevated up to 4 h (Figure 4.3B). This suggests that IL-6 was being synthesized 
within 1 h, as seen on immunoblots of total extracts (Figure 4.3A), and then steadily secreted 
by the cardiomyocytes to the culture media. To test this hypothesis, I performed further slot-
blotting experiments in which, following stimulation of cardiomyocytes, the media was 
collected and replaced every hour up to 3 h with concomitant collection of the media from 
unstimulated cardiomyocytes for controls (Figure 4.4). After 1 h (0-1 h) of stimulation of 
cardiomyocytes with ET-1, the conditioned media contained elevated levels of IL-6 protein 
compared with controls. However, during the second and third hour there was no significant 
further increase in the levels of IL-6 protein of stimulated cardiomyocytes as compared with 
controls, although it was evident that the change in the media has an effect on its own 
influencing to increase the levels of IL-6 (Figure 4.4). These results suggest that, following 
ET-1 stimulation of cardiomyocytes in culture, most of the IL-6 protein is synthesized within 
the first 2 h, as evidenced by immunoblotting (Figure 4.3A), and is steadily released to the 
media where it remains stable and is probably not degraded to any significant extent (Figure 
4.3B and 4.4). 
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Figure 4.4 IL-6 is secreted by cardiomyocytes shortly after stimulation with ET-1. 
Cardiomyocytes were unstimulated (Control) or exposed to 100 nM ET-1, and the 
conditioned medium collected and replaced every 1 h for up to 3 h following the initial 
stimulation with ET-1. Conditioned media was slot-blotted and probed with IL-6 antibodies. 
A representative image is shown in the upper panel. The blots were analysed by scanning 
densitometry and the combined data are shown in the lower panels as means ± S.E.M. for 
three independent preparations of cardiomyocytes. (# p< 0.01 relative to control m1h, one 
way ANOVA with Tukey post test). 
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4.3.4 IL-6 mRNA and protein are also upregulated in cardiomyocytes by H2O2 
I then, similarly, evaluated the time course of induction of IL-6 mRNA in cardiomyocytes 
exposed to H2O2 using SQ-PCR. Under basal conditions, IL-6 mRNA abundance was low 
and remained low up to 1 h following stimulation with H2O2. There was then a transient, but 
potent, induction of IL-6 mRNA, with levels returning to near-basal levels by 2 h (Figure 
4.5). To confirm that translation of IL-6 mRNA also occurs in response to H2O2, I then 
evaluated the expression of IL-6 protein by immunoblotting. As shown in Figure 4.6A, IL-6 
was identified as one band of ~25 kDa. The protein abundance of IL-6 was low under basal 
conditions and was induced following stimulation with H2O2 with maximal expression at 1 h, 
although it remained elevated for up to 4 h. To evaluate the secretion of IL-6 protein by 
cardiomyocytes following stimulation with H2O2, slot-blotting was performed using the 
collected media. As shown in Figure 4.6B, there is increased secretion of IL-6 protein by 
cardiomyocytes at 1 h and this remained elevated for up to 4 h.  
 
The above studies suggest that IL-6 protein is synthesized principally at 1 h, as shown by 
immunoblotting, and is secreted by the cardiomyocyte from this early time point, as 
suggested by slot-blotting. However, it is not clear from these experiments whether IL-6 
continues to be secreted after 1 h with a constant rate of degradation or instead it is secreted 
at earlier time points but not degraded. To clarify this further, the conditioned media was 
collected every hour for up to 3 h following H2O2 stimulation, and the media of unstimulated 
cardiomyocytes was also collected simultaneously every hour for the same period of time to 
serve as controls for this experiment. From the data presented in Figure 4.7, it is evident that 
the change in the media has an effect on its own in the control as well as treated cells. 
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However, it is also clear that following stimulation of cardiomyocytes with H2O2, IL-6 is 
mainly secreted by cardiomyocytes at 1 h (figure 4.7). Thus, the observed persistent elevated 
levels of IL-6 in the media following several hours of stimulation with H2O2 as shown in 
Figure 4.6B, is probably more a reflection of this initial secretion without significant 
degradation, rather than a continuous secretion with a concomitant degradation. 
 
4.3.5 ATF3 binds to the promoter of IL-6 in response to ET-1 or oxidative stress 
My experiments indicate that ATF3 and IL-6 are both IEGs upregulated by ET-1 or H2O2, 
and upregulation of both appears to require activation of the ERK1/2 cascade (Figures 3.5 
and 4.2). Previous studies have suggested that ATF3 is a negative regulator of IL-6 in the 
mouse immune system thus controlling the inflammatory response (Gilchrist et al., 2006). I 
therefore examined the rat IL-6 gene promoter for the presence of an ATF/CRE binding site 
that could be a target binding site for ATF3 in this gene. Using the online TRANSFACT 4.0 
tool (http://www.gene-regulation.com/pub/programs/alibaba2/ index.html) I established the 
presence of a predicted ATF/CRE consensus binding site within the promoter of IL-6 located 
165 bp upstream from the transcriptional start site of the IL-6 gene (Figure 4.8). This 
suggested that ATF3 could be involved in the regulation of IL-6 gene expression. 
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Figure 4.5 IL-6 mRNA is upregulated in cardiomyocytes in response to H2O2. Myocytes 
were unstimulated (controls, zero time) or exposed to 0.2 mM H2O2 for the indicated periods 
of time. The expression of IL-6 mRNA was analysed by SQ-PCR and a representative image 
from a single experiment is shown in the upper panel. Densitometric analysis of the data is 
provided in the lower panel and expressed relative to controls after normalization with the 
housekeeping gene GAPDH for three independent cardiomyocyte preparations. (* p< 0.001 
relative to control, one way ANOVA with Tukey post test). 
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Figure 4.6 IL-6 protein is upregulated in cardiomyocytes by H2O2. Cardiomyocytes were 
unstimulated (controls, zero time), or exposed to 0.2 mM H2O2 for the indicated periods of 
time. In (A), total protein extracts were immunoblotted with antibodies to IL-6 and a 
representative image is shown in the upper panel. In (B), conditioned media was collected, 
slot-blotted and then probed with IL-6 antibodies and a representative image is shown in the 
upper panel. The blots were analysed by scanning densitometry and the combined data are 
shown in the lower panels as means ± S.E.M. for three independent preparations of 
cardiomyocytes. (* p< 0.01; # p< 0.001 relative to control, one way ANOVA with Tukey 
post test).
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Figure 4.7 IL-6 is secreted by cardiomyocytes shortly after stimulation with H2O2. 
Myocytes were unstimulated (Controls) or exposed to 0.2 mM H2O2 and the supernatants 
collected and then replaced every 1 h for up to 3 h following initial stimulation with H2O2. 
Collected supernatants were slot-blotted and then probed with IL-6 antibodies and a 
representative image is shown in the upper panel. The blots were analysed by scanning 
densitometry and the combined data are shown in the lower panel as means ± S.E.M. for 
three independent preparations of cardiomyocytes. (* p< 0.05 relative to Control m1h, one 
way ANOVA with Tukey post test). 
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To confirm that ATF3 binds to the promoter of IL-6 at this ATF/CRE binding site, ChIP 
assays were performed. Using antibodies to ATF3, ATF3 (crosslinked to DNA) was 
immunoprecipitated from cardiomyocytes which were unstimulated [Control (+)], or 
stimulated with 100 nM ET-1 (1 h) or 0.2 mM H2O2 (2 h), [ET-1 (+) or H2O2 (+) 
respectively]. As an additional negative control, DNA was also extracted from 
cardiomyocytes stimulated with 100 nM ET-1 (1 h) or 0.2 mM H2O2 (2 h) and the 
immunoprecipitation process performed in the absence of antibodies [ET-1 (-) or H2O2 (-) 
respectively]. The IL-6 promoter DNA was detected by PCR, using primers located 118 bp 
upstream and 105 bp downstream to the ATF/CRE binding site, which amplifies a product of 
223 bp (Figure 4.8). The ATF3 antibodies immunoprecipitated IL-6 promoter DNA from 
cardiomyocytes stimulated by ET-1 but not from unstimulated cardiomyocytes (Figure 4.9). 
As expected, IL-6 promoter DNA was not significantly amplified from samples that were not 
subject to immunoprecipitation with ATF3 antibodies. These results suggest that ATF3 binds 
to the endogenous promoter of IL-6 in response to ET-1. To confirm the specificity of the 
ChIP assay, immunoprecipitated DNA samples were subjected to PCR using primers to an 
arbitrary sequence 2000 bp 3’ to the IL-6 gene promoter and this was compared with those 
using the input DNA. As shown in Figure 4.10, there were only background levels of 
amplification of this sequence when immunoprecipitated DNA was evaluated, but 
significantly more when the input DNA was amplified, thus confirming the specificity of the 
ChIP assay. 
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ATF
consensus
IL-6 promoter sequence (ENSRNOG00000010278)
AAAATTAGAAGAGTAAATCCTGGCCTCTTATTAATTCATGAGTGTTT
GTGTGTGCGCACATGTGTTTAAATAACATCAGCTTTAGCTTCACTTT
CTCCTTATAAAACATTGTGCATTTCAGTTTTTCCCCCTATCAAGTGC
TCAAGTGCTGAGTCACTTTTAAAGAAAGAAAAAGAGTGATCAGGCTT
CTTAAGGATAGCCTCAAGGATGACTTAAACACACTTTCCCCCTCCTA
GCTGTGATTCTTTGGATGCTAAATGACGTCACATTGTGCAATCTTAA
TAAGGTTTCCAATCAGCCCCACCCACTCTGGCCCCACCCCCACCCTC
CAACAAAGATTTTTATCAAATGTGGGATTTTCCCATGAGTCTCAAAA
GTAGAGAGTCGACTCCCAATAAATATGAGACTGGGGATGTCTGTAGC
TCATTCTGTCTCGAGCCCACCAGGAACGAAAGTCAACTCCATCTGCC
CTTCAGGAACAGCTATGAAGTTTCTCTCCGCAAGTAAGTGAAGGCAG
TTTCTCGCCCTCTGGCGGAGCTATTGAGACTGTGAGAGGAGTG
Upstream
primer
Downstream
primer
Start site
Figure 4.8 The IL-6 promoter possesses an ATF consensus binding site. Promoter 
analysis was performed using the online tool TRANFACT 4.0. The ATF/CREB consensus is 
indicated in red. The transcriptional start site and first codon within the first exon is shown in 
green. The location of primers for the ChIP assay (see also Figures 4-9 and 4-11), which are 
localized upstream and downstream of the ATF consensus are shown in blue. Rat IL-6 
promoter sequence was obtained from Ensembl (ENSRNOG00000010278). 
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The ATF3 antibodies also immunoprecipitated IL-6 promoter DNA from cardiomyocytes 
stimulated by H2O2,but not from unstimulated cardiomyocytes (Figure 4.11). As expected, 
IL-6 promoter DNA was not significantly amplified from samples that were stimulated with 
H2O2 but not immunoprecipitated. These results suggest that ATF3 binds to the endogenous 
promoter of IL-6 under conditions of H2O2 stimulation in cardiomyocytes. To confirm the 
specificity of the ChIP assay, immunoprecipitated DNA samples were subjected to PCR 
using primers to an arbitrary sequence lying 2000 bp 3’ to the IL-6 gene promoter and 
compared with that using the input DNA. Again, only background levels of amplification of 
this sequence were present when immunoprecipitated DNA was subjected to PCR but 
significantly more when the input DNA was evaluated, which confirms the specificity of the 
ChIP assay (Figure 4.12). 
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Figure 4.9 ATF3 binds to the promoter of IL-6 in cardiomyocytes stimulated with ET-1. 
Cardiomyocytes were unstimulated and immunoprecipitated [Control (+)], or stimulated with 
100 nM ET-1 for 1 h and immunoprecipitated [ET-1 (+)], or stimulated with 100 nM ET-1 
for 1 h but no immunoprecipitated [ET-1 (-)]. DNA crosslinked to ATF3 was 
immunoprecipitated by ChIP assay using antibodies to ATF3 (IP DNA). IL-6 promoter DNA 
was detected by PCR (representative image, top panel). DNA from samples prior to 
immunoprecipitation (Input DNA) was used as a positive control (representative image, 
middle panel). Both PCRs were performed for 32 cycles. The densitometric analysis is shown 
with values normalised to the input DNA in the lower panel. Results are means ± SEM for 
three independent experiments [# p< 0.001 relative to control (+), one way ANOVA with 
Tukey post test]. 
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Figure 4.10 Determination of ChIP assay specificity (ET-1). Cardiomyocytes were 
unstimulated and immunoprecipitated [Control (+)], or stimulated with 100 nM ET-1 for 1 h 
and immunoprecipitated [ET-1 (+)], or stimulated with 100 nM ET-1 for 1 h but no 
immunoprecipitated [ET-1 (-)]. DNA crosslinked to ATF3 was immunoprecipitated by ChIP 
assay using antibodies to ATF3 (IP DNA). PCR was performed to detect an arbitrary DNA 
sequence 2000 bp 3’ to the IL-6 promoter. DNA from samples prior to immunoprecipitation 
(Input DNA) was used as a positive control. Both PCRs were performed for 32 cycles. 
Representative images of three independent experiments are shown. 
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Figure 4.11 ATF3 binds to the promoter of IL-6 in cardiomyocytes stimulated with 
H2O2. Cardiomyocytes were unstimulated and immunoprecipitated [Control (+)], or 
stimulated with 0.2 mM H2O2 for 2 h and immunoprecipitated [H2O2 (+)], or stimulated with 
0.2 mM H2O2 for 2 h but no immunoprecipitated [H2O2 (-)]. DNA crosslinked to ATF3 was 
immunoprecipitated by ChIP assay using antibody to ATF3 (IP DNA). IL-6 promoter DNA 
was detected by PCR (representative image, top panel). DNA from samples prior to 
immunoprecipitation (Input DNA) was used as a positive control (representative image, 
middle panel). Both PCRs were performed for 32 cycles. The densitometric analysis is shown 
with values normalised to the input DNA in the lower panel. Results are means ± SEM for 
three independent experiments (# p< 0.001 relative to control (+), one way ANOVA with 
Tukey post test). 
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Figure 4.12 Determination of ChIP assay specificity (H2O2). Cardiomyocytes were 
unstimulated and immunoprecipitated [Control (+)], or stimulated with 0.2 mM H2O2 for 2 h 
and immunoprecipitated [H2O2 (+)], or stimulated with 0.2 mM H2O2 for 2 h but no 
immunoprecipitated [H2O2 (-)]. DNA crosslinked to ATF3 was immunoprecipitated by ChIP 
assay using antibody to ATF3 (IP DNA). PCR was performed to detect an arbitrary DNA 
sequence 2000 bp 3’ to the IL-6 promoter. DNA from samples prior to immunoprecipitation 
(Input DNA) was used as a positive control. Both PCRs were performed for 32 cycles. 
Representative images of three independent experiments are shown.
 183
4.4 Discussion 
4.4.1 Expression of IL-6 mRNA and protein in cardiomyocytes  
The above studies demonstrate that IL-6 mRNA and protein abundance increased in response 
to stimulation of cardiomyocytes by ET-1 or H2O2. Thus, the expression of IL-6 mRNA was 
potently induced by both ET-1 and H2O2 as assessed by SQ-PCR and Q-PCR (Figures 4.1 
and 4.5) in agreement with previous microarray studies from our laboratory (Cullingford et 
al., manuscript submitted) (Table 4.1). In addition to increasing IL-6 mRNA abundance, ET-
1 or H2O2 also caused an increase in the expression of the IL-6 protein, suggesting that, after 
synthesis of mRNA, the rate of translation of IL-6 mRNA into protein is also subsequently 
increased with concomitant secretion of IL-6 by the cardiomyocytes within the first hour 
(Figures 4.3, 4.4, 4.6, and 4.7).  
 
The induction of IL-6 by ET-1 was statistically significant and in agreement with previous 
studies. Thus, using cultured cardiomyocytes, Saito et al., (1999) have previously reported 
that ET-1 induces the expression of IL-6, as well as LIF, but not CT-1 mRNA levels, with a 
peak of expression observed at 1 h for both IL-6 and LIF. Similarly, a recent report evaluated 
the postnatal effects of cardiac overexpression of human ET-1 using a conditional cardiac-
specific tetracycline-regulated (tet-off) gene expression system, in which expression of ET-1 
is inactivated by the administration of the tetracycline doxycycline (DOX) (Yang et al., 
2004). Following DOX withdrawal in transgenic animals, dilated cardiomyopathy 
(characterized by an interstitial inflammatory cell infiltrate on histological examination, 
associated with signs of overt heart failure) was observed between 5 to 11 weeks (Yang et al., 
2004). Mortality rates were around 50% within 8 weeks following DOX withdrawal, whereas 
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transgenic animals maintained on DOX did not exhibit a significant increase in mortality 
compared with control non-transgenic mice. Evaluation of cytokines expressed in the 
myocardium at 2 week intervals following DOX withdrawal revealed that mRNA levels of 
IL-6, TNFα, IL-1 and interferon- γ (INF-γ) were all expressed at low levels under basal 
conditions but significantly increased at 6 to 8 weeks. Histological analysis conducted in 
parallel revealed that a progressive inflammatory process develops progressively and is 
widespread at 6 weeks following DOX removal (Yang et al., 2004). This study suggests that 
cardiac ET-1 overexpression in the heart during the postnatal period causes dilated 
cardiomyopathy associated with increased expression of inflammatory cytokines including 
IL-6, thus leading to a pattern of inflammatory cardiomyopathy, heart failure and increased 
mortality (Yang et al., 2004). Another GqPCR agonist, ANGII not only causes induction of 
LIF and IL-6 mRNA expression in cardiomyocytes, but also induces CT-1, all with a similar 
time course of expression as that observed in my studies (i.e. maximal expression of IL-6 at 
30 minutes with decline in mRNA abundance after 2 h). A concomitant increase in IL-6 
protein secretion at 2 h was also observed (Sano et al., 2000). 
 
ET-1 has also been reported to induce IL-6 expression in other cell systems. Thus, in human 
vascular smooth muscle cells, ET-1 induces the expression of IL-6 mRNA at 30 minutes with 
a rapid decline in the levels of expression afterwards (Browatzki et al., 2000). The IL-6 
secretion was also evaluated in this same study following 24 h of stimulation with ET-1, and 
showed a significant increase in the secretion of this cytokine. This study concluded that, in 
the context of vascular smooth muscle cells, ET-1 appears to be involved in the pathogenesis 
of atherosclerosis at least in part by inducing the release of proinflammatory cytokines such 
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as IL-6 (Browatzki et al., 2000). In a rat endothelial cells line (WAE-1), ET-1 causes 
induction of IL-6 mRNA expression at 6 h in a concentration dependent manner, which 
correlates with secreted IL-6 protein (Xin et al., 1995). Similarly, in osteoblasts, the 
immature cells of bone, ET-1 induces the expression of IL-6 mRNA at 1-2 h with 
concomitant increase in IL-6 protein in supernatant (Perkins et al., 1997). In the settings of 
osteoblasts, ET-1 appears to increased bone turnover (e.g. resorption) by the upregulation of 
inflammatory cytokines like IL-6 (Perkins et al., 1997; Kawamura et al., 1999).  
 
The effects of H2O2 on the induction of IL-6 mRNA and protein secretion were also 
statistically significant, and to my knowledge this is the first report of the direct induction of 
IL-6 by H2O2 in cardiomyocytes. A previous report has documented the expression of IL-6 in 
the heart of dogs following ischaemia or ischemia/reperfusion. In this model, the induction of 
IL-6 following ischaemia alone for 1-4 h was minimal, whereas 1 h ischaemia coupled with 3 
h reperfusion results in a marked increase in IL-6 mRNA levels as assessed by Northern blot 
analysis (Kukielka et al., 1995). As discussed previously (section 1.6), following 
ischaemia/reperfusion there is increased production of ROS including H2O2 (Ambrosio et al., 
1993; Du et al., 1998) Thus, the potent induction by ischaemia/reperfusion of IL-6 is 
probably secondary to the elevated levels of ROS production in the myocardium which occur 
during reperfusion, compared with ischaemia alone which induces comparatively less ROS 
production (Ambrosio et al., 1993; Du et al., 1998; Clerk et al, 2003). In other cell types, 
there have been reports of increased expression of IL-6 directly by ROS species such as 
H2O2. Thus, H2O2 induces IL-6 protein expression/secretion in cardiac fibroblasts following 
stimulation for over 4-24 h (Colston et al., 2002). More recently, ANGII-induced expression 
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of IL-6 was reported in cardiac fibroblasts, and this is mediated by ROS production (Sano et 
al., 2001). Exogenously applied H2O2 also induces IL-6 mRNA in the same cell system in a 
concentration dependent manner, an effect that is mediated by the ERK1/2 and p38-MAPK 
cascades (Sano et al., 2001). 
 
The role of IL-6 and other members of this family of cytokines in cardiomyocytes exposed to 
ET-1 is not completely understood. However, as discussed in section 1.3.3, there is ample 
evidence implicating IL-6, LIF and CT-1 in myocyte elongation and a causal role in eccentric 
hypertrophy through activation of the ERK5 cascade (Hunter and Chien, 1999; Nicol et al., 
2001). Consistent with a role in the induction of myocyte elongation by these cytokines 
through the ERK5 cascade, adenoviral-mediated overexpression of constitutively active 
MKK5 causes serial assembly of sarcomeres, whereas a dominant-negative form of MKK5 
prevents LIF-induced elongation of cardiomyocytes (Nicol et al., 2001). Similarly, 
cardiospecific overexpression of constitutively-activated MKK5 in transgenic mice results in 
eccentric hypertrophy, heart failure and sudden death (Nicol et al., 2001). Additional 
evidence implicating IL-6 family members such as CT-1 and LIF in the pathophysiology of 
heart failure is the observation that the myocardial expression of these cytokines is elevated 
in animal models of heart failure (Aoyama et al., 2000; Jougasaki et al., 2003). The levels of 
CT-1 mRNA are also elevated in explanted hearts from patients with heart failure, however 
the protein levels of gp130 are decreased, with a concomitant increase in the mRNA levels of 
this gene, indicating that gp130 protein turnover is augmented, probably as a consequence of 
an adaptive desensitization and degradation mechanism with concomitant reduced protein 
synthesis (Zolk et al., 2002). Consistent with tissue levels, circulating levels of CT-1 are 
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increased in patients with dilated cardiomyopathy (Tsutamoto et al., 2001). Recently, 
circulating levels of IL-6 and CT-1 have been proposed as important prognostic markers of 
death and/or heart failure in patients post-myocardial infarction (Takahashi et al., 2003; 
Fisman et al., 2006). 
 
In rat hearts subjected to right ventricular (RV) pressure or RV volume overload BNP is 
upregulated in the RV overloaded ventricles for both stimuli, but comparatively, the levels of 
IL-6, TNFα, and pre-pro-ET-1 (pp-ET-1) are higher upon volume-overload than pressure-
overload (Roncon-Alburquerque Jr, et al., 2006). In addition, local expression levels of BNP, 
IL-6, TNFα and ppET-1 positively correlate with RV end-diastolic pressures (Roncon-
Alburquerque Jr, et al., 2006). Of note, mRNA levels of IL-6 and other cytokines such as 
TNFα and IL-1β are significantly increased in the hearts and serum samples of patients that 
required LVAD therapy (as a bridge to heart transplant due to the rapid deterioration of their 
disease process), compared with those that are more stable and could await a heart transplant 
(Birks et al., 2001). This suggests that IL-6 and other cytokines may be involved in the 
worsening of heart failure at late stages of the disease. Consistent with this idea, in a model 
of chronic intermittent hypoxia in rats over 4 weeks results in LV concentric cardiac 
hypertrophy), whereas intermittent hypoxia over 8 weeks leads to eccentric cardiac 
hypertrophy (Chen et al., 2007). mRNA and protein levels of TNFα, IGF-1, and the activity 
of p38-MAPK and STAT-1 and STAT3 were elevated in the 4 weeks intermittent hypoxia 
group compared with normoxic rat controls. However, after 8 weeks of intermittent hypoxia, 
in addition to the above factors, IL-6 mRNA and protein, and MEK5 and ERK5 activity, 
were also elevated, indicating that IL-6-gp-130 receptor activation is associated with late 
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eccentric hypertrophy and dilatation after prolonged hypoxia (Chen et al., 2007). Given the 
nature of the stimuli, it could be argued that, possibly, alterations in redox systems initially 
lead to concentric hypertrophy and after sustained hypoxia further alterations in these 
systems lead to changes in gene expression associated with eccentric hypertrophy and LV 
dilatation. 
 
Taken together, it seems that increased expression of IL-6 family of cytokines in the heart, 
and activation of the ERK5 signalling cascade through their cognate receptors are implicated 
in the development of eccentric hypertrophy and in the process of ventricular remodelling, 
probably by regulation of cardiomyocyte elongation and subsequent ventricular dilatation. 
Although the mechanistic details are still unclear, their deregulated expression at later stages 
of the disease could be secondary to increased oxidative stress and/or neurohumoral 
activation. Thus, it is likely that the induction of these cytokines is probably part of a 
maladaptive response to hypertrophic agonists such as ET-1, which in addition to concentric 
hypertrophy in the initial stages, also has the potential of inducing eccentric hypertrophy and 
myocardial dysfunction at later stages. However, the final outcome may depend of the 
particular circumstances influencing the cardiac milieu at the time of expression of these 
cytokines. 
 
There is also strong evidence indicating that gp130 cytokines, in addition to the ERK5 
cascade, also activate the ERK1/2 cascade, JAK/STAT3 signalling and the PKB/Akt 
pathway, all of which appear to mediate cytoprotective effects in the heart (reviewed in 
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Hilfiker-Kleiner et al., 2006). Thus, LIF stimulation or adenoviral-mediated overexpression 
of constitutively-active STAT3 (caSTAT3) in cardiomyocytes significantly reduces the 
production of ROS species following hypoxia/reoxygeneation (Negoro et al., 2001a). This 
effect appears to be mainly mediated by the induction of Mn2+SOD, thus increasing the ROS 
scavenging capacity of the cardiomyocyte. Similarly, infusion of a complex of IL-6 with the 
soluble IL-6 receptor inhibits cardiomyocyte apoptosis and limits the infarct size following 
ischaemia/reperfusion in rats, thus suggesting that IL-6 is cytoprotective under conditions of 
increased ROS production (Matsushita, et al., 2005). Consistent with a cytoprotective role for 
the activation of gp130 signalling, mice with cardiospecific-knockout of gp130, although 
displaying a normal phenotype under basal conditions, exhibit increased apoptosis of 
cardiomyocytes and myocardial dysfunction early after induction of pressure-overload 
(Hirota et al., 1999). LIF activation of gp130 signalling through PKB/Akt reduces apoptosis 
induced by the anticancer drug doxorubicin in cardiomyocytes, suggesting a cytoprotective 
role for this cascade when activated by IL-6 members under cytotoxic conditions (Negoro et 
al., 2001b). It has been postulated that the mechanisms of cytoprotection by the gp130 
activated pathways may include the ability of several of these cascades to induce the 
expression or restore the activities of antiapoptotic and cytoprotective proteins such as Bcl-
xL, an antiapoptotic Bcl-2 family member (Fujio et al., 1997; Negoro et al., 2001b) or, as 
described above, the ROS scavenger Mn2+SOD in cardiomyocytes (Negoro et al., 2001a). 
Therefore, stimulation of cardiomyocytes with H2O2 and resultant increased expression of 
IL-6 as has been demonstrated here may represent an attempt by the cell to cope with this 
stress by the subsequent activation of cytoprotective pathways through the gp130 signalling 
complex and downstream pathways. 
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 4.4.2 IL-6 is an IEG upregulated in cardiomyocytes in response to ET-1 through the 
ERK1/2 cascade 
I have also shown that IL-6 is an IEG that is upregulated by ET-1 through the ERK1/2 
cascade. Thus, IL-6 mRNA expression is rapidly and transiently induced following ET-1 
stimulation in a process that does not require de novo protein synthesis as suggested by the 
lack of inhibition of its transcriptional expression by the protein synthesis inhibitor 
cycloheximide (Figure 4.2). Although this has not been previously shown in cardiomyocytes, 
there is ample evidence that IL-6 is an IEG in other systems particularly in the settings of the 
acute defence responses against pathogens in which IL-6 plays a central role in inflammatory 
and immune processes (Iwamoto and Konicek, 1997; reviewed in Kishimoto, 2006), and in 
the setting of liver injury with IL-6 facilitating liver regeneration (Laurent et al., 2001; 
reviewed in Iimuro et al., 2007). That the upregulation of this IEG following ET-1 
stimulation is mediated through the ERK1/2 cascade (Figure 4.2) is also in agreement with 
previous studies. Thus, ET-1 induction of IL-6 synthesis in osteoblasts is mediated by the 
ERK1/2 cascade (Kawamura et al., 1999). It has also been reported that IL-6 induction by 
ANGII is mediated by the activation of the ERK1/2 and p38-MAPK cascades in cardiac 
fibroblasts. Although it is possible that, in cardiomyocytes, activation of other MAPKs such 
as JNKs or p38-MAPKs is involved in the response leading to IL-6 induction following ET-1 
stimulation, I concentrated my studies on the ERK1/2 cascade because of the ample evidence 
of the prominent involvement of this pathway in the cardiac hypertrophic response both in 
vitro and in vivo (section 1.3.1.6) (Bueno et al., 2000; Yue et al., 2000; Sugden., 2001; 
Sugden., 2003).  
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 4.4.3 ATF3 binds to the promoter of IL-6 in response to ET-1 or H2O2 stimulation 
ChIP assays were performed to assess the binding of ATF3 to the endogenous ATF-CRE 
consensus present in the promoter of the IL-6 gene under conditions of ET-1 and H2O2 
stimulation and demonstrated that, following exposure of cardiomyocytes to ET-1 or H2O2, 
ATF3 becomes bound to the promoter of this gene (Figures 4.9 and 4.11). Thus, my results 
suggest that IL-6 is a downstream target gene of ATF3 following hypertrophic stimulation of 
cardiomyocytes by ET-1, or upon oxidative stress following H2O2 stimulation. This is 
consistent with a previous study indicating that following stimulation of monocytes with 
LPS, ATF3 binds to the promoter of IL-6 and is a negative regulator of this gene (Gilchrist et 
al., 2006). However, the studies in this chapter do not firmly establish whether ATF3 is a 
positive or negative regulator of IL-6 expression. Experiments involving overexpression or 
knockdown of the ATF3 protein levels will help to clarify the role of ATF3 in the regulation 
of IL-6. The observation that, following induction of IL-6 mRNA by either ET-1 or H2O2, the 
time when IL-6 mRNA returns to near basal levels correlates with the time of maximal 
expression of ATF3 protein for either agonist (Figures 3.7, 3.8, 4.1 and 4.5) (Table 4.2), 
suggests that ATF3 may be involved in a negative regulatory feedback loop to downregulate 
IL-6 in cardiomyocytes following ET-1 or H2O2 stimulation (Figure 4.13). This is further 
supported by accumulating evidence suggesting that ATF3 is mainly a negative regulator of 
transcription in other cell systems (section 3.1.1.2) (Chen et al., 1994; Wolfgang et al., 1997; 
Wolfgang et al., 2000; Gao et al., 2004; Gilchrist et al., 2006). Further experiments aimed to 
clarify these findings will be presented in the forthcoming chapter. 
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Table 4.2 Comparison of the induced levels of expression of ATF3 protein and those of IL-6 
mRNA following ET-1 or H2O2 stimulation of cardiomyocytes. 
 
Endothelin-1 stimulation 
ATF3 protein IL-6 mRNA 
control 13.4 control 1 
30 min 59.2 30 min 8.5 
1 h 556.3 1 h 2.6 
2 h 488.6 2 h 1.3 
4 h 168.8 4 h 1.9 
6 h 33.0 6 h 1.1 
H2O2 stimulation 
ATF3 protein IL-6 mRNA 
control 31.6 control 1 
30 min 35.7 30 min 1.2 
1 h 255.6 1 h 20.8 
2 h 683.8 2 h 4.1 
4 h 257.2 4 h 2.2 
6 h 104.3 6 h 0.8 
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Figure 4.13 ATF3 forms a possible negative feedback loop for IL-6 regulation in 
cardiomyocytes in response to ET-1 or oxidative stress. In (A), following upregulation of 
ATF3 and IL-6 mRNA by ET-1 (30 min) through the ERK1/2 cascade, ATF3 mRNA is 
translated into protein and the active ATF3 then binds to the promoter of IL-6 within 1 h 
potentially repressing the IL-6 gene. Similarly in (B), following stimulation of 
cardiomyocytes with H2O2 there is upregulation of ATF3 and IL-6 mRNA at 1 h. Then the 
synthesized ATF3 protein binds to the promoter of IL-6 and potentially represses IL-6 gene 
expression.  
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Chapter 5 
 
Identification of novel downstream targets of ATF3 in 
cardiomyocytes 
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5.1 Introduction 
Cardiomyocytes are terminally-differentiated cells which withdraw from the cell cycle 
soon after birth. Maturational growth (e.g. eutrophy) is therefore achieved by the 
enlargement of individual cardiomyocytes in the postnatal period. The establishment of a 
particular phenotype in the cardiomyocyte (e.g. hypertrophy upon pressure overload) is 
regulated by complex regulatory mechanisms. As discussed in section 1.2, it is 
established that many hypertrophic agonists, including ET-1, are capable of regulating the 
hypertrophic process acting through cognate receptors located at the cell membrane of the 
cardiomyocytes (Sugden and Clerk, 1998; Molkentin et al., 2001, Sugden, 2003). The 
flow of information in the signalling cascades activated by hypertrophic agonists leads to 
rapid downstream activation of protein kinases such as the ERK1/2 (within 5 min), which 
play an important role in the hypertrophic process as has been demonstrated in vitro and 
in vivo (Sections 1.3.1.5 and 1.3.1.6). ERK1/2 then phosphorylates target proteins 
including several transcription factors that subsequently bind to the promoters of several 
genes. Thus, cardiomyocyte hypertrophy is associated with changes in gene expression 
including IEGs (e.g.  c-jun, c-fos, c-myc) with re-expression of the “foetal pattern” of 
gene expression (e.g. ANP; BNP, β-myosin heavy chain), which are often used as 
markers of hypertrophy (Hoshijima and Chien, 2002; Dorn and Force, 2005). Early 
studies indicated that IEGs are induced rapidly in cardiomyocytes by hypertrophic stimuli 
(Starksen et al., 1986; Iwaki et al., 1990), suggesting that these promote later changes in 
gene expression associated with the hypertrophic phenotype. Indeed, many of the genes 
that are activated during this acute phase are themselves transcription factors that will 
regulate a second wave of gene expression presumably responsible for the sub-acute and 
chronic changes of the phenotype leading to cardiac hypertrophy (Hoshijima et al., 2002; 
Clerk et al., 2005; Clerk et al., 2007). 
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 In chapters 3 and 4 of this thesis, I demonstrated that two of the IEGs upregulated in 
cardiomyocytes by ET-1 through the ERK1/2 cascade are ATF3 and IL-6, and these same 
genes are also upregulated in response to H2O2. Using ChIP assays, I also demonstrated 
that ATF3 binds to the promoter of IL-6 following stimulation with ET-1 or H2O2, 
suggesting that ATF3 may be involved in the regulation of IL-6 expression under these 
conditions (Figures 4.9 and 4.11). It is likely that the regulatory function of ATF3 over 
the IL-6 gene forms a negative feedback mechanism for modulating the expression of IL-
6. In support of this hypothesis, previous studies have shown that ATF3 is a negative 
regulator of IL-6 in monocytes stimulated with LPS, thus reducing excessive amounts of 
IL-6. In this way, ATF3 prevents deleterious chronic inflammatory responses (Gilchrist et 
al., 2006).  
 
Parallel studies from our laboratory have recently explored the initial waves of gene 
expression in cardiomyocytes stimulated with ET-1 using microarray analysis. These 
studies were aimed at the identification of temporally-regulated of genes in the initial 
stages of the hypertrophic response (0.5, 1, 2 and 4 hours), before the morphological and 
physiological changes develop fully (Cullingford et al., manuscript submitted). The 
clusters of IEGs exhibit differential temporal and in most cases transient 
upregulation/downregulation. Of the functional groups, very few were associated with 
end-stage cardiac hypertrophy (Dorn et al., 2003). Instead, many were associated with 
gene or protein expression, or with signalling (Cullingford et al., manuscript submitted). 
This suggests that there is a phasic expression of early response genes which is probably 
required for the propagation of the signal beyond the primary signalling pathways through 
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transcriptional networks towards the end stage phenotype. It is likely that these networks 
would modulate cardiomyocyte responsiveness to the cardiac milieu before the changes in 
the phenotype are completed. Of note, some IEGs were upregulated by ET-1 at 1 h and 
had reduced expression at 2 h, despite being significantly superinduced by cycloheximide 
at 2 h or even at 1 h. For these IEGs, synthesis of a negative regulator could be required to 
suppress the response. Thus I reasoned that one such protein could indeed be ATF3 since 
most accumulating evidence suggests that this transcription factor acts mainly as a 
negative regulator of transcription in other systems (section 3.1.1.2) (Chen et al., 1994; 
Wolfgang et al., 1997; Wolfgang et al., 2000; Gao et al., 2004; Gilchrist et al., 2006; Li et 
al., 2007). Indeed, our results indicate that by the time the expression of ATF3 protein is 
maximal following 1 h ET-1, IL-6 mRNA expression is already reduced after a transient 
induction, supporting a negative regulatory role for ATF3 in IL-6 regulation (Figures 3.7, 
4.1 and Table 4.2). Furthermore, as demonstrated through ChIP assays, ATF3 is bound to 
the IL-6 promoter after 1 h of ET-1 stimulation (Figure 4.9). These observations add 
support to the hypothesis that ATF3 may be involved in a negative feedback loop 
probably turning off the transcription of IL-6 and other IEGs following ET-1 stimulation 
of cardiomyocytes. 
 
In this chapter, the role of ATF3 following stimulation of cardiomyocyte with ET-1 was 
evaluated. First, I performed an analysis of the promoters of IEGs that were superinduced 
following treatment with cycloheximide in combination with ET-1 at 2 h, to evaluate the 
presence of predicted ATF/CRE consensus binding sequences. Then, I performed 
knockdown of the ATF3 gene with adenoviral-mediated overexpression of an antisense 
sequence targeting ATF3 mRNA. Finally, I evaluated the effect of ATF3 knockdown on 
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the expression levels of IL-6 and other IEGs that could be potential target genes of ATF3, 
and which also possess ATF/CRE consensus binding sites in their promoters.  
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5.2 Methods  
5.2.1 Infection of cardiomyocytes with adenovirus containing Flag sequence or ATF3 
antisense sequence 
Replication-deficient adenoviruses for expression of a full-length rat ATF3 antisense 
RNA for the whole coding sequence (AS-ATF3), were prepared by Dr Stephen Fuller, a 
member of our research group, using the AdEasy™ XL Adenoviral Vector System 
(Stratagene) (section 2.12). Adenoviral infection of cardiomyocytes was performed 
overnight at a multiplicity of infection (moi) of 10-100, in 4 ml (60 mm culture dishes) 
serum-free maintenance medium [DMEM/Medium 199 (4:1, v/v) overnight at 37 ºC in a 
humidified, 5 % CO2 incubator]. 
 
5.2.2 RT-PCR 
Cardiomyocytes were exposed to 10 nM ET-1 for 1 h. Total RNA was extracted and 
cDNA synthesized (see sections 2.3 and 2.5). Q-PCR was performed (see section 2.6.1) to 
assess expression of ATF3, epiregulin (Ereg), c-Fos, FosB, immediate early response 2 
(Ier2), IL-6, c-Jun, nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor zeta (Nfκbiz), prostaglandin-endoperoxide synthase 2 (Ptgs2), CT-1 and 
GAPDH mRNA (see Table 2.2 in general methods for primers). For Q-PCR the cycles 
were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 
59°C for 60 sec. Following Q-PCR, a dissociation curve analysis was performed to check 
for aberrant amplification products. Q-PCR analysis of GAPDH was performed in each 
96-well plate as an endogenous control and the relative quantitation protocol was used. 
Values are expressed as fold stimulation. 
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 5.2.3 Immunoblotting 
Cardiomyocytes were exposed to 10 nM ET-1 for 1 h. Nuclear proteins were extracted 
and immunoblotting was then perfomed (sections 2.8.2 and 2.9). Briefly, proteins (25 μg) 
were subjected to SDS-PAGE with a 12% polyacrylamide resolving gel and 6% stacking 
gel. Proteins were transferred to nitrocellulose membranes and probed with primary 
antibodies to ATF3 (SC-188, Santa Cruz Biotechnology Inc) or ATF2 antibodies (SC-
187, Santa Cruz Biotechnology Inc.). Immunoreactive bands were detected by enhanced 
chemiluminescence and analysed semi-quantitatively by scanning densitometry. Values 
are expressed as arbitrary units. 
 
5.2.4 Promoter analysis 
The analysis of the promoter sequence of genes was performed using the tool 
TRANSFAC 4.0 available at the website address (http://www.gene-
regulation.com/pub/programs/alibaba2/index.html?).  
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5.3 Results 
5.3.1 Several IEGs upregulated by ET-1 contain ATF/CRE sites in their promoters 
Since ATF3 is potently induced by hypertrophic stimuli such as ET-1 (Chapter 3 Figures 
3.3, 3.4 and 3.7), and this response is mediated through the ERK1/2 cascade (Figures 3.5, 
3.6 and 3.7), a kinase cascade that plays an important role in cardiac hypertrophy (Section 
1.3.1.4), it is likely that ATF3 plays an important role in the regulation of the 
hypertrophic response. Using microarray analysis, parallel studies from our laboratory 
have identified several IEGs which were upregulated by ET-1 at 1 h and whose 
expression was reduced at 2 h, but which were superinduced when the cells were 
preincubated with cycloheximide and then treated with ET-1 for 2 h (Table 5.1). The 
behaviour of the expression of these genes suggested that, under conditions of ET-1 
treatment alone for up to 2 h, a negative regulator of their transcription is being expressed. 
In the absence of the synthesis of this inhibitor (i.e. in the presence of cycloheximide), 
there was a potent superinduction of their mRNA abundances. I hypothesized that, for at 
least some of the genes, ATF3 could be the negative regulator. I therefore performed 
promoter analysis of the gene sequences for all of these IEGs (Table 5.1) with the online 
tool TRANSFACT 4.0. The analysis indicated that 15 out of 18 of these genes exhibited 
ATF/CRE or related sequences in their promoters (Table 5.1). In Figures 5.1 to 5.4 the 
promoter sequences for some of these genes (e.g. LIF, Ereg, FosB and c-jun) is shown, 
indicating the ATF/CRE consensus or related binding sites. The analysis of the IL-6 
promoter sequence which contains an ATF/CRE binding site was already presented in 
Chapter 4, Figure 4.8.  
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 Table 5.1 IEGs upregulated by cycloheximide alone or in combination with ET-1 
(Microarray analysis*). 
Gene Symbol Probeset Number 
ATF/ 
CRE 
Site 
CHX 
(1 h) 
ET-1 
(1 h) 
ET-1 + 
CHX 
(1 h) 
CHX 
(2 h) 
ET-1 
(2 h) 
ET-1+ 
CHX 
(2 h) 
Axud1 1389402_at No 6.14 7.14 14.42 11.37 7.93 27.26 
Bdkrb1 1369807_at Yes 3.45 2.16 5.14 11.23 2.20 18.77 
Dusp1 1368147_at Yes 7.19 3.06 11.97 11.27 2.42 16.45 
Egr2 1387306_a_at Yes 5.8 8.46 25.2 10.29 1.35 42.06 
Egr3 1392791_at Yes 10.26 19.94 26.36 20.65 5.03 42.44 
Egr4 1387442_at No 60.18 50.23 927.9 198.79 8.14 1748.96 
Ereg 1385150_at Yes 3.55 3.15 5.07 13.82 1.32 15.43 
Fos 1375043_at Yes 24.39 9.78 52.24 25.35 1.25 67.37 
FosB 1373759_at Yes 49.24 210.90 562.7 26.13 7.06 303.37 
Ier2 1372389_at Yes 9.02 3.43 23.17 12.9 1.70 29.36 
Il6 1369191_at Yes 15.02 5.58 22.07 31.09 2.37 53.37 
Jun 1374404_at Yes 8.79 2.61 14.96 13.34 1.23 20.56 
LIF 1393728_at Yes 11.91 4.88 11.96 20.79 2.62 26.22 
Nfκbiz 1378032_at Yes 6.27 3.05 10.75 12.03 2.29 17.74 
Nr4a1 1386935_at Yes 6.92 17.55 22.38 10.26 3.66 28.89 
Nr4a3 1369067_at Yes 9.07 26.05 43.27 15.35 13.78 65.50 
Ptgs2 1368527_at Yes 10.01 10.56 19.27 19.22 3.42 31.06 
Tnfaip3 1385641_at No 5.45 2.42 7.08 10.43 1.59 13.97 
* Cardiomyocytes were exposed to 100 nM ET-1 or 20 µM cycloheximide (CHX) alone or in combination 
with ET-1 for the indicated times. RNA was extracted, cRNA was prepared and samples hybridized to 
Affymetrix rat genome 230 2.0 arrays.  Array data were analysed by MicroArray Suite 5.0 followed by 
Genespring 7.31.  Results are expressed relative to unstimulated control (n = 3).  
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Leukemia inhibitory factor promoter sequence
AGAGATACAACCTCATACTCTTTCCAGGTTCCACCCCAGGTACCAGT
CCATAGAAGGGACGGCTGATGGCTGTAAGGGGGCGAGGTCCTCCAGC
CCGCCGGCAGCAAACCCCTTTGTCATCTCTTTGCCCACTGGCAATGG
GCAGACTGAAGAACAGCCACCCCTGAGGTGGCTTCCAGCGTCCTCAT
TCTGCTCCACTTTATGACTGTCTAAAGTTCAAAGGGGCCCTAGCCCC
ACTTCTTGGAAACTGCTTCTCAGTGGAACCCCAGCCCAACTCCTCTT
GCTGCCCCACAAAGGCAGCCTCTAGTCTGTTGCCACCCTCCCAAACT
CAGATAAAACTGGGCAGTCCGAAGGGCACAGGCTGAGGACTCCTCTG
AACCCCCCTGAGACCCTTTCCCCACCAGACCCATCTGCAAACAATGC
CTAGTGCAAACCACTCAGGAAAACCACAGGGCGTTTTTTTTTTTTTT
TTTTTGTTGAAGACTTCATTATAATTTTATCAATCAAATTCTTAGAA
GAAGGAAAAAGTCTGCCCTCCCCACCCTCCCCCCTCACCCTTCCCCC
CTCCCCCTTCACTCTCACTTTCTTCCATTCATAATTTCCTATGATGC
ACCTCAAACAACTTCCTGGACCGGGGATCCCGGCTAAATATAGC
CAGTATATAAA
TGT
TTCTCTGTCTTACAACACAGGCTC TCAGGCAAATTC
CCCATTTGAGCATGAACTTCTGAAAACGGCCTGCATCTAAGGTCTCC
TCCAAGGCCCTCTGGAGTCCAGCCCATAATGAAGGTCTTGGCCACAG
GTAAATCCATGCGCCGGGCGCCGATTACGAGTCCCCGCTGC
TATA box
Consensus
CREMtau
Consensus CREB
Consensus
Start site
 
Figure 5.1 ATF/CRE consensus sites in the rat LIF promoter. Promoter analysis was 
performed using the online tool TRANFACT 4.0. The predicted cAMP-responsive 
element modulator-tau (CREMtau) consensus is shown in blue, cAMP response element-
binding (CREB) consensus is shown in pink. Two TATA box consensus sequences are 
also shown in red. The transcriptional start site and first codon within the first exon is 
shown in green. The rat LIF promoter sequence was obtained from Ensembl 
(ENSRNOG00000007002). 
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Epiregulin promoter sequence
GAAAGACAAAATAGGGCTTTCTTCATAATTACTAGACTTCGAAGTGA
TAAATGTCTGAATCACGTTG
CTCAAA
TGACATCTGG
GAAGATGAGGGGGCCGGGAAGGAAGGT
GTGAAGGTGAAAGGTGTGAAGGTGAAAGGCGTTTCCGGGCAGTTGAA
CAGGGGCAGAGCTTTGGAGCCACCGACAGGCTTCAAGTATGTTCCCA
AACAGGGAGTTATTCCAGCCCTGAGTTGGCAACTCAGCTCTCCAAAA
GTATGCGGTGGAAACACCAGCCCTGACTACGACAGTCACCCACAGCA
ACTAAAGCCACCCACTACCCGGCAGATGACCCCACAGAACAAACCAA
CCCATCTGGTCCAAGCTCCCCACCTCCTCAGGGCTTGAGTCTGAAGA
TAGGGAGGGTGGAAAACTTTGGGGAGTAGTCCCAGCCTCACTAGAAG
GACATTCATTC CCCTCCTCTCAGGTAGGTGTTCCTGAGAGG
GAGGA CCAGTCCTCCGCTGGCCACCACTCCTCCCCCC
GGGGGGTGGCATTAGGAAACCCTGGACAACCCGCTAGTAAGTCCTCG
CGTGCCTAAGCACCTCCCCAGACTTATAAAGGTCACTGTGTGGCGCC
CTAGTTCAGCTCACTTGCCTGGCTGCTTGGAGTCACAGCGACTTGCT
TGACCCTGGTCTCTGGATCAGCCCGGTTCCTACTCAGCCACAGGCGC
CTTGCTCCTATCCGCCGTCCAGCGCTCTGCGAGCTGCACCGAGAGAA
GGATGGAGACTTTCCCCGCCGCTTGGGTCCTGGCACTGCTTTGCCTT
ATF
Consensus
AP-1
Consensus
First codon
AP-1
Consensus
Start site
 
Figure 5.2 ATF/CRE consensus sequences in the promoter of the rat Ereg gene. 
Promoter analysis was performed using the online tool TRANFACT 4.0. A predicted 
ATF consensus binding site is shown in purple. Two AP-1 sites are shown in red. The 
transcriptional start site and first exon are shown in brown with the first codon shown in 
green. Rat Ereg promoter sequence was obtained from Ensembl 
(ENSRNOG00000002771). 
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FosB promoter sequence
GCGCGCGCCGGAGCGAGGGATTCCCTCTGACGTCATTGCTAGGATAC
CAAACAAACAGTCGGCCGCGCCGGCCGAGCTCCTTATATGGCTAATT
GCGTCACAGGAACTCCGGGGAGGGCGGGGCGGGATCCCCTCCCGCGG
AGCCCCTCAGAACACAGTCTTGGAGACCCCCGAGACCCCCAGGGTTA
CTCTATGGGCAGGTGGCAGGTGCACGAGGCCCTGGGGGTCTCCACAA
GGGGCTCAGGAGGCGGGAAGGGAGAGTTCGGGAGGTTTGTGCATGGA
GTTGCGGGTGACGCAAGCAGGGGGGCGGGTCCCGGAGGCATAAATTC
AGCTCCGGGCTCCCGGTTTCATTCATAAGACTGGAGCGGCTACGCCG
GGGACACGCGGAGTCGGGGCTTGCTGGACTTGACTACTGGTGACTCT
TTCTTTTTCTTCTTCTTGGAGGCCGTGAATAATTTTATAGATATATA
CATTTTTTTTTAACTGGAGAGAAAGTTTTGTGGGTTTCCTTTTTGCA
AGACTCTTTCTAGATCGTTCTTCTGATTCGTCCGGGGGATAGACTTA
CTTTCTGTGGGCTTCTGGATCGTGGCCCTCTGCTCTCCCTCATTTCT
TTGGACGCCTGGACGGGATTAGAAAGGTATCTGAATCGCACGCTGCA
CCGCGGCACTGCCCGGCGGGTTTCTGGGCGGGGAGCGATCCCCGCGT
CGCCCCCCGTGAAACCGACAGAGCCTGGACTTTCAGGAGGTACAGCG
GAGGTCTGAAGGGGACCTGGGAGCGCAACAGAGGGAACTTGCATCGA
AACTTGGGCAGTTCTCCGAACCGGAGACTAAGCTTCCCCGAGCAGCG
CACTTTGGAGACGTGTCCGGTCTACTCCGGACTCGCATCTCATCCCA
CTCGGCCATAGCCTTGGCTTCCAGAAGACCTCAGCGTGGTCACAGGG
GCCCCCCTGTGCCCAGGGAAATGTTTCAAGCTTTCCCCGGAGACTAC
GACTCCGGCTCCCGGTGTAGCTCATCACCCTCC
CREB
Consensus
ATF
Consensus
TATA box
ATF
Consensus
Start site
 
Figure 5.3 ATF/CRE consensus sequence in the promoter of the rat FosB gene. 
Promoter analysis was performed using the online tool TRANFACT 4.0. Two predicted 
ATF consensus sequences are shown in purple, a CREB consensus sequence is shown in 
pink. TATA box sequence is shown in red. The location of the transcriptional start site 
(which also corresponds to the first codon) within the first exon is shown in green. Rat 
FosB promoter sequence was obtained from Ensembl (ENSRNOG00000016811). 
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 c-jun promoter sequence
CGACGCAAGCCAATGGGAAGGCCTTGGGGTGACATCATGGGCTATTT
TTAGGGATTGACTGGTAGCAGATAAGTGTTGAGCTCAGGCTGGATAA
GGACTCAGAGTTGCACTGAGTGTGGCAGAGACTGCCTAGCTGGAGAG
CGCTCAGGCAGACAGACAGACGGACGGACTCGGCTAACCTGGTCGTC
CGCGGACTCCGGGCTGTTCATCTGTTTGTCTTCATTTTCTGACCAAC
TGCCTGGATCCAGCGCCCGCAGCTCCTGCACCGGTGTTTTGGGGAGC
ACTTGGAGAGTCCCTTCTCCCGCTTTTCCCGGAGAAGAAGCTCACAA
GTCCCGGCACTGCTGACAGCATCGAGAACGGCTCCGGACCGCGCGAG
GAAATAGGCGAGCGGCTACCGGCCAGCAACTTTCCTGACCCAGAGGA
CCGGGAACAAGTGGCCCGGAGCGAACTTTTGCAAAACCTCTTCTGCG
CCTAAGGCTGCCACCGAGACCGTAAAGAAAAGGGAGAAGAGGAACCT
ATACTCATACCAGCTCGCACAGGCGGCTGAAGTTGGGCGAGTGCTAG
CCGCGGCTGCCTAGCGTCCCCCTCCCCCTCACAGCGGAGGAGGGGAC
AGTTGTCGGAGGCCGGGCGGCAGAGCCCGATCGCGGGCTTCCACCAA
GAATTCCGTGACGACTGGTCTGCGCCGCCGGAGAACCTCTGTC
 
 
 
 
 
 
 GCTG
GGGCTGGTCCGCGGGCTCCGAGGAACCGCTGCTTCCCGAGAGCGCTC
 
 
 
 
Figure 5.4 ATF/CRE consensus sequences in the rat c-Jun promoter. Promoter 
analysis was performed using the online tool TRANSFAC 4.0. Two predicted ATF/CRE 
sites are indicated in pink Also an early growth response 1 (Egr-1) binding site is 
indicated in red and an activator protein 1 (AP-1) site is indicated in blue. The 
transcriptional start site in the first exon (also corresponding to the first codon) of the c-
Jun gene is indicated in green. Rat c-jun promoter sequence was obtained from Ensembl 
(ENSRNOG00000026293). 
CGTGAGTGACCGCGACTTTTCAAAGCTCCGGATCGCGCGGGAGCCAA
CCAACGTGAGTGCAAGCGGTGTCTTAACCCTGCGCTCCCTGGAGCGA
ACTGGGGAGGAGGGCGCAGGGGGGAGCACTGCGGTCTGGAGCGCACG
CTCCTAAACAAACTTTGTTACTGAAGCGGGGACGCGCGGGTATCCCC
CGCTTCCCGGCGCGCTGTTGCGGCCCCGAAACTTCTGCGCACAGCCC
AGGCTAACCCCGCGTGAAGTGACCGACTGTTCTATGACTGCAAAGAT
GGAAACGACCTTCTACGACGATGCCCTCAACGCCTCGTTCCTCCAGT
Egr-1
Consensus
ATF/CRE
Consensus
Start site
AP-1
Consensus
ATF/CRE
Consensus
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5.3.2 Knockdown of the ATF3 gene using adenoviral mediated overexpression of the 
antisense sequence of ATF3. 
A full length ATF3 antisense-containing adenovirus was constructed by Dr Stephen 
Fuller from our laboratory as described in section 2.12. Infections of cardiomyocytes at a 
multiplicity of infection (MOI) ~10 – 100 took place overnight with either an ATF3 
antisense-containing adenovirus (ATF3-A/S) or with a Flag-Shuttle virus, containing only 
the p-Shuttle vector and the Flag sequence (DYKDDDDK) (Flag-Shuttle), this later 
serving as a control for any adenoviral-mediated unspecific effects. The next day infected 
cardiomyocytes were either left untreated (controls) or were stimulated with 10 nM ET-1 
for 1 h. I first evaluated the effects of the adenoviral-mediated overexpression of ATF3 
antisense (ATF3-A/S) on the expression levels of endogenous ATF3 using Q-PCR 
analysis of extracted mRNA, and immunoblotting of nuclear extracts. Adenoviral-
mediated overexpression of ATF3-A/S resulted in significant reduction of mRNA levels 
of the ATF3 gene with respect to Flag-Shuttle infected cardiomyocytes following ET-1 
treatment (Figure 5.5A). Adenoviral-mediated overexpression of ATF3-A/S also caused a 
significant inhibition of ET-1-induced ATF3 protein levels, reducing expression of the 
ATF3 protein to 43 (± 3) % relative to Flag-Shuttle following ET-1 stimulation (Figure 
5.5B upper panel). These experiments also demonstrated that infections with Flag-Shuttle 
alone had no effect on the expression of ATF3, thus confirming that the effect on ATF3 
knockdown was mediated by the overexpressed ATF3 antisense sequence and not by non-
specific effects as a consequence of adenoviral infection of cardiomyocytes. The protein 
levels of ATF2, another ATF/CRE family member expressed in cardiomyocytes, were not 
altered after adenoviral infections under identical treatment conditions (Figure 5.5B 
middle panel), demonstrating that the effect of ATF3-A/S on cellular proteins was not a 
consequence of general inhibition of global protein translation. Previous studies have 
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shown that ATF2 is phosphorylated following ET-1 treatment (Clerk and Sugden, 1997). 
Consistent with this, the presence of a reduced mobility band for ATF2 was observed 
following ET-1 stimulation of cardiomyocytes (Figure 5.5B middle panel).  
 
5.3.3 Effects of ATF3 knockdown on the expression of IL-6 in cardiomyocytes 
stimulated by ET-1. 
Previously, I have shown that IL-6 mRNA and protein levels increase in response to ET-1 
stimulation (Chapter 4). Furthermore, ATF3 binds to the promoter of IL-6 following ET-1 
stimulation and may be involved in a negative feedback loop to repress IL-6 expression 
(Chapter 4). To evaluate the possibility that ATF3 is a negative regulator of IL-6, I 
examined the effects of ATF3 knockdown (see above section 5.3.2) on the expression 
levels of IL-6 using Q-PCR. ATF3 protein knockdown resulted in significant 
superinduction of IL-6 following stimulation of cardiomyocytes with ET-1 for 1 h (Figure 
5.6). This suggests that, under conditions of reduced ATF3 protein levels, following ET-1 
stimulation IL-6 mRNA expression becomes de-regulated resulting in superinduction of 
the mRNA abundance of IL-6. These results also confirm that IL-6 is one of the 
downstream targets of ATF3 regulation following ET-1 stimulation of cardiomyocytes. 
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Figure 5.5 Effects of ATF3 knockdown on mRNA and protein levels of ATF3 in 
cardiomyocytes. Cardiomyocytes were infected overnight with a Flag-Shuttle adenovirus 
(p-Shuttle vector containing the Flag sequence), or with ATF3-A/S adenovirus 
(containing the ATF3 antisense sequence). Next day, cardiomyocytes were either left 
untreated or stimulated with 10 nM ET-1 for 1 h. In (A), the expression of ATF3 mRNA 
was analysed by Q-PCR, with simultaneous analysis of GAPDH in each 96-well plate as 
an endogenous control using the relative quantification protocol. Results are means ± 
S.E.M. for three independent cardiomyocyte preparations. In (B), nuclear extracts were 
immunoblotted with antibodies to ATF3 (upper panel) or ATF2 (middle panel). 
Representative images are shown. The blots of ATF3 were analysed by scanning 
densitometry and the combined data are shown in the lower panel as means ± S.E.M. for 
three independent preparations of cardiomyocytes. (* p< 0.01, # p< 0.001 relative to Flag-
Suttle+ET-1, one way ANOVA with Tukey post test). 
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Figure 5.6 Knockdown of ATF3 causes increased expression of IL-6 after ET-1 
treatment of cardiomyocytes. Cardiomyocytes were infected overnight with a Flag-
Shuttle adenovirus (p-Shuttle vector containing the Flag sequence), or with ATF3-A/S 
adenovirus (containing the ATF3 antisense sequence). Next day, cardiomyocytes were 
either left untreated or stimulated with 10 nM ET-1 for 1 h. Unstimulated cells were used 
as controls for both adenoviral conditions (Flag-Shuttle and ATF3-A/S). The expression 
of IL-6 mRNA was analysed by Q-PCR, with simultaneous analysis of GAPDH in each 
96-well plate as an endogenous control using the relative quantification protocol. Results 
are means ± S.E.M. for three independent cardiomyocyte preparations. (# p< 0.001, 
relative to Flag-Shuttle+ET-1, one way ANOVA with Tukey post test). 
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5.3.4 Several immediate early genes are downstream targets of ATF3 
As shown in Table 5.1, 15 out of 18 immediate early genes that are superinduced by 
preincubation with the protein synthesis inhibitor cycloheximide followed by treatment 
with ET-1 at 1 and 2 hours, have at least one ATF/CRE consensus or related binding site 
in their promoters. As shown in the preceding section, knockdown of ATF3 protein 
results in superinduction of IL-6 mRNA expression levels, a gene that is also one of the 
IEGs superinduced under these conditions. To test the hypothesis that at least some of the 
other genes with ATF/CRE consensus sequences in their promoters were also 
downstream target genes of ATF3 regulation, Q-PCR analysis was performed to 
interrogate the expression levels of eight selected genes (Ereg, c-Fos, FosB, Ier2, c-Jun, 
LIF, Nfκbiz, and Ptgs2), using mRNA extracted from cardiomyocytes under conditions of 
knockdown of ATF3 protein as described above (section 5.3.2). With this approach, I 
identified six genes that were superinduced by knockdown of ATF3 protein and two 
whose mRNA levels did not change under these same conditions.  
 
Knockdown of ATF3 protein resulted in significant superinduction of LIF, Ereg and 
Nfκbiz (Figure 5.7, A to C). This suggests that these genes are probable downstream 
target genes of ATF3, and that, as with IL-6, ATF3 may operate in a negative feedback 
loop to repress their transcription following stimulation with ET-1. The genes c-Fos, Ier2 
and Ptgs2 were also slightly superinduced by ATF3 knockdown, however this effect did 
not reached statistical significance (Figure 5.7, D to F). Nevertheless, these genes are 
possible downstream targets of ATF3 with similar negative regulatory effects on their 
transcription but it is likely that other transcription factor(s) could also be involved in 
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their transient expression following ET-1 stimulation (Cullingford et al., manuscript 
submitted). 
 
5.3.5 The transient pattern of induction of c-jun and FosB is possibly mediated by an 
alternative mechanism not involving the transcription factor ATF3 
I also performed Q-PCR analysis to evaluate the effects of ATF3 knockdown on c-Jun 
and FosB mRNA abundance following ET-1 stimulation. The analysis indicates that 
following ATF3 knockdown, the mRNA levels of c-Jun and FosB remain unchanged 
indicating that these genes are probably not downstream target genes of ATF3 (Figure 
5.8). 
 
5.3.6 CT-1 another member of the gp130 cytokines is affected in an opposite manner 
after knockdown of ATF3 in cardiomyocytes 
My analysis indicated that two out of three of the most studied members of the IL-6 
family of cytokines, IL-6 and LIF are probable targets of ATF3 downregulation, as 
indicated by superinduction of their mRNA abundance after knockdown of ATF3 
following ET-1 stimulation (Figures 5.6 and 5.7B). CT-1 is another member of the gp130 
cytokines with important functions in the pathophysiology of eccentric hypertrophy and 
also appears to promote dilatation of the heart leading to heart failure (Wollert et al., 
1996; Hunter and Chien, 1999). 
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Figure 5.7 Knockdown of ATF3 causes superinduction of LIF, Ereg, Nfκbiz, Ptgs2, 
Ier2 and Fos mRNA expression in cardiomyocytes upon ET-1 stimulation. 
Cardiomyocytes were infected overnight with a Flag-Shuttle adenovirus (p-Shuttle vector 
containing the Flag sequence), or with ATF3-A/S adenovirus (containing the ATF3 
antisense sequence). Next day, cardiomyocytes were either left untreated or stimulated 
with 10 nM ET-1 for 1 h. Unstimulated cells were used as controls for both adenoviral 
conditions (Flag-Shuttle and ATF3-A/S). The expression of (A) Ereg Ereg, (B) LIF, (C) 
Nfκbiz, (D) Ptgs2, (E) Ier2, and (F) Fos mRNA levels was analysed by Q-PCR, with 
simultaneous analysis of GAPDH in each 96-well plate as an endogenous control using 
the relative quantification protocol. Results are means ± S.E.M. for three independent 
cardiomyocyte preparations. (* p<0.05; # p< 0.001, relative to Flag-Shuttle+ET-1, one 
way ANOVA with Tukey post test). 
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Figure 5.8 Knockdown of ATF3 does not affect the expression levels of the IEGs 
FosB and c-Jun in response to ET-1. Cardiomyocytes were infected overnight with a 
Flag-Shuttle adenovirus (p-Shuttle vector containing the Flag sequence), or with ATF3-
A/S adenovirus (containing the ATF3 antisense sequence). Next day, cardiomyocytes 
were either left untreated or stimulated with 10 nM ET-1 for 1 h. Unstimulated cells were 
used as controls for both adenoviral conditions (Flag-Shuttle and ATF3-A/S). The 
expression levels of (A) FosB (B) c-Jun mRNA were analysed by Q-PCR, with 
simultaneous analysis of GAPDH in each 96-well plate as an endogenous control using 
the relative quantification protocol. Results are means ± S.E.M. for three independent 
cardiomyocyte preparations. 
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Previous studies have shown that the human CT-1 gene contains an ATF/CRE consensus 
sequence in its promoter (Erdmann et al., 1998) (Figure 5.9 and 5.10). The analysis of the 
rat CT-1 gene with the tool TRANSFACT 4.0 showed that its promoter does indeed 
possess a predicted ATF/CRE consensus sequence but in a different location relative to 
the transcription start site with respect to the human CT-1 gene (Figures 5.9 to 5.11). 
Further analysis of the rat and human CT-1 genes using the multiple alignment tool 
MultiAlin (Corpet, 1988), reveals that the human ATF/CRE consensus sequence 
previously described in the literature was not conserved in the rat CT-1 gene promoter 
(Figure 5.9). In fact, the analysis of the human CT-1 gene with the TRANFACT tool 
reveals the presence of another ATF/CRE consensus on the human CT-1 promoter 
(Figure 5.10). However, even though the ATF/CRE consensuses of human and rat do not 
overlap, I can conclude that the CT-1 promoters of both species possess ATF/CRE sites 
which could be bound by ATF3 (Figures 5.9 to 5.11). Interestingly, parallel studies from 
our laboratory indicate that although IL-6 and LIF are IEGs induced following 
stimulation of cardiomyocytes with ET-1, CT-1 is not one of these IEGs. In accordance 
with this observation, knockdown of ATF3 not only did not induce its expression but on 
the contrary caused a marked downregulation of the basal levels (Figure 5.12). 
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 ATF/CRE site Human
ATF/CRE site Rat
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 The human CT-1 promoter contains an ATF/CRE consensus that differs 
from the predicted ATF/CRE consensus in the rat CT-1 promoter. The human and rat 
CT-1 gene promoter regions obtained from Ensembl (Human CT-1: ENSG00000150281; 
Rat CT-1: ENSRNOG00000018962) were analysed with the MultiAlin tool. The 
previously described human ATF/CRE consensus is shown boxed in brown, and the rat 
ATF/CRE site is shown boxed in purple. Both promoter regions differ considerably for 
each species (see also Figures 5.10 and 5.11). 
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Human CT-1 promoter sequence
CCTGCACACTCACACGCACACAAATCCACTCGCACACACGCATGCTC
ACACGCACACACGTCCGCATGCACGCACACACGCAGACACACGCAAG
CGCACACACACACGGGCCTCCTCGTCTTCATTCACAAACCCCATTAG
CTTCTGTTGTCTATGGGCTTCCTCGACAGACCGCGAGCCCCTCGCGG
GGGCCAGAAACCAAGTATGGATCATCCCTATGTGCCTTCCTTTCCGT
CTACACCAGGTTAATGGGGTTGACGTATGGGTGTGACTTCCTGTCCA
GGTCTCTGTAGCTTGTTCTCCTGGGGGTGGGGGGCGGGGTGTGATTG
TTACTAGGCCTGCTAAGAAGAGGAGAGCAGTGTATCTGTCTCCCTCC
TGGTGGGTGTGACAATGAGATTGGAAGCCATCTAAGATAGGCCAGGA
GATGTATGTCTGGACAAACATGCCCCAAGCCTGACGGCCCCCATCGT
AGCCTCCCTCGCAAGCCGCGCCCCAGACTAGAGAGAGGGCCTGCGCA
TTCCTGTCCTGCCAGTCCGGCAGTTCCCTCTCCTGTCTCCTCAGCTT
TACACCCAAAGCAGCCGCTGCCTCAGGTCCAAGCCTGAGCCCGCGGC
AGAACATTGGGCTGCCTCCCAGGCCCTGACACCCCCAGCCCCGAGGT
CCTGTCCACCCGGCAGACAACTTGCCTTCCCCCTCGGGCCCCTTCCC
CCACTAGGCCCCACGGACGAGGAGCTGAGCTCAGGGCCAAGGAATCC
TGTCTCAAAAGGGGGGGTAGGATGAAATGTTTGGGGTCTGGGCTCTG
ATTGGCTGCGCCCGGGCCACGCCCCCAGCCCTTTCCCCTTTCTCCCC
CCTCGAAAGGGGGGCGTGAAGGGAGCCGGGATCAGCCAGGGGCCAGC
ATGAGCCGGAGGGAGGGAAGTCTGG
AP-1
Consensus
ATF/CRE
Consensus
Start site
Novel
ATF/CRE
Consensus
First codon
 
Figure 5.10 ATF/CRE consensus sequences in the human CT-1 gene promoter. 
Promoter analysis was performed using the online tool TRANFACT 4.0. A previously 
described ATF/CRE site is shown in red; a novel predicted ATF/CRE site is shown in 
pink. An AP-1 consensus site is shown in blue, with the transcriptional start site and first 
codon within the first exon shown in brown and green respectively. The human CT-1 
promoter sequence was obtained from Ensembl (ENSG00000150281). 
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Rat CT-1 promoter sequence
AAAGAAGATTGGAAACATTGCTGAACAGGTCCACTTCCCCCATATCC
TCATAACTTTTCTCTTCCACTACCTTTGTTGGGTGGTGGGCAAGAGG
AGAGGTTGAACGTTTATTAAAAGTAGGTTGAAAAAAAAAAGTAGGTT
GCAAAAGGTGTGCCTACACTCCATTATCTGAAACCTGAAACCAATGT
GGATCCTCTGTGCCAGTGCCCAAGGCGCTTGGGAACCAATAGTAGAG
GCAAGTGTGTCCAGTCCTTTCAGAGTCTACCCTGGGTTGATGAGTCG
CTGTTTGGGTGTGTCCTCTAAGCTTGTGTTCACCTGTGTAGAAGACT
GGGTCCAAACGCCTTAGTATATCTGCCTATGTGTGGGAGGGTTTGTA
ATGAATGGTAAGTGAGGGGCAGGCTGTCTCTCTTCTGATCAGTGTGA
CAGAGAAAGTAGAAGGTATCCAAGTTAACTAGACCGGGGGTGCATGC
CTTAGGTGCACCCTAACCTAAACAGGGC
 
 
 
 
 
TCCCCTGGCCTCTCTTTGT
CTTCCCCCAAAAGGAGGACCTGATGGCATT 
 
 
 
 
Figure 5.11 ATF/CRE consensus site in the rat CT-1 gene promoter. Promoter 
analysis was performed using the online tool TRANFACT 4.0. The ATF/CRE consensus 
is shown in pink, one AP-1 consensus is shown in blue and an NFkappaB (Rel) consensus 
is shown in red. The transcriptional start site and first codon within the first exon are 
shown in brown and green respectively. The rat CT-1 promoter sequence was obtained 
from Ensembl (ENSRNOG00000018962). 
 
 
CTTCTCCCGCCAGTCCT
GCACCTTTCCTCTCGGGTTTCCCAGCTTTTCCCTCCAAAGCAGCCAA
TAATCTATCTCAGGTCTGAGCCTGAGTCTCCTCCCAACAGGACACAG
AACTGCGTTTAAAGGCCCAAGTTCCCATTCACTGTGCCAACACCTGC
CTCCCAATTCTGGCCCCTTCCCAGTCTAAGCTCACAAGCCGGTTACT
GAGCTCTGGGCCAAGGAATTTTGCCTGAAAGTAATGGTGGGAAGGAA
ATATTTGGGGTCTGAGCTATGATTGGCCGAGCCCGAGCCACGCCCCT
AGCCCTTTCCCCCTTTTTCCCCCCCTCCCCTCCTCCTCCCCGGTAAG
GGTGTGTTGAAGGAAACAGGATCAGCCTGGGGCCAGCATGAGCCAGA
GGGAGGGAAGTCTGG
NFkappaB
Consensus
AP-1
Consensus
Start site
ATF/CRE
Consensus
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Figure 5.12 Effect of ATF3 knockdown on CT-1 mRNA levels following ET-1 
stimulation. Cardiomyocytes were infected overnight with a Flag-Shuttle adenovirus (p-
Shuttle vector containing the Flag sequence), or with ATF3-A/S adenovirus (containing 
the ATF3 antisense sequence). Next day, cardiomyocytes were either left untreated or 
stimulated with 10 nM ET-1 for 1 h. Unstimulated cells were used as controls for both 
adenoviral conditions (Flag-Shuttle and ATF3-A/S). The expression levels of CT-1 
mRNA were analysed by Q-PCR, with simultaneous analysis of GAPDH in each 96-well 
plate as an endogenous control using the relative quantification protocol. Results are 
means ± S.E.M. for three independent cardiomyocyte preparations. (* p<0.01 relative to 
Flag-Shuttle+ET-1; # p< 0.001 relative to Flag-Shuttle, one way ANOVA with Tukey 
post test). 
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5.3.7 Ereg and LIF mRNA expression is transient following stimulation with ET-1 
The above experiments indicated that IL-6, LIF, Ereg and Nfκbiz were all significantly 
superinduced after knockdown of ATF3 followed by ET-1 stimulation, suggesting that 
ATF3 is involved in their negative regulation. The regulation of these genes by ATF3 is 
likely to be suppression of their transcriptional activation rather than stability. Therefore, 
I performed Q-PCR analysis to evaluate the mRNA expression levels of ATF3 (see also 
Figure 3.3), IL-6 (see also Figure 4.3) LIF and Ereg using mRNA extracted from 
cardiomyocytes unstimulated (controls) or exposed to 100 nM ET-1 for up to 8 h (Figure 
5.13). This analysis indicated that the expression of these genes is also transient as 
suggested by parallel studies from our laboratory using microarray analysis (Cullingford 
et al., manuscript submitted). Thus, ATF3 and IL-6 had a peak of expression at 30 
minutes with some decline after 1 h and a return to near basal levels after 2 h (Figure 
5.13A and B). A similar transient induction was also observed for Ereg and LIF, however 
the peak of expression of Ereg was observed at 1 h, and that of LIF was observed between 
30 min and 1 h but, in both cases, levels returned to basal within 2 h (Figure 5.13 C and 
D). All of this is consistent with the observation that IL-6, LIF and Ereg were identified 
as IEGs upregulated in cardiomyocytes by ET-1 and whose transient expression pattern 
could be the result of a negative regulatory effect of ATF3 on their transcriptional 
activation. 
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Figure 5.13 Expression of ATF3, IL-6, LIF and Ereg mRNA in response to ET-1 in 
cardiomyocytes. Cardiomyocytes were unstimulated (controls, zero time) or exposed to 
ET-1 (100 nM), for the indicated periods of time. The expression of (A) ATF3, (B) IL-6, 
(C) Ereg or (D) LIF mRNA was analysed by Q-PCR, with simultaneous analysis of 
GAPDH in each 96-well plate as an endogenous control using the relative quantification 
protocol. Results are means ± S.E.M. for four independent cardiomyocyte preparations. (* 
p< 0.05; # p< 0.01, relative to control, one-way ANOVA with Tukey post test). 
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5.4 Discussion 
5.4.1 Role of ATF3 in the transcriptional repression of several IEGs in cardiomyocytes 
In vitro studies have shown that ATF3 is an activator of transcription when bound as a 
heterodimer with for example c-Jun or JunD to specific ATF/CRE or related binding sites 
(Hsu et al., 1992; Chu et al., 1994). Interestingly, the ATF3/JunB heterodimer can either 
activate or repress transcription depending on the promoter context (Hsu et al., 1992). In 
contrast, ATF3 homodimers (ATF3/ATF3) are negative regulators of transcription (Chen 
et al., 1994; Wolfgang et al., 2000). Although this ability to form heterodimers and 
homodimers and therefore positively or negatively regulate transcription suggests a 
versatility in the regulation of gene expression by ATF3, most studies to date have shown 
that ATF3 acts mainly as a transcriptional repressor in vitro and in vivo. Thus, ATF3 
homodimers are negative regulators of transcription of its own promoter (Chen et al., 
1994; Wolfgang et al., 2000), as well as the proapoptotic transcription factor CHOP 
[C/EBP (CCAAT/enhancer binding protein) homologous protein] (Wolfgang et al., 
1997). ATF3 has been also implicated in the negative regulation of PLB in 
cardiomyocytes following its induction by adenylyl cyclase IV or isoproterenol (Gao et 
al., 2004), and is involved in a negative feedback loop repressing IL-6 or IL-12 
expression in monocytes following stimulation with lipopolysaccharide (Gilchrist et al., 
2006). 
 
Viral-mediated antisense overexpression in cells, tissues and in whole animals has long 
been recognized as an effective method to knockdown genes to evaluate the effects of the 
target gene in biological processes (Green et al., 1986). Thus, overexpression mediated by 
retroviral vector of an ANGII type 1B (AT1B) receptor antisense resulted in knockdown of 
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the AT1B receptor and reduced ANGII actions in neurons from hypertensive rats (Lu and 
Raizada, 1995). This same retroviral AT1B-antisense system was also effective in 
controlling blood pressure in spontaneously hypertensive rats after a single injection to 5 
days old rats (Iyer et al., 1996), and in reducing cardiac hypertrophy secondary to the 
cardiac actions of ANGII in the renin-transgenic rat following a single intracardiac 
injection to 5 days old rats (Pachori et al., 2002). To determine the role of ATF3 in 
cardiomyocytes following ET-1 stimulation, I used adenoviral-mediated overexpression 
of ATF3 antisense to the full coding sequence. As shown in figure 5.5, ATF3-A/S 
overexpression resulted in significant reduction of both ATF3 mRNA and protein levels 
induced by ET-1, and this response was specific as no effect on the levels of ATF3 
mRNA or protein was observed with the Flag-Shuttle vector. A further confirmation of 
the specificity is that ATF3 protein levels were downregulated in the absence of any 
change in the expression levels of ATF2 protein in nuclear extracts (Figure 5.5B). 
 
To evaluate the effects of ATF3 knockdown following hypertrophic stimuli in the form of 
ET-1 stimulation of cardiomyocytes, the expression levels of several IEGs was evaluated 
using Q-PCR analysis (Table 5.1). First I confirmed that IL-6 is a downstream target of 
ATF3 regulation by showing that ATF3-A/S mediated knockdown of the ATF3 protein 
results in superinduced expression of IL-6 mRNA (Figure 5.6). This superinduction was 
statistically significant and in accord with previous studies using bone marrow derived 
macrophages derived from ATF3 -/- mice in which stimulation with LPS resulted in a 
substantial increase in the expression levels of IL-6 compared to cells derived from wild-
type animals (Gilchrist et al., 2006; Withmore et al., 2007). In the study of Gilchrist et al., 
(2006), the in vivo effects of absence of ATF3 following exposure to LPS were even 
more dramatic. Thus, ATF3 -/- mice not only produced more IL-6 as measured from 
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peritoneal macrophages, but also exhibited a more severe endotoxic shock probably 
secondary to sustained inflammation. 100 % of ATF3 null animals died within 24 h of 
LPS injection, whereas none of the wild-type mice had succumbed by this time period 
(Gilchrist et al., 2006).  
 
To extend the observation made with IL-6, I also demonstrated that other IEGs were also 
superinduced after ATF3 knockdown (Figure 5.7). Among these, LIF, another member of 
the gp130 cytokines (section 1.3.3), Ereg, a member of the EGF related growth factors 
(section 1.3.2), and Nfκbiz, also known as inhibitor of nuclear factor kappa B (NF-κB) 
zeta (IκB-ζ), were all found to be significantly superinduced by ATF3 protein knockdown 
following stimulation with ET-1 in cardiomyocytes (Figure 5.7 A to C). Therefore these 
genes are probable target genes of ATF3. To our knowledge this is the first report of these 
genes as potential downstream targets of ATF3 in any cell system. I also found that Ptgs2, 
c-Fos and Ier2 have a tendency to be superinduced under the same ATF3 knockdown 
conditions (Figure 5.7 D to F). However, this effect did not reach statistical significance. 
For these genes, I suggest that either the time point selected at 1 h is possibly too early to 
fully appreciate the effects of ATF3 protein knockdown, or alternatively the effect of 
ATF3 is shared with another transcriptional repressor that is present despite the reduced 
levels of ATF3. In contrast, c-Jun and FosB are probably not downstream targets of ATF3 
transcriptional repression as indicated by the lack of effect in their mRNA abundance 
under similar ATF3 protein knockdown conditions (Figure 5.8). 
 
 LIF as well as IL-6 and CT-1, is a cytokine capable of inducing eccentric hypertrophy 
and is therefore considered important for the pathophysiology of heart failure (Hunter and 
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Chien, 1999; Nicol et al., 2000). The role of Ereg has yet to be established in 
cardiomyocytes. Studies in other systems indicate that Ereg expression is induced in 
vascular smooth muscle cells (VSMCs) following stimulation with ANGII, ET-1 or α-
thrombin, and is a potent mitogenic factor for these cells (Taylor et al., 1999). 
Importantly, alterations in the phenotype of VSMCs from a differentiated towards a de-
differentiated state are of critical importance in the pathogenesis of vascular diseases such 
as atherosclerosis (Ross, 1993). Recently, Ereg was reported as a de-differentiation factor 
in VSMCs a response that is mediated through the activation of the ERK1/2 and p38-
MAPK pathways (Takahashi et al., 2003). Ereg is also upregulated following stimulation 
of VSMCs with lysophosphatidic acid and PDGF-BB, two potent VSMC-de-
differentiation factors. These data and the finding of increased Ereg expression in human 
atherosclerotic lesions and in rat arteries subjected catheter balloon injury, suggests that 
Ereg is an important factor in the pathophysiology of atherosclerosis (Takahashi et al., 
2003). Ereg is also implicated as an important growth regulating factor in several cell 
types (Toyoda et al., 1997), and the finding of increased levels of this protein in several 
cancers and epithelial tumour cell lines indicates that it may play a role in the progression 
of carcinomas (Toyoda et al., 1997; Lindvall et al., 2003; Yamamoto et al., 2004a). 
 
The transcription factor NF-κB is an important regulator of innate and adaptive immune 
responses, and also plays a key role in apoptosis, cell proliferation and differentiation (Li 
and Verma, 2002; Hayden and Ghosh, 2004; Bonizzi and Karin, 2004). Uncontrolled 
activation of NF-κB, as seen in severe infections, is in part responsible of life-threatening 
conditions such as endotoxic (septic) shock. Therefore, the activity of NF-κB is highly 
controlled in normal cells. In normal quiescent cells, NF-κB is tethered in the cytoplasm 
in a complex with its inhibitory proteins IκB-α, IκB-β and IκB-ε (reviewed in Bonizzi and 
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Karin, 2004). Nfκbiz, the predicted rat orthologue of human IκB-ζ, was recently 
characterized as a novel NF-κB inhibitor, which is strongly induced in response to LPS in 
several cells and tissues in vitro and in vivo (Kitamura et al., 2000; Haruta et al., 2001; 
Yamazaki et al., 2001). Unlike other IκB proteins, IκB-ζ is localized to the nucleus where 
it is capable of potentiating as well as repressing the transcriptional activities of NF-κB 
(Yamazaki et al., 2001; Motoyama et al., 2005). The role of IκB-ζ is not completely 
understood. However, its acute expression in response to inflammatory stimuli and its 
negative and positive effects on NF-κB transcription suggest that it is an important 
regulator of the immune response in vivo. Similarly the role of this novel protein in the 
cardiovascular system remains to be explored. 
 
Despite the roles of Ereg and Nfκbiz (IκB-ζ) in cardiomyocytes being currently unknown, 
studies in other systems indicate that these two genes are important regulators of the 
expression of IL-6 in cells of the immune system. Thus, bone marrow derived 
macrophages and dendritic cells (BMDMs and BMDCs) from Ereg -/- mice exhibit 
reduced production of IL-6 levels following stimulation with the bacterial antigen 
peptidoglycan, indicating that Ereg has a key role in peptidoglycan-induced 
proinflammatory cytokine production in these cells (Sugiyama et al., 2005).  As described 
above, IκB-ζ is a positive regulator of NF-κB transcriptional activities and this effect has 
been mapped to its N-terminus (Motoyama et al., 2005). Consistent with a positive effect 
on NF-κB activities, overexpression of IκB-ζ augments IL-6 production in response to 
LPS (Motoyama et al., 2005). In contrast, peritoneal macrophages from IκB-ζ deficient 
mice exhibit severe reduction in the production levels of IL-6 following LPS and IL-1β 
stimulation (Yamamoto et al., 2004). This suggests that IκB-ζ is a key element in the 
regulation of proinflammatory cytokines such as IL-6 in response to LPS and IL-1β. 
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Thus, both Nfκbiz and Ereg act as positive regulators of IL-6 expression in other systems. 
Taken together, these findings in other systems and the results from our studies suggest 
that ATF3 is probably involved in a negative regulatory network which targets the 
repression of genes such as IL-6 and LIF, and also of positive regulators of IL-6 such as 
Ereg and IκB-ζ in cardiomyocytes following stimulation with ET-1. This suggests that 
ATF3 may be a modulator of the hypertrophic response. This effect may be mediated at 
least in part by preventing the expression of genes that could lead to eccentric 
hypertrophy such as IL-6 family members, thus probably favouring the development of 
concentric rather than eccentric hypertrophy following ET-1 stimulation. 
 
Interestingly, my studies of the mRNA expression levels of CT-1 following knockdown 
of ATF3 indicate that the above generalization is not extensible to all gp130 cytokines. In 
contrast to the observed superinduction of IL-6 and LIF, knockdown of ATF3 protein 
resulted in significant downregulation of CT-1 mRNA levels following ET-1 stimulation 
(Figure 5.12). This effect and the observation that ET-1 alone had a negative effect on the 
expression levels of CT-1 suggest that, in contrast to IL-6 and LIF, ATF3 does not 
negatively regulate CT-1 expression, and possibly a negative regulator of CT-1 is 
expressed following ET-1 stimulation, an effect that is accentuated after ATF3 
knockdown. This also suggests that CT-1 could be positively regulated by ATF3 and 
further experiments are required (e.g. ATF3 overexpression in cardiomyocytes) to clarify 
this issue. Although CT-1 mRNA levels are upregulated in cardiomyocytes, this effect 
has been ascribed to catecholamines acting through β-adrenergic receptors (Funamoto et 
al., 2000; Lowes et al., 2002) and in response to ANGII (Sano et al., 2000) but not by ET-
1 stimulation, which is in agreement with our findings of no upregulation of the levels of 
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this gene in microarray studies from our laboratory (Clerk et al., 2005; Cullingford et al., 
manuscript submitted). 
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Chapter 6 
 
Expression of Cyp1a1 and Aldh3a1 in response to 
MAPK cascade inhibitors or doxorubicin in 
cardiomyocytes 
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6.1 Introduction 
 
6.1.1 Chemotherapeutic agents and cardiac toxicity 
The anthracycline doxorubicin and related compounds such as daunorubicin and 
epirubicin, are among the most potent anticancer drugs available today.  Their use in 
combination with other chemotherapeutic drugs, has proved to be very successful in 
inducing tumour remission and, in some cases, doxorubicin is considered to cure some 
tumours (e.g. acute lymphoblastic leukaemia, the commonest of all childhood tumours) 
(Horan et al., 2006). However, doxorubicin and related compounds have a high incidence 
of cardiac toxicity which usually limits their utility. Most chemotherapeutic drugs in 
current use target proliferating cells causing their death. However, because their use is 
systemic (as they are not specifically designed to target cancerous cells), they also affect 
proliferating cells throughout the body causing many side effects. These drugs also affect 
the heart and, whereas other tissues in the body have the capacity for regeneration and 
therefore are able to replace cells lost as a consequence of chemotherapy, the limited 
capacity for regeneration of cardiomyocytes renders the heart highly vulnerable to this 
damage. Cumulative doses of doxorubicin below 450 mg/m2 (administered in bolus of 50 
mg/m2) which are usually considered “safe” and are the goal in most patients receiving 
doxorubicin could still result in delayed cardiotoxicity manifested as heart failure (Shan et 
al., 1996).  
 
Anthracycline cardiotoxicity appears to be mediated at least in part through their 
increased generation of O2˙¯, which is quickly converted to H2O2 (Dorr, 1996; Kumar et 
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al., 2002). This is consistent with the observation of increased rates of apoptosis in 
cardiomyocytes exposed to doxorubicin or daunorubicin secondary to the production of 
ROS (Sawyer et al. 1999; reviewed in Minotti et al., 2004). All of this makes therapy with 
doxorubicin a clinical challenge for modern medicine. Novel formulations and related 
compounds are under investigation, and there is a constant search for potent anticancer 
drugs with a better profile of adverse reactions. 
 
Targeting of intracellular signalling cascades for the development of novel anticancer 
drugs is a rapidly evolving area of research in recent years. ERK1/2 are activated by 
MKK1/2, which, in turn, are activated by the Raf family of MKKKs (section 1.3.1.5). 
Although, in the heart, activation of the ERK1/2 cascade is associated with hypertrophic 
growth of cardiomyocytes and cardiac hypertrophy (section 1.3.1.6), in proliferating cells 
this cascade leads to cell growth, division and survival and has been implicated in the 
development of cancer (Sebolt-Leopold and Herrera, 2004). Several human tumours have 
activating mutations in Raf kinases and its upstream activator Ras (Malumbres and 
Barbacid, 2003; Wellbrock et al., 2004; Aviel-Ronen et al., 2006; Zebisch et al., 2006), 
and therefore activation of the ERK1/2 cascade is a common characteristic of several 
types of cancer, with ERK1/2 as the only known substrates for MKK1/2. Recently, B-Raf 
has been identified as a protooncogene implicated in up to 60% of human cancers 
(particularly melanoma and thyroid cancers) (Niculescu-Duvaz et al., 2006; Kohno and 
Pouyssegur, 2006). All of these features make this cascade unique and particularly 
attractive for the development of new anticancer drugs (Downward, 2003; Sebolt-Leopold 
et al., 2004; Kohno and Pouyssegur, 2006). There are several compounds that selectively 
inhibit MKK1/2.  The compounds PD184352 (CI-1040), PD0325901 and ARRY-142883 
have a pharmacological profile suitable for use in clinical settings and are currently in 
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different stages of phase I and phase II clinical oncology trials. Although the clinical trials 
completed so far with PD184352 (Rinehart et al., 2004; LoRusso et al., 2005) show that 
this drug is well tolerated and have good safety/efficacy profile in the short term, its 
potential toxicity in long term clinical trials remains unknown. Phase I clinical trials with 
PD0325901 and ARRY-142883 are still underway. 
 
The PKB/Akt signalling pathway has an important role in regulating cell growth in 
several cell systems and has been proposed as a mediator of cardiac hypertrophy (1.3.2.2). 
The PKB/Akt pathway is also particularly implicated in cell survival and prevention of 
apoptosis in several systems including the heart (Tong et al., 2002; Clerk et al., 2003; 
Martelli et al., 2007; McCubrey et al., 2007). Activation of several components of this 
pathway correlates with the development of several forms of cancer, including breast 
cancer (Hutchinson et al., 2001) thyroid carcinoma (Ringel et al., 2001) and colon 
adenocarcimona (Khaleghpour et al., 2004), and therefore the blockade of this pathway is 
actively being considered as an important target for the development of novel 
antineoplastic drugs (reviewed in Kim et al., 2005). As an example, the PI3K inhibitor 
LY294002 exerts antitumorigenic effects and induces apoptosis in human colon cancer 
cells both in vitro and in vivo (Semba et al., 2002).  
 
RPTKs that respond to peptide growth factors such as EGF activate both the ERK1/2 and 
the PI3K-PKB/Akt pathways (section 1.4) (Schlessinger, 2000). Overstimulation of the 
EGF receptor (e.g. overexpression of ErbB2) or mutations that result in its constitutive 
activation are associated with certain types of cancer including up to 35% of breast 
cancers (Kauranemi and Kallioniemi, 2006). Therefore, RPTKs are themselves attractive 
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therapeutic targets for cancer. A recently developed anticancer drug is trastuzumab 
(Herceptin), a humanized antibody that targets ErbB2 and therefore inhibits EGF receptor 
signalling probably by preventing ErbB2 dimerization with for example ErbB1, or ErbB4 
(section 1.3.2). The use of this drug particularly in association with anthracyclines has 
been recently reported to cause cardiotoxicity (Suter et al., 2004). Although this 
cardiotoxicity appears to be reversible in most cases, up to 5% of patients develop systolic 
cardiac dysfunction and ~1% develops heart failure (Hayes and Pickard, 2006). There is 
also one report indicating that up to 28%  of patients experienced some degree of 
cardiotoxicity following one year of therapy with trastuzumab, as indicated by a decrease 
in ejection fraction below normal levels of 50%, decrease in 20 percentage points in the 
left ventricular ejection fraction compared with baseline, or signs and/or symptoms of 
heart failure (Guarneri et al., 2006). However, despite the high incidence of 
cardiotoxicity, discontinuation of therapy resulted in recovery in the functional or 
haemodynamic status in all but three patients, although there was one patient with cardiac 
related death during the study (Guarneri et al., 2006). Therefore, although therapy with 
this novel drug may cause some degree of cardiotoxicity in a high percentage of patients, 
this appears to be self limited and there is recovery following termination or 
discontinuation of therapy. However, long term effects of chronic therapy are still 
unknown. 
  
Studies from our laboratory which used microarray analysis to dissect the role of ERK1/2 
in the expression of genes resulting from ET-1 stimulation in cardiomyocytes (Kennedy 
et al., 2006) identified a subset of genes that are upregulated or downregulated by U0126, 
a specific inhibitor of MKK1/2 (Favata et al., 1998). Among the six genes which were 
upregulated, the genes for aldehyde dehydrogenase family 3 member a1 (Aldh3a1), two 
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members of the cytochrome P450 enzymes (Cyp1a1, Cyp1b1), and NAD(P)H 
dehydrogenase quinone 1 (NQO1), are classically induced by the transcription factor aryl 
hydrocarbon receptor (AhR) following binding to their promoter in xenobiotic response 
elements (XRE) in response to polycyclic aromatic hydrocarbons like dioxin and 
benzo[a]pyrene (Denison et al, 2002). This suggests that one effect of U0126 in 
cardiomyocytes is to stimulate XRE, also known as dioxin response element (DRE), in 
the promoters of these genes, potentially via the AhR. These genes are xenobiotic 
metabolizing enzymes, and Cyp1a1 induction is considered a marker gene of dioxin-
induced toxicity. The consequences of their activation are strongly linked to 
carcinogenesis and developmental defects in several species including humans (Mandal, 
2005). The significance of activation of this response in the heart has not yet been 
considered, but cardiotoxicity is a potential side effect. In this chapter the expression of 
the genes Cyp1a1 and Aldh3a1 was evaluated in cardiomyocytes exposed to ERK1/2 
inhibitors, and these results extended to evaluation of their expression in response to the 
JNK cascade inhibitor SP600125, the p38-MAPK cascade inhibitor SB203580, and the 
PI3K inhibitor LY294002, as well as in response to doxorubicin. 
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6.2 Methods 
6.2.1 SQ-PCR 
Cardiomyocytes were exposed to 10 μM U0126, 25 μM PD98059, 10 μM SP600125, 10 
μM SB203580, or 50 μM LY294002 (for 0-4 h), or exposed to 5 μM doxorubicin (0-12 
hours). Total RNA was extracted and cDNA synthesized (Sections 2.3 and 2.5). SQ-PCR 
was performed (Section 2.6) to assess expression of Cyp1a1 and Aldh3a1 mRNA.  
PCR reactions were performed in 50 ml of 1X Buffer IV® (ABgene) containing 0.5–1.0 
ng cDNA, 1U Taq polymerase, 0.2mM each of dATP, dCTP, dGTP and dTTP and 100 
pmol forward and reverse primers [cytochrome P450 family 1 member 1 (Cyp1a1): 
forward 5’-CAA AGC CCA TGT TCC TGT TT-3’, reverse 5’-AGC GGT TCA TGA 
CTG TAC CC-3’, 237 bp product; aldehyde dehydrogenase family 3 member 1 (Ald3a1): 
forward 5’-GGC TGT GTA GGA GTT GCA AT-3’, reverse 5’-ACC TAT GAC AAG 
GAC CAC AC-3’, 245 bp product; glyceraldehyde 3’ phosphate dehydrogenase 
(GAPDH): forward 5’-ACC ACA GTC CAT GCC ATC AC-3’, reverse 5’-TCC ACC 
ACC CTG TTG CTG TA-3’, 452 bp product)]. For Cyp1a1 and Aldh3a1, samples were 
subjected to 27 cycles of denaturation (94 °C, 30 s), annealing (59 °C, 30 s) and extension 
(72 °C, 30 s). For of amplification GAPDH 22 cycles were performed. Bands were 
detected under UV light and sizes were estimated by comparison with a φX174 RF DNA 
Hae III digest DNA ladder (ABgene) or a 100 bp ladder (Invitrogen). 
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6.3 Results 
 
6.3.1 Expression of Cyp1a1 and Aldh3a1 with ERK1/2 inhibitors U0126 and PD98059 
in cardiomyocytes 
Drugs which selectively block the MKK1/2 signalling in the ERK1/2 cascade [e.g. 
PD184352 (CI-1040), PD0325901 and ARRY-142883] are being evaluated for use in 
clinical oncology. The completed phase I-II clinical trials so far indicate that PD184352 is 
generally well tolerated with minor side effects (Rinehart et al., 2004; LoRusso et al., 
2005).  However, their long term safety and efficacy in patients treated for cancer remains 
to be established.  U0126 is structurally related to PD184352 and PD0325901 (Kohno et 
al., 2006). According to microarray data (Kennedy et al., 2006), U0126, a specific 
inhibitor of the ERK1/2 cascade (Favata et al., 1998; Davies et al., 2000) [although it also 
inhibits the ERK5 cascade at higher concentrations (Mody et al., 2001)], induces the 
expression of stress-responsive genes, four of which are classically induced by the AhR in 
response to polycyclic aromatic hydrocarbons like dioxin or Benzo[a]pyrene stimulation. 
The effect of 10 μM U0126 on the expression of Cyp1a1 and Aldh3a1 mRNA in 
cardiomyocytes was confirmed by SQ-PCR. Both Cyp1a1 and Aldh3a1 mRNAs were 
expressed at low levels under basal conditions, but were highly induced after incubation 
of the cells with U0126 up to 4 h (Figure 6.1A and B). To determine whether an 
alternative, structurally related inhibitor of the MKK1/2 has a similar effect, 
cardiomyocytes were exposed to PD98059 (25 μM). Cyp1a1 and Aldh3a1 were also 
induced by PD98059 over 4 h (Figure 6.1C and D), although the response was observed 
from 1 h, somewhat earlier than with U0126 (Figure 6.1A and B). 
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Figure 6.1 Upregulation of Cyp1a1 and Aldh3a1 by ERK1/2 inhibitors in 
cardiomyocytes. Cardiomyocytes were unstimulated (controls, zero time) or exposed to 
10 μM U0126 (A, B) or 25 μM PD98059 (C, D), for the indicated times. The expression 
of Cyp1a1 and Aldh3a1 mRNA was analysed by SQ-PCR. Control PCR reactions were 
carried out in the absence of reverse transcriptase (-RT). Densitometric analysis of the 
data is provided in the lower panels and expressed relative to controls after normalization 
with the housekeeping gene GAPDH. Results are means ± S.E.M. for three independent 
cardiomyocyte preparations. ( * p< 0.05; # p< 0.01; $ p< 0.001, one way ANOVA with 
Tukey post test).  
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 6.3.2 Doxorubicin and inhibitors of JNKs (SP600125) or p38-MAPKs (SB203580), but 
not the PI3K inhibitor LY294002, induce the expression of Cyp1a1 and Aldh3a1 in 
cardiomyocytes.  
Dioxin and benzo[a]pyrene (Figure 6.2A and B) possess planar hydrocarbon rings 
(halogenated in the case of dioxin) which are required for interaction with the AhR 
(Waller et al., 1995), and it is possible that the planar hydrocarbon rings in U0126 and 
related compounds (Figure 6.2D-F) interact directly with the AhR in a similar way. 
Anthracyclines such as doxorubicin also possess planar hydrocarbon rings (Figure 6.2C). 
The effects of doxorubicin on the expression of Cyp1a1 and Aldh3a1 mRNA in 
cardiomyocytes were therefore investigated. Doxorubicin (5 μM) indeed induced the 
expression of Cyp1a1 and Aldh3a1 (Figure 6.3), although this effect was delayed 
compared with ERK1/2 inhibitors particularly for Cyp1a1 (Figure 6.3A).  
 
Inhibitors of JNKs and p38-MAPKs are currently being developed for use in the 
treatment of chronic inflammatory and allergic diseases (Duan et al., 2006; O'Neill., 
2006). In experimental settings, the compounds SP600125 (an inhibitor of JNKs) and 
SB203580 (which inhibits p38-MAPKα/β) are commonly used to delineate the 
involvement of these cascades in cellular processes. These compounds also possesses 
planar hydrocarbon rings (Figure 6.2G and H), therefore the effects of these drugs on 
Cyp1a1 and Aldh3a1 expression were assessed. Both Cyp1a1 and Aldh3a1 were induced 
in cardiomyocytes incubated with either SP600125 or SB203580 (Figure 6.4). 
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The PI3K pathway is clearly cytoprotective in cardiomyocytes as in other cells (Tong et 
al., 2002; Clerk et al., 2003; Martelli et al., 2007; McCubrey et al., 2007) and is an 
alternative target for chemotherapy (Faivre et al., 2006).  LY294002 is a selective 
inhibitor of PI3K (Vlahos et al., 1994) and, like U0126, PD98059, SB203580 and 
SP600125, it possesses planar hydrocarbon rings (Figure 6.2I).  However, in contrast to 
the effects of inhibitors of the MAPK cascades (see preceding sections), treatment of 
cardiomyocytes with LY294002 (50 μM) had a tendency to downregulate the basal levels 
of Cyp1a1 and Aldh3a1 mRNA expression although this was not statistically significant 
(Figure 6.5). 
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Figure 6.2 Chemical structures. Genotoxic agents 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(dioxin) (A) and benzo[a]pyrene (B); chemotherapeutic agent doxorubicin (C). MAPK 
inhibitors: ERK inhibitors U0126 (D), PD98059 (E) and PD184352; JNK inhibitor 
SP600125 (G), p38-MAPK inhibitor SB203580 (H). PI3K inhibitor LY294002 (I).
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Figure 6.3 Upregulation of Cyp1a1 and Aldh3a1 by doxorubicin in cardiomyocytes. 
Cardiomyocytes were unstimulated (controls, zero time) or exposed to 5 μM doxorubicin, 
for the indicated times. The expression of Cyp1a1 (A) and Aldh3a1 (B) mRNA was 
analysed by SQ-PCR. Densitometric analysis of the data is provided in the lower panels 
and expressed relative to controls after normalization with the housekeeping gene 
GAPDH. Results are means ± S.E.M. for three independent cardiomyocyte preparations. 
(* p< 0.05; # p< 0.01, one way ANOVA with Tukey post test). 
 242
  
 
 
 
0      1       2       4Time (h)
(A) (B)
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Upregulation of Cyp1a1 and Aldh3a1 by inhibitors of JNK and p38-
MAPKα/β in cardiomyocytes. Cardiomyocytes were unstimulated (controls, zero time) 
or exposed to (A-B) 10 μM SP600125, or (C-D) 10 μM SB203580 for the indicated 
times. The expression of Cyp1a1 and Aldh3a1 mRNA was analysed by SQ-PCR. 
Densitometric analysis of the data is provided in the lower panels and expressed relative 
to controls after normalization with the housekeeping gene GAPDH. Results are means ± 
S.E.M. for two independent cardiomyocyte preparations. (* p< 0.05; # p< 0.01, one way 
ANOVA with Tukey post test) 
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Figure 6.5 Downregulation of Cyp1a1 and Aldh3a1 by LY294002 in cardiomyocytes. 
Cardiomyocytes were unstimulated (controls, zero time) or exposed to 50 μM LY294002, 
for the indicated times. The expression of Cyp1a1 and Aldh3a1 mRNA was analysed by 
SQ-PCR. Control PCR reactions were carried out in the absence of reverse transcriptase 
(-RT). Densitometric analysis of the data is provided in the lower panels and expressed 
relative to controls after normalization with the housekeeping gene GAPDH. Results are 
means ± S.E.M. for three independent cardiomyocyte preparations. 
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 6.4 Discussion 
6.4.1 Induction of Cyp1a1 and Aldh3a1 by ERK1/2 inhibitors in cardiomyocytes 
The genes Cyp1a1 and Aldh3a1 which are classically induced in response to AhR were 
expressed at low levels in cardiomyocytes under basal conditions, but there was an 
increase in expression of both genes in response to U0126 (Figure 6.1A and B). The 
classical response to AhR activation by dioxins and other AhR ligands is very often 
evaluated by the induction of the prototypical gene Cyp1a1, and therefore our 
observations so far are in agreement with what has been previously reported in the 
literature. For example, in rat hepatocytes and human hepatoma cells, exposure to U0126 
leads to significant upregulation in the levels of mRNA, protein abundance, as well as 
increased enzymatic activity of Cyp1a1, an effect which appears to be mediated by 
activation of AhR (Andreux et al., 2004). Our data therefore suggests that, in 
cardiomyocytes as in other cells, U0126 stimulates the AhR which then binds to the XRE 
in the promoter of these genes. This is consistent with the finding that in hepatocytes 
U0126 and related ERK1/2 inhibitors (PD98059 or PD184352) increase Cyp1a1 
expression, an effect that is probably dependent on inhibition of the basal ERK1/2 
signalling which triggers the response secondary to AhR stabilization (Chen et al., 2005). 
This is also in agreement with the finding that PD98059 also induced the expression of 
Cyp1a1 and Aldh3a1 in cardiomyocytes (Figure 6.1C and D), although this effect was 
more rapid than for U0126 (Figure 6.1A and B). 
 
However, although the toxic effects of dioxins are well recognized and dioxins promote 
defects in the developing heart (Goldstone and Stegman, 2006), the significance of the 
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dioxin response in the adult heart is not obvious. Thus, in some studies, dioxins do not 
significantly activate the Cyp1a1 promoter in the adult heart (Lund et al., 2003; 
Galijatovic et al., 2004), suggesting that the AhR itself may not be expressed in the 
developed heart. Interestingly, deletion of the AhR in mice results in cardiac hypertrophy 
and fibrosis, but this effect appears to be mediated by secondary elevation of the plasma 
levels of ANGII and ET-1 (Lund et al., 2003, 2005, 2006). Therefore, it is also possible 
that the effects of U0126 and or PD98059 on cardiomyocyte AhR-responsive genes are 
not mediated directly by AhR itself, but by a related factor (Saatcioglu et al., 1990; Luo et 
al., 1997). 
 
6.4.2 Induction of Cyp1a1 and Aldh3a1 by JNK and p38-MAPKα/β inhibitors in 
cardiomyocytes 
The evaluation of the effects of other MAPK inhibitors on AhR-dependent genes 
indicated that SP600125 an inhibitor of JNK and SB203580 a commonly used selective 
inhibitor of p38-MAPKα/β also increased the expression of Cyp1a1 and Aldh3a1 mRNAs 
(Figure 6.3). In contrast, the PI3K inhibitor LY294002 caused a slight downregulation of 
the Cyp1a1 and Aldh3a1 mRNAs (Figure 6.5). This is in agreement with previous 
observations showing that LY294002 suppresses the upregulation of Cyp1a1 in response 
to dioxin, though potentially independent of any inhibition of PI3K (Guo et al., 2000). 
Additionally, our results are in contrast with previous observations indicating that 
SP600125 is an antagonist of the AhR (Joiackim et al., 2003). With our current data, we 
cannot rule out or confirm the possibility that activation or blockade of the AhR pathway 
is involved in these responses to MAPK inhibitors and LY294002. Further experiments 
are required to clarify the involvement of AhR in these responses. 
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6.4.3 Induction of Cyp1a1 and Aldh3a1 by doxorubicin in cardiomyocytes 
Doxorubicin, which (like the protein kinase inhibitors used in this study) possesses planar 
hydrocarbon rings (Figure 6.2C), also induced the expression of Cyp1a1 and Aldh3a1 
(Figure 6.3) although the effect was delayed compared to U0126. To our knowledge, this 
is the first time that upregulation of these genes in response to doxorubicin has been 
identified. Doxorubicin is one of the most potent anticancer drugs available. However, a 
characteristic cardiomyopathy is a frequent side effect with its use in the clinical settings. 
One of the mechanisms implicated in this cardiotoxicity is the production of ROS and 
secondary apoptosis of cardiomyocytes (Wu et al., 2002; Minotti et al., 2004).  The data 
presented here may represent an additional mechanism of toxicity in the pathophysiology 
of doxorubicin induced cardiomyopathy. Cyp1a1 is a monoxidase that utilizes oxygen 
(via a NAD(P)H-dependent electron transport chain) to oxidize xenobiotics. Importantly, 
like all cytochrome P450 enzymes the coupling of the reaction to molecular oxygen leads 
to generation of ROS and therefore to increased oxidative stress in the cell (Zangar et al., 
2004). This is consistent with the sustained increase in oxidative stress that has been 
observed in mice following the intraperitoneal injection of dioxin (Shertzer et al., 1998). 
Since cardiomyocytes are highly vulnerable to increased oxidative stress (section 1.7), 
increased expression of Cyp1a1 associated to increased production of ROS might be 
expected to be detrimental to cardiomyocytes. Given that doxorubicin induces the 
expression of Cyp1a1, this could also contribute to the increase in oxidative stress and 
apoptosis in cardiomyocytes exposed to this drug (Minotti et al., 2004). 
 
The following observations also support the hypothesis that induction of Cyp1a1 and 
Aldh3a1 may represent additional mechanisms through which doxorubicin cause 
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cardiotoxicity. Resveratrol, an important antioxidant found in the diet and wines (Fremont 
et al., 2000), has potential beneficial effects as an adjuvant in anticancer therapy (Rezk et 
al., 2006). The mechanisms by which this compound mediates its effects are not 
completely understood, but the induction of cellular antioxidants and phase 2 enzymes 
has been proposed in experimental studies using H9c2 cardiomyocytes (Cao et al., 2004). 
Interestingly, this compound is also a known AhR ligand and antagonist (Casper et al., 
1999; Ciolino et al., 1999), therefore part of its potential beneficial effects could be the 
negative regulation of AhR-dependent genes in the heart. Whether the effects of induction 
of Cyp1a1 and Aldh3a1 genes by MAPK inhibitors and doxorubicin as shown herein are 
detrimental to the heart remain unknown and further experiments are required to clarify 
this. Another consideration is that several of the protein kinase inhibitors (and related 
compounds) used in the studies presented herein are being considered for therapeutic use 
in cancer, chronic inflammatory processes and cardiac diseases, and possible adverse 
effects could be envisaged since they upregulate AhR-dependent genes.  
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Chapter 7 
 
Summary of results and general discussion 
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7.1 Summary of results 
 
7.1. 1. Expression of ATF3 in response to ET-1 or H2O2 
The mRNA abundance and protein levels of the transcription factor ATF3 were potently 
and transiently induced in response to ET-1 or H2O2 in cardiomyocytes. Upregulation of 
ATF3 mRNA by ET-1 did not require de novo protein synthesis indicating that ATF3 is 
an IEG. Upregulation of ATF3 mRNA and protein was inhibited by U0126 an inhibitor of 
the ERK1/2 cascade indicating that its upregulation was mediated primarily through the 
ERK1/2 cascade. However, ATF3 mRNA expression also required an input from the JNK 
cascade following ET-1 stimulation. 
 
7.1. 2. Expression of IL-6 in response to ET-1 or H2O2 
Stimuli such as ET-1 or H2O2 caused transient upregulation of the mRNA and protein 
levels of the cytokine, IL-6. IL-6 protein was secreted by cardiac myocytes shortly after 
its expression in response to both agonists. IL-6 mRNA induction in response to ET-1 did 
not require de novo protein synthesis and this effect was blocked by the ERK1/2 cascade 
inhibitor U0126. IL-6 is therefore another IEG that is induced in cardiomyocytes through 
the ERK1/2 cascade in response to ET-1. 
 
7.1.3. ATF3 binds to the promoter of IL-6 following ET-1 or H2O2 stimulation 
A bioinformatics approach showed that the rat IL-6 gene possesses an ATF/CRE binding 
consensus sequence in its promoter region, and ChIP assays demonstrated that ATF3 
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binding to the promoter of this gene increased following ET-1 or H2O2 stimulation. 
Interestingly, peak levels of ATF3 protein have an inverse relationship with respect to the 
mRNA levels of IL-6 suggesting that ATF3 may be involved in a negative regulatory 
feedback repressing IL-6 transcription following ET-1 or H2O2 stimulation (Gilchrist et 
al., 2006).  
 
7.1.4 Role of ATF3 in the regulation of IL-6 and other IEGs following ET-1 
stimulation of cardiomyocytes 
Using an adenovirus encoding the ATF3 antisense sequence (ATF3-A/S), mRNA and 
protein levels of ATF3 were successfully and specifically downregulated following ET-1 
stimulation. Under these conditions, IL-6 mRNA abundance was potently superinduced 
indicating that the effect of ATF3 when bound to the promoter of IL-6 was the repression 
of IL-6 transcription. Similarly, the mRNA abundances of the genes LIF, Ereg and Nfκbiz 
were also superinduced by knockdown of ATF3 protein, indicating that these immediate 
early genes are also targets of ATF3 repression in cardiomyocytes. 
 
7.1.5 Induction of Cyp1a1 and Aldh3a1 by MAPK inhibitors and doxorubicin in 
cardiomyocytes 
We have shown that the chemotherapeutic agent, doxorubicin, induces the expression of 
the xenobiotic enzymes Cyp1a1 and Aldh3a1 in cardiomyocytes, two of the genes 
regulated by the AhR transcription factor in response to toxic agents such as dioxin and 
related carcinogenic compounds. Similarly, the ERK1/2 cascade inhibitors U0126 and 
PD98059 as well as the JNK inhibitor, SP600125, and p38-MAPKα/β inhibitor 
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SB203580, as well as doxorubicin, all induced the expression of these same genes. In 
contrast, the PI3K inhibitor, LY294002, did not induce this response but resulted in 
slightly reduced expression levels of these genes. Whether the expression of these genes 
in response to doxorubicin or inhibitors of MAPK cascades results in cardiomyocyte 
toxicity remains to be determined.  
 
7.2 General discussion 
The studies presented in this thesis have examined the expression of ATF3 and IL-6 
genes in response to ET-1 or H2O2 in cardiomyocytes. The effect of ATF3 on the mRNA 
expression levels of IL-6 and other IEGs that are transiently induced upon ET-1 
stimulation were also evaluated. All studies were carried out in cultured cardiomyocytes, 
a model system that allows the evaluation of changes in gene expression specifically in 
the contractile cells of the heart, as opposed to whole hearts in which intermixed cell 
content may obscure the response of the cardiomyocytes. 
 
7.2.1 Expression of ATF3 in cardiomyocytes 
In Chapter 3, the expression of ATF3 in response to ET-1 or H2O2 was evaluated. The 
potent and transient induction of its mRNA correlated with its translation into protein 
with both agonists. ATF3 was also identified as an IEG upregulated by ET-1 whose 
expression is highly dependent on the ERK1/2 cascade with some input received from the 
JNK cascade. This effect of ERK1/2 and JNK on the expression of ATF3 is in agreement 
with some but not all previous reports in other cell systems. Thus, induction of ATF3 
expression by the non-steroidal anti-inflammatory drug sulindac in colon cancer cells is 
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mediated through the increase in the transcriptional activity of Egr-1 on the ATF3 
promoter (Bottone et al., 2005). This effect was inhibited by overexpression of a 
dominant negative ERK1 (dn-ERK1) and by the ERK1/2 cascade inhibitor PD98059, 
indicating the importance of this pathway in regulating ATF3 expression in this system 
(Bottone et al., 2005). In endothelial cells, JNKs appear to be involved in the upregulation 
of ATF3. Thus, in human umbilical vein endothelial cells (HUVECs), ATF3 expression 
in response to homocysteine is preceded by a sustained increase in JNK phosphorylation. 
Treatment of HUVEC cells with the p38-MAPK cascade inhibitor SB203580 or the 
ERK1/2 cascade inhibitor PD98059 has no effect on the expression levels of ATF3. 
Using reporter assays with the ATF3 1850 bp region of the 5’ flanking sequence fused to 
the luciferase reporter gene, luciferase was induced 2-fold following homocysteine 
stimulation in HUVEC cells. Incubation of the cells with expression plasmids containing 
dominant negative mutants of the upstream MKKs of JNK (dn-MKK4 and dn-MKK7) 
results in complete inhibition of ATF3 luciferase activity, whereas pre-treatment of the 
cells with SB203580 or PD98059 hs no effect on the luciferase activity (Cai et al., 2000). 
This suggests that ATF3 expression following stimulation of HUVEC cells with 
homocysteine is mediated through the JNK and not the ERK1/2 or p38-MAPK cascades. 
 
More recently, a bidirectional role for JNKs and ERK1/2 on ATF3 expression in 
endothelial cells was described in response to TNFα. Thus, in HUVECs ATF3 expression 
is increased by TNFα and this is abolished by dn-MKK7 expression plasmids, whereas a 
constitutively-active MKK7 (ca-MKK7) increases expression of ATF3 (Inoue et al., 
2004). A dominant negative mutant of the upstream MKK of p38-MAPK (dn-MKK6) 
does not cause any reduction in the expression of ATF3 following exposure to TNFα, and 
ca-MKK6 does not cause any induction of ATF3. Interestingly, a dn-mutant of MKK1 
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(one of the upstream MKKs for ERK1/2) causes a significant increase in ATF3 
expression whereas a ca-MKK1 results in reduced expression of ATF3 following TNFα 
stimulation. Overall these results suggest that ATF3 expression following TNFα 
stimulation in HUVECs is induced through the JNK cascade, with the ERK1/2 cascade 
having an opposite effect and downregulating ATF3 expression (Inoue et al., 2004). This 
was also further confirmed using the ERK1/2 cascade inhibitors PD98059 and U0126, 
which result in enhanced expression of ATF3 following treatment of HUVECs with 
TNFα (Inoue et al., 2004). 
 
Recently, one study addressed in some detail the involvement of the MAPKs cascades in 
the expression of ATF3 in several cell lines using the agonists anisomycin (which was 
used as a stress model because of its ability to increase the activity of all MAPKs), IL-1β, 
TNFα and H2O2. This study suggests that ATF3 expression at the mRNA and protein 
levels is regulated by the p38-MAPK signalling cascade (Lu et al., 2007). Thus, 
anisomycin-induced expression of ATF3 is not decreased by the ERK1/2 cascade 
inhibitor PD98059, and there is no increased expression of ATF3 with ca-ERK (resulting 
from expression of a fusion protein of ERK2 and its upstream MAPK kinase MKK1), 
indicating that the ERK1/2 cascade is neither necessary nor sufficient to cause ATF3 
expression (Lu et al., 2007). Similarly, inhibition of the JNK pathway with the cell 
permeable peptide JNK-inhibitor (JNKi), which contains the minimal inhibitory region of 
the human protein JNK interacting protein (JIP) and is linked to a ten amino acid 
sequence of the HIV-transactivator of transcription (HIV-Tat) sequence which allows 
rapid cell and nuclear penetration (Schwarze et al., 1999; Bonny et al., 2001), does not 
decrease the expression levels of ATF3 following anisomycin treatment. In addition, 
neither JNK1 nor ca-MKK7 expression plasmids result in increased ATF3 gene 
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expression. This suggests that, as in the case of the ERK1/2 cascade, JNK is neither 
necessary nor sufficient to cause ATF3 gene expression (Lu et al., 2007). In contrast, 
preincubation with the p38-MAPK inhibitor, SB203580, results in decreased expression 
of ATF3 in response to anisomycin as well as to IL-1β, TNFα and H2O2, and similar 
results were also found with the use of dn-MKK6 expression plasmids. Furthermore, ca-
MKK6 causes increased ATF3 gene expression. Taken together these studies indicate that 
the p38-MAPK cascade is both necessary and sufficient to cause ATF3 expression in 
response to stress and cytokines in several cell lines (Lu et al., 2007). Although some of 
the above studies are in agreement with our finding of the involvement of the ERK1/2 and 
JNK cascades in the expression of ATF3 following stimulation of cardiomyocytes with 
ET-1, the divergent results found by others using other cell systems and agonists highlight 
the importance of considering the dependence on the context for the actions ATF3 which 
is also manifested in the signalling pathways controlling its expression. 
 
The fact that ET-1 or H2O2 are capable of potently inducing expression of the ATF3 
transcription factor, suggests that it may play an important role in cardiomyocyte 
hypertrophy following ET-1 stimulation and/or in apoptosis following oxidative stress. 
Previous studies have suggested that ATF3 may indeed play a cytoprotective role 
following exposure of cardiomyocytes to the cardiotoxic anticancer drug, doxorubicin 
(Nobori et al., 2002), a known pro-apoptotic agent in cardiomyocytes and other cell types 
probably because it induces the formation of ROS (Kumar et al., 2002; Minotti et al., 
2004). Induction of ATF3 mRNA and protein in cardiomyocytes by doxorubicin is 
transient suggesting a role for ATF3 in response to doxorubicin (Nobori et al., 2002). In 
addition, adenoviral-mediated overexpression of ATF3 correlates with reduced rates of 
cardiomyocyte apoptosis, indicating that the role of ATF3 under these conditions is 
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cytoprotective (Nobori et al., 2002). My results on the expression of ATF3 following 
doxorubicin stimulation contrast for the most part with those previously reported (Nobori 
et al., 2002), with significant downregulation observed following doxorubicin exposure 
(Figures 3.10 and 3.11). The reasons for these contrasting results are not evident. 
However, the methodology that I employed to evaluate mRNA levels (SQ-PCR), differs 
from that of Nobori et al., (2002), who employed Northern-blot analysis. In addition, I 
used 3 μM doxorubicin whereas their study used 1 μM. My studies of the concentration-
dependency of ATF3 expression did not find significant mRNA upregulation with 1 μM 
and the greatest effect was observed with 3 μM. However, this effect did not reach 
statistical significance either (Figure 3.10). Nevertheless, assuming technical difficulties 
prevented me from replicating the previously described upregulation of ATF3 with 
doxorubicin, the data of Nobori et al., (2002) suggest that ATF3 induction in response to 
oxidative stress in the form of doxorubicin-mediated induction of reactive oxygen species 
is cardioprotective. In a similar way, our results using H2O2 indicate a potent upregulation 
of this transcription factor under conditions of increased ROS production and therefore 
ATF3 may play a similar cytoprotective here. The role of ATF3 upregulation following 
stimulation of cardiomyocytes with ET-1 or H2O2 remains to be established with further 
studies (see below sections 7.2.2 and 7.2.3). 
 
7.2.2 Expression of IL-6 in cardiomyocytes 
In Chapter 4, I evaluated the expression of IL-6. My results indicate that mRNA 
expression of this gene is statistically signicant and transient following ET-1 or H2O2 
stimulation. I was also able to demonstrate that IL-6 is an IEG upregulated in response to 
ET-1 through the ERK1/2 cascade. IL-6 protein is synthesized by cardiomyocytes after 
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translation of mRNA into protein. The studies of Chapter 4 also indicate that IL-6 protein 
is secreted by cardiomyocytes, but this occurs within the first hour following stimulation 
with ET-1 or H2O2. It was then shown that the IL-6 promoter region contains and 
ATF/CRE consensus binding site, and using ChIP assays, I was able to demonstrate that 
ATF3 binding to the IL-6 promoter increases following 1 h stimulation with ET-1 or after 
2 h stimulation with H2O2. It was not clear from these studies whether ATF3 was 
activating or repressing IL-6 transcription, a versatility that has been previously described 
for ATF3 actions (section 3.1.1.2). However, evaluation of the expression levels of ATF3 
protein in relation to IL-6 mRNA demonstrated an inverse relationship between the peak 
of expression of ATF3 protein and the return to near basal levels of IL-6 mRNA 
following transient induction by ET-1 or H2O2. This suggested that ATF3 may be 
involved in a negative regulatory feedback and therefore is involved in downregulation of 
IL-6 following its induction by these agonists. This was consistent with previous studies 
that have shown such a repressive effect of ATF3 on IL-6 expression in other systems 
(Gilchrist et al., 2006). Thus, IL-6 expression was induced in monocytes exposed to 
bacterial LPS and ATF3 was found to be bound the IL-6 promoter using ChIP assays. 
Similarly, IL-6 expression was superinduced in monocytes derived from ATF3 -/- mice 
exposed to LPS (Gilchrist et al., 2006).  
 
7.2.3 ATF3 is a negative regulator of IL-6 and several other IEGs that are induced by 
ET-1 in cardiomyocytes 
Experiments were then performed to elucidate the role of ATF3 in IL-6 regulation 
following ET-1 stimulation of cardiomyocytes. In Chapter 5, I was able to successfully 
downregulate the ET-1-induced expression of ATF3 mRNA and protein using adenoviral-
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mediated overexpression of the ATF3 antisense targeting the full coding region. Similarly 
it was shown that under conditions of ATF3 protein knockdown, IL-6 mRNA levels were 
significantly upregulated (superinduced) following stimulation of cardiomyocytes with 
ET-1, thus confirming that ATF3 is a repressor of IL-6 when bound to the IL-6 promoter 
in response to ET-1. It is likely that this regulatory role of ATF3 over the expression 
levels of IL-6 in cardiomyocytes could prove to be very important in vivo as suggested by 
studies in other systems. Thus, ATF3 null mice that received an intraperitoneal injection 
of LPS exhibited more than tenfold increase in circulating levels of IL-6 compared with 
wild-type animals and this was accompanied by increased mortality (100 % in null mice, 
compared with 0% in wild-type animals after 24 h) secondary to severe inflammation 
(endotoxic shock) (Gilchrist et al., 2006). Similarly, and in support of a pathological role 
for increased levels of IL-6 in the heart, a recent study showed that transgenic mice with 
cardiospecific overexpression of ET-1 in the postnatal period leads to the development of 
a type of cardiomyopathy characterized by an inflammatory infiltrate and increased 
expression of cytokines including IL-6 expression levels in the heart. This suggests that 
unregulated expression of ET-1 which also induces increased expression of IL-6 (among 
other cytokines) in the heart is clearly of pathological significance (Yang et al., 2004).  
 
It is also important to consider other potential pathological effects of IL-6 not in relation 
to the inflammatory actions of this cytokine. As a whole, the gp130 cytokines have been 
consistently found to be involved in myocyte elongation in vitro, which results in 
eccentric hypertrophy of the heart in vivo due to the circumferential disposition of 
cardiomyocytes in the heart. Thus, IL-6, LIF and CT-1 are all implicated in the 
development of cardiomyocyte elongation in vitro (Wollert et al., 1996). Therefore, since 
the discovery of CT-1 this cytokine, as well as IL-6 and LIF, has been implicated in the 
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development of dilatation of the heart and the pathogenesis of heart failure (Hunter and 
Chien, 1999). Consistent with this, rats subjected to intermittent hypoxia for 4 weeks 
develop concentric LV hypertrophy associated with increased mRNA and protein levels 
of TNFα and IGF-1, as well as phosphorylated p38-MAPK and STAT-1 and STAT3 
compared with normoxic controls. Interestingly, more prolonged intermittent hypoxia (8 
weeks) leads to the development of LV eccentric hypertrophy and, in addition to the 
above changes in gene expression and signalling activation, there is also increased 
expression of IL-6 mRNA and protein with activation of the MKK5-ERK5 pathway 
(Chen et al., 2007). This suggests that intermittent hypoxia for 4 weeks may cause a redox 
imbalance that will initially lead to the development of concentric cardiac hypertrophy, 
but after more prolonged hypoxia this redox imbalance may also lead to the development 
of eccentric hypertrophy and left ventricular dilatation following the activation of the IL-
6-gp-130 signalling system through the MKK5-ERK5 pathway. This is consistent with 
the observation that the ERK5 pathway is activated by IL-6 family members, and that this 
leads in vitro to the development of cardiomyocyte elongation, which is replicated by 
adenoviral-mediated overexpression of MKK5 in cardiomyocytes (Nicol et al., 2001). In 
fact, transgenic mice with cardiac overexpression of activated MKK5 develop dilated 
cardiomyopathy secondary to eccentric hypertrophy as the main morphological 
characteristic (Nicol et al., 2001). 
 
By evaluating the mRNA expression of LIF, Ereg and Nfκbiz (also known as IκB-ζ) 
under conditions of ATF3 protein knockdown, I was able to identify these genes as 
additional IEGs that were significantly superinduced (and by implication targets of ATF3 
repression) following ET-1 stimulation of cardiomyocytes. Although the actions of Ereg 
and IκB-ζ remain to be determined in cardiomyocytes, these genes have been identified as 
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important regulators of IL-6 secretion in other systems. Thus, peritoneal macrophages 
from IκB-ζ deficient mice exhibited severe reduction in the production levels of IL-6 
following LPS and IL-1β stimulation (Yamamoto et al., 2004), suggesting that IκB-ζ is a 
key element in the regulation of proinflammatory cytokines such as IL-6 in response to 
LPS and IL-1β. Similarly, bone marrow derived macrophages and dendritic cells (BMDM 
and BMDC) from Ereg-null mice exhibit reduced IL-6 expression levels following 
stimulation with the bacterial antigen peptidoglycan compared to those from wild-type 
animals (Sugiyama et al., 2005), suggesting that Ereg plays an important role in 
peptidoglycan-induced expression of IL-6 in these cells. Taken together, our data indicate 
that ATF3 may be involved in a regulatory network that represses the expression of IL-6 
and LIF and other positive regulators of IL-6 expression such as Ereg and IκB-ζ. This 
suggests that ATF3 may be a modulator of hypertrophy which could be involved in the 
fine tuning of the response and probably does so in a way that prevents the expression of 
genes that could lead to a maladaptative form of cardiac hypertrophy (eccentric 
hypertrophy), and therefore probably favours the development of concentric hypertrophy 
following ET-1 stimulation. This however is not a generalized effect of ATF3 on all 
members of the IL-6 family as our data indicate that CT-1, which is not induced by ET-1 
in our microarray studies, is not a target of ATF3 regulation in the cardiomyocyte at least 
following ET-1 stimulation. 
 
7.2.4 Molecular mechanisms of ATF3 functions  
Recent studies of the molecular mechanisms of ATF3 action in several cell systems 
indicate that, in addition to binding to ATF/CRE consensus sites (5’-TGACGTCA-3’) 
and activator protein-1 consensus sequences (5'-TGAGTCA-3') on target genes (Hai et 
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al., 1999) (section 3.1.1.2), ATF3 also recruits HDACs which results in the increased 
deacetylation of histones and therefore in repression of gene expression (section 1.5.1.1). 
ATF3 is involved in a negative feedback loop, downregulating IL-6 and IL-12b and thus 
modulating the inflammatory response secondary to activation of Toll-like receptors in 
vitro and in vivo (Gilchrist et al., 2006). In this model, ATF3 inhibits IL-6 and IL-12b 
transcription by directly recruiting histone deacetylase 1 (HDAC1), a class II HDAC, thus 
inducing histone deacetylation and thereby restricting access of Rel transcription factors 
to the promoters of IL-6 and Il-12b (Gilchrist et al., 2006). It is likely that ATF3 could 
lead to transcriptional repression of IL-6, LIF, Ereg and Nfκbiz at least in part through a 
mechanism involving the recruitment of HDAC to their promoters. However this should 
be confirmed through further experiments. 
 
7.2.5 Induction of Cyp1a1 and Aldh3a1 by MAPK inhibitors or doxorubicin in 
cardiomyocytes 
In Chapter 6, I showed that several MAPK cascade inhibitors or doxorubicin were able to 
induce the expression of the xenobiotic metabolizing enzymes Cyp1a1 and Aldh3a1, 
which are classically induced in response to AhR, thus confirming and expanding the 
observations made by previous microarray studies from our laboratory (Kennedy et al., 
2006). The classical response to AhR activation by dioxins and other AhR ligands is very 
often evaluated by the induction of the prototypical gene Cyp1a1, and therefore our 
observations are in agreement with what has been previously reported in other cell 
systems. For example, in rat hepatocytes and human hepatoma cells, exposure to U0126 
leads to significant upregulation in the levels of mRNA, protein abundance, as well as 
increased enzymatic activity of Cyp1a1, an effect which appears to be mediated by 
activation of AhR (Andrieux et al., 2004). Similarly, in hepatocytes U0126 and related 
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ERK1/2 cascade inhibitors (PD98059 or PD184352) increase Cyp1a1 expression, an 
effect that is probably dependent on inhibition of the basal ERK1/2 signalling which 
triggers the response secondary to AhR stabilization (Chen et al., 2005). This is also in 
agreement with the results presented in Chapter 6 indicating that PD98059 also induces 
the expression of Cyp1a1 and Aldh3a1, although this effect was more rapid than for 
U0126. 
 
The evaluation of the effects of other MAPK cascades inhibitors on AhR-dependent 
genes indicated that the JNK inhibitor SP600125 and the p38-MAPK inhibitor SB203580 
increased the expression of Cyp1a1 and Aldh3a1 mRNAs. In contrast, the PI3K inhibitor 
LY294002 caused a slight downregulation of the Cyp1a1 and Aldh3a1 mRNAs. This is in 
agreement with previous observations showing that LY294002 suppresses the 
upregulation of Cyp1a1 in response to dioxin, though potentially independent of any 
inhibition of PI3K (Guo et al., 2000). Additionally, my results contrast with previous 
observations made in immortalized human breast epithelial cell line MCF10A indicating 
that SP600125 is a ligand though antagonist of the AhR (Joiackim et al., 2003). With our 
current data, we can not rule out or confirm the possibility that activation or blockade of 
the AhR pathway is involved in these responses to MAPK inhibitors and LY294002, and 
further experiments are required to clarify this point. 
 
Doxorubicin, which (like the protein kinase inhibitors used in this study) possesses planar 
hydrocarbon rings (Figure 6.2), also induced the expression of Cyp1a1 and Aldh3a1. To 
our knowledge, this is the first time that upregulation of these genes in response to 
doxorubicin has been identified. Doxorubicin is one of the most potent and effective 
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anticancer drugs available. However, a characteristic cardiomyopathy is a frequent side 
effect with its use in the clinical settings. One of the mechanisms implicated in this 
cardiotoxicity is the production of ROS and secondary apoptosis of cardiomyocytes (Wu 
et al., 2002; Minotti et al., 2004).  The data presented here may represent an additional 
mechanism of toxicity in the pathophysiology of doxorubicin-induced cardiomyopathy. 
Cyp1a1 is a monoxidase that utilizes oxygen (via a NAD(P)H-dependent electron 
transport chain) to oxidize xenobiotics. Importantly, like all cytochrome P450 enzymes, 
the coupling of the reaction to molecular oxygen leads to generation of ROS and therefore 
to increased oxidative stress in the cell (Zangar et al., 2004). This is consistent with the 
sustained increase in oxidative stress that has been observed in mouse following the 
intraperitoneal injection of dioxin (Shertzer et al., 1998). Since cardiomyocytes are highly 
vulnerable to increased oxidative stress (section 1.4), increased expression of Cyp1a1 
associated to increased production of ROS might be expected to be detrimental to 
cardiomyocytes. Given that doxorubicin induces the expression of Cyp1a1, this could also 
contribute to the increase in oxidative stress and apoptosis in cardiomyocytes exposed to 
this drug (Minotti et al., 2004). 
 
The following observations also support the hypothesis that induction of Cyp1a1 and 
Aldh3a1 may represent additional mechanisms through which doxorubicin cause 
cardiotoxicity. Resveratrol, an important antioxidant found in the diet and wines (Fremont 
et al., 2000), has potential beneficial effects as adjuvant in anticancer therapy (Rezk et al., 
2006). The mechanisms by which this compound mediates its effects are not completely 
understood, but the induction of cellular antioxidants and phase 2 enzymes has been 
proposed in experimental studies using H9c2 cardiomyocytes (Cao et al., 2004). 
Interestingly, this compound is also a known AhR ligand and antagonist (Casper et al., 
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1999; Ciolino et al., 1999), therefore part of its potential beneficial effects could be the 
negative regulation of AhR-dependent genes in the heart. Whether the effects of induction 
of Cyp1a1 and Aldh3a1 genes by MAPK inhibitors and doxorubicin as shown herein are 
detrimental to the heart remain unknown and further experiments are required to clarify 
this. Another consideration is that several of the protein kinase inhibitors (and related 
compounds) used in the studies presented in Chapter 6 are being considered for 
therapeutic use in cancer, chronic inflammatory processes and cardiac diseases, and 
possible adverse effects could be envisaged since they upregulate AhR-dependent genes.  
 
7.3 Future work 
 
7.3.1 Confirmation of binding of ATF3 to the promoters of LIF, Ereg and Nfκbiz 
I have demonstrated that ATF3 protein knockdown leads to upregulation of IL-6 as well 
as LIF, Ereg and Nfκbiz, and also demonstrated that upon ET-1 stimulation of 
cardiomyocytes ATF3 is bound to the promoter of IL-6 using ChIP assays. In further 
experiments it is necessary to confirm that ATF3 binds to the promoters of other potential 
target genes of ATF3 using ChIP assays under conditions of ET-1 stimulation. 
 
7.3.2 Effect of ATF3 knockdown on cardiomyocyte morphology following ET-1 
stimulation 
One of the main findings of this thesis is that ATF3 probably effects a repressor activity 
on several genes of the gp130 cytokines (IL-6 and LIF), as well as in genes that could be 
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positive regulators of IL-6 expression (Ereg and Nfκbiz). This suggests that ATF3 is 
probably involved in a regulatory network that favours the development of concentric 
rather than eccentric hypertrophy following ET-1 stimulation and therefore has a role in 
fine-tuning of the hypertrophic response by this and may be other agonists. To confirm 
this hypothesis it could be useful to evaluate the effects of ATF3 knockdown following 
ET-1 stimulation on the cellular dimensions of the cardiomyocytes using planimetry and 
morphometric analysis. It is anticipated that increased levels of IL-6 and LIF, as well as 
Ereg and Nfκbiz could lead to an increase in myocyte length to width ratio. The effects of 
this morphological change will therefore translate into eccentric hypertrophy in the in 
vivo system due to the circumferential disposition of cardiomyocytes in the heart. This 
could be of pathological significance during processes such as ventricular dilatation of the 
heart following sustained pressure overload as in chronic hypertension, probably leading 
to the development of heart failure. 
 
7.3.3 Role of ATF3 in cardiomyocytes following exposure to apoptotic concentrations 
of H2O2 
In Chapter 4, I showed that ATF3 is potently induced by H2O2 and that this transcription 
factor is bound to the promoter of IL-6 following 2 h exposure of cardiomyocytes to 0.2 
mM H2O2. However, whether ATF3 is a repressor or activator of IL-6 under these 
conditions remains to be determined. To further delineate the role of ATF3 on IL-6 
regulation, further experiments should evaluate the effects of ATF3 knockdown on IL-6 
mRNA levels. In addition, previous studies have shown that increased oxidative stress in 
the form of doxorubicin leads to ATF3 induction and this appears to be cytoprotective as 
adenoviral mediated overexpression of ATF3 lead to reduced apoptosis in 
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cardiomyocytes treated with doxorubicin (Nobori et al., 2002). Dr Stephen Fuller, from 
our laboratory, has also prepared adenoviruses expressing the full length rat ATF3 sense 
sequence which will allow overexpression of ATF3 in cardiomyocytes. The effects of 
adenoviral-mediated overexpression or knockdown on cardiomyocyte apoptosis evaluated 
using a combination of techniques such as TUNEL, cleavage of caspases, and changes in 
morphology could be useful in determining the role of ATF3 under increased oxidative 
stress in the form of H2O2. 
 
7.3.4 Identification of other potential target genes regulated by ATF3 following 
stimulation of cardiomyocytes with ET-1 
One of the most important tasks following completion of the genomic sequencing of the 
human and other genomes (International Human Genome Sequencing Consortium, 2004) 
is the understanding of how changes in the patterns of expression of genes in different 
cells and tissues, lead to alterations in the phenotype accompanying adaptive responses 
such as cardiac hypertrophy or pathological processes such as ventricular remodelling 
following myocardial infarction or sustained pressure overload. To this end, the 
identification of additional downstream genes regulated by ATF3 is an important 
complement to the studies presented in this thesis. The use of microarray studies in 
conjunction with knockdown of ATF3 following ET-1 stimulation will also help to 
identify novel target genes of ATF3, and these could be also confirmed using additional 
ChIP assays under conditions of ET-1 stimulation. 
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APENDIX A  
Reagents and chemicals 
 
 
Supplier  Reagent  
AB Gene  10× Buffer IV (PCR) 
ØX174 RF DNA Hae III digest DNA ladder 
Taq polymerase  
Alexis Biochemicals  GF109203X 
LY294002 
Microcystin 
SB203580  
Amersham  Hyperfilm 
Poly di-dc sodium salt 
Rainbow molecular weight marker (RPN 800)  
BD Biosciences  Chromaspin columns pore size 10  
BDH  Acrylamide 
Benzamide 
Bis-acrylamide 
Boric acid 
EDTA 
Ethanol 
Glucose 
Glycine 
Glyerol 
Glycerophosphate 
HEPES 
Isopropanol 
MgCl2  
MgSO4  
Methanol  
Methylated spirit  
Nonidet® P40 (NP40)  
KCl  
NaCl  
NaF  
Na2HPO4  
Na3VO4  
Sodium dodecyl sulphate (SDS)  
Sucrose  
Tris  
Triton X100  
Tween 20  
Beckton Dickenson Primaria culture dishes  
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Biogenesis  RNAzol Bee™  
BioRad  Bradford Reagent  
BOC gases  Liquid N2  
DAKO  Horseradish peroxidase-conjugated secondary antibodies  
Harlan  Neonatal (two day old) Sprague-Dawley rats  
Invitrogen  100 bp DNA ladder  
Agarose  
dATP, dCTP, dGTP, dTTP  
DNase I Amp Grade (1 U / μl)  
DNase I reaction buffer  
Dulbecco’s modified Eagle’s medium (DMEM)  
M199  
Foetal Calf serum  
Horse Serum  
M-MLV reverse transcriptase  
Penicillin and streptomycin  
Phosphate buffered saline (PBS) (10×)  
RNaseOut® 5×  
1st strand buffer (cDNA synthesis)  
Trypan blue solution  
MWG Biotech  PCR primers  
New England Biolabs  Primary antibodies  
Promega  Random hexamers  
Santa Cruz 
Biotechnology  
Chemiluminescence reagents 
Primary antibodies  
Schleicher and Schuell  Nitrocellulose membrane (Protan®)  
Sigma  Ammonium persulphate 
Bovine serum albumin  
Bromophenol blue  
Chloroform  
Cycloheximide  
Dithiothreitol (DTT)  
oligonucleotides  
Endothelin (ET-1)  
Ethidium bromide  
Gelatin  
H2O2 Leupeptin  
Pancreatin  
Phenylmethylsulfonyl fluoride  
Protein A-Sepharose  
Sonicated salmon sperm DNA  
TEMED Trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane  
Waitrose  Non-fat milk powder  
Worthington  Collagenase  
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